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ABSTRACT 
The aim of my Ph. D. research is to develop drug-polyester nanoconjugates (NCs) as a novel 
translational polymeric drug delivery system that can successfully evade non-specific uptake by 
reticuloendothelial system (RES) and facilitate targeted cancer diagnosis and therapy. By uniquely 
integrating well-established chemical reaction-controlled ring opening polymerization (ROP) with 
nanoprecipitation technique, I successfully developed a polymeric NC system based on poly(lactic 
acid) and poly(O-carboxyanhydrides) (OCA) that allows for the quantitative loading and 
controlled release of a variety of anticancer drugs. The developed NC system could be easily 
modified with parmidronate, one of bisphosphonates commonly used as the treatment for disease 
characterized by osteolysis, to selectively deliver doxorubicin (Doxo) to the bone tissues and 
substantially to improve their therapeutic efficiency in inhibiting the growth of osteosarcoma in 
both murine and canine models. More importantly, the developed NCs could avidly bind to human 
serum albumin, a ubiquitous protein in the blood, to bypass the endothelium barrier and penetrate 
into tumor tissues more deeply and efficiently. When compared with PEGylated NCs, these 
albumin-bound NCs showed significantly reduced accumulation in RES and enhanced tumor 
accumulation, which consequently contributed to higher their tumor inhibition capabilities. In 
addition, the developed NC system allows easy incorporation of X-ray computed tomography (CT) 
contrast agents to largely facilitate personalized therapy by improving diagnosis accuracy and 
monitoring therapeutic efficacy. Through the synthetic and formulation strategy I developed, a 
large quantity (grams or larger-scale) of drug-polyester NCs can be easily obtained, which can be 
used as a model drug delivery system for fundamental studies as well as a real drug delivery system 
for disease treatment in clinical settings.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
1.1.1 Polymeric nanomedicine for cancer therapy 
The past several decades have witnessed the explosive development of nanomedicine for 
cancer diagnosis and treatment.1,2  By integrating nanotechnology with medicine, this emerging 
field is expected to change the landscape of oncology.3-6 Among a variety of nanomedicine 
platforms developed, polymeric nanomedicine that involves the use of polymeric nanoparticles 
(NPs) as drug delivery vehicles has attracted much interest.7-10 Polymeric NPs are ideally designed 
to carry a sufficient amount of therapeutic agents, efficiently cross various physiological barries 
to the diseased site and release the cargos in a fully controlled manner to maximize the therapeutic 
efficacy. Numerous efforts have been devoted to the development of polymeric NPs to meet these 
criteria since 1970s.9,11,12 A handful of polymeric NPs have been developed for preclinical or 
clinical studies, and some of them have been approved for clinical cancer treatment.13-15 For 
example,  poly(ethylene glycol) (PEG) coated liposomal doxorubicin  (Doxil)16-18 and albumin-
bound paclitaxel (Abraxane) have been approved by US Food and Drug Administration (FDA) for 
treating a variety of cancer including metastatic breast cancer, recurrent ovarian cancer, and 
myeloma.19-21 Docetaxel (Dtxl)-loaded, aptamer (Apt)-conjugated poly(ethylene glycol)-
poly(lactide-co-glycolide) (PEG-PLGA) NPs exhibited remarkable in vivo efficacy against 
xenograft prostate cancer model in preclinical studies.22,23 Camptothecin (CPT)-conjugated, 
cyclodextrin (CD)-based polymeric NPs (CRLX101) have been evaluated for treating recurrent 
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ovarian, tubal, and peritoneal cancer in Phase II clinical trial.24-26 Currently, there are over three 
dozen under clinical evaluation and more are expected in the coming years.  
 
1.1.2 Rational design of polymeric NPs 
The use of  abovementioned polymeric NPs for targeting and treating primary tumors 
mainly relied on the enhanced permeation and retention effect (EPR effect).1,3,6 The EPR effect 
refers to the accumulation of NPs in the tumor tissues based on the intrinsic nature of tumor 
microenvironment including the highly permeable tumor vasculature and severely limited 
lymphatic drainage of the interstitial fluid.27 The efficiency of this approach is largely determined 
by the physicochemical properties of the delivery systems. To fulfill the requirements of EPR 
effect, NPs with certain size range are preferred to achieve time-dependent accumulation in tumor 
tissues and thus substantially improve the biodistribution and pharmacokinetic profile of 
therapeutic modality. There is a general consensus that particles with sizes over 200 nm tend to be 
cleared from the circulation rapidly due to the induction of undesired responses by the 
reticuloendothelial system (RES). Particles with sizes less than 10 nm could be cleared from the 
renal system. There have been several reports demonstrating the size dependence of polymeric 
NPs on the tumor accumulation and penetration.28-31 For example, Kataoka group has 
demonstrated that long-circulating, drug-loaded polymeric micelles with diameters of 30, 50, 70 
and 100 nm all could penetrate highly permeable tumors in mice, but only the 30 nm micelles 
could penetrate poorly permeable pancreatic tumors to achieve significant efficacy.31 
Surface characteristics of polymeric NPs also play an important role to influence the in 
vivo performance of NPs. Positively charged NPs are often cleared much faster from circulation 
than the neutral or negatively charged NPs.32,33 Surface modification with poly(ethylene glycol) 
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(PEG) is critical to achieve prolonged NP circulation and reduce plasma protein absorption to NPs 
which could lead to opsonization, a process that involves surface deposition of blood opsonic 
factors for enhanced recognition by macrophages.4,34  
 
1.1.3 Development of polyester-based nanomedicine  
Polyesters are a class of biodegradable and biocompatible polymers that have been widely 
used to formulate polymeric NPs.35 Well-known examples include poly(lactide) (PLA), 
poly(glycolide) (PGA), and poly(lactide-co-glycolide) (PLGA). They are readily available from 
inexpensive, renewable resources through ring-opening polymerization (ROP) of lactide (LA), 
glycolide (GA), and a mixture of LA and GA, respectively. As such, they have received increasing 
attention over the past several decades and have been applied in various biomedical applications 
such as restorable suture and implant, drug delivery and tissue engineering.4,10,36,37  For biomedical 
applications such as drug delivery and tissue engineering, it is highly necessitated to modulate the 
polymer MW, tacticity, polydispersity, and degradability in response to a specific utility. 
Therefore, additional efforts have been put into the synthesis of various topologically different 
polyesters with star, brush, cyclic, or cross-linked structures to further tailor their 
hydrophilicity/hydrophobicity and degradability.38 While the physical properties of polyesters can 
be possibly tuned through co-polymerization, the lack of side chain functionality is a major 
limitation to the application of these materials in new fields.   
Thus, numerous efforts have been devoted to developing methodology that allows facile 
preparation of polyesters with a variety of functionalities for wide-spread utilities.39 Although 
challenging, the introduction of functional groups into polymers derived from ROP can yield 
functional polyesters with favorable properties. In the past several decades, there have been few 
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reports of introducing functionalities to the side chains of PLA by designing and polymerizing 
lactide-like monomers.40-43 For example, Hennink group reported the synthesis of hydroxyl-
containing LA analogues from O-benzyl serine (Ser(Bn)). Hillmyer group reported the 
polymerization of bifunctional lactide derivatives to prepare PLA derivatives with enhanced 
mechanical properties.44 However, the multiple-step syntheses to obtain the substitute LA 
monomers often suffer from undesired low yield and large batch-to-batch variations, preventing 
the large-scale production of functional polyesters.  
Considering the structural similarity between amino acids and α-hydroxyl acids and the 
availability of a wide range of terminal group functionalities on amino acids, much effort has been 
devoted to developing new monomers and preparing side-chain functionalized polyesters via ROP 
of the corresponding monomers. One such example is the readily available 1,3-dioxane-2,4-diones, 
so-called O-carboxyanhydrides (OCA), a class of five-membered ring compounds derived from 
amino acids which has been proven to be a promising candidate for the synthesis of functionalized 
polyesters.45-47 To date, several OCA monomers derived from alanine, glutamic acid, 
phenylalanine and tyrosine have been developed to prepare well-defined polyesters with 
functionalized side chains for drug, and gene delivery applications. 
 
1.1.4 In vivo cancer targeting 
Generally, there are two strategies for cancer targeting: passive and active targeting. 
Passive targeting exploits the characteristic features of tumor biology that allow nanocarriers to 
accumulate in the tumor by the EPR effect.48 However, it should be aware that not all tumor 
vasculatures are leaky. The heterogeneous distribution of pore sizes in tumor vasculature has been 
observed both between tumors (inter-tumor heterogeneity) and within tumors (intra-tumor 
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heterogeneity), which largely impairs uniform delivery and efficacy of therapeutic agents in 
tumors.48  
Active approaches to achieve cancer targeting are through the incorporation of targeting 
ligands (e.g., antibodies,49,50 aptamers,51,52 and small molecules53,54) that can bind to overexpressed 
antigens or receptors overexpressed on the target cells, providing a more efficient way to deliver 
the anticancer agents to the tumor tissues as compared with passive targeting. Antibodies (Abs) 
are the most well-known targeting ligands used in the targeted drug delivery systems. Though 
highly specific, Abs are usually derived from animals or through phage display techniques and the 
potential immunogenicity may limit their wide clinical use. The conjugation of Abs to the NPs are 
usually achieved though coupling chemistry, however, lack of site-specific conjugation and batch-
to-batch variations may lead to reduced targeting specificity and efficiency.49 Aptamers (Apts) are 
single-stranded DNA or RNA that could fold into unique three-dimensional conformations and 
bind to target antigens with extremely high affinity and specificity. Apts are typically non-
immunogenic as they are developed via a combinational chemistry approach called systematic 
evolution of ligands by exponential enrichment (SELEX).51 Because synthesis of Apts is an 
entirely chemical process, the batch-to-batch inconsistency thus can be significantly reduced. 
Importantly, Apts can be easily functionalized with controllable chemical functional groups on 
their termini to permit orthogonal conjugations. These unique properties of Apts demonstrated the 
great promise to be used in nanomedicine-mediated cancer targeting. In addition to Abs and Apts, 
some small organic molecules as active targeting ligands have been extensively investigated due 
to their facial synthesis in large scale and easy incorporation into nanomedicine.55-57 For instance, 
pamidronate (Pam), one of bisphosphonates, has been commonly used as the treatment for disease 
characterized by osteolysis, for its high affinity towards hydroxyapatite, fast distribution, and 
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accumulation in bones.58 Those characteristics of Pam led to explore its utility for targeting bone 
tissues.  
 
1.2 Scope and Organization 
The aim of my PhD research is to design a translational polymeric NP system for improved 
targeted cancer therapy. To achieve this goal, I developed a strategy by uniquely integrating well-
established controlled ring opening polymerization (ROP) with NP formulation to formulate a 
novel polymeric NP system. This strategy allows for the quantitative incorporation of therapeutics 
into the delivery system with predetermined drug loading and high conjugation efficiency. The 
formulated NPs are sub 100-nm size with narrow size distributions (Chapter 2). The drug release 
kinetics could be tuned by changing the covalent linkers between drug and polymer (Chapter 2). 
The in vivo stability and cancer targeting of these developed NPs can be further improved by 
modulating the hydrophobicity through controlled ROP of more hydrophobic OCA monomer 
(Chapter 3). Importantly, the resulting hydrophobic NPs could avidly bind to human serum 
albumin, a ubiquitous protein in the blood, to cross tumor endothelial barrier and accumulate into 
tumor tissues more efficiently (Chapter 4). When modified with pamidronate, these developed NPs 
could be selectively targeted to bone tumors to treat malignant osteosarcoma (Chapter 5). In 
addition to relying on the biological interaction between the specific cell surfaces and targeting 
ligands, the in vivo cancer targeting of these NPs can also be achieved through efficient 
bioorthogonal chemical conjugation (Chapter 6). Furthermore, the developed NP system allows 
for the easy incorporation of X-ray computed tomography (CT) contrast agents and thus largely 
facilitates personalized therapy by improving diagnosis accuracy and monitoring therapeutic 
efficacy (Chapter 7).  
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CHAPTER 2 
SYNTHESIS AND FORMULATION OF CAMPTOTHECIN-N-POLY(LACTIC ACID) 
NANOCONJUGATES 
 
 
2.1 Introduction 
Polymeric nanomedicines have developed explosively in the past several decades,1-3 
among which polymeric nanoparticles (NPs)-based drug delivery systems have attracted much 
interest.2,4,5 Poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) are the most widely 
used polyesters for the preparation of polymeric NPs due to its excellent safety profiles, tunable 
degradation kinetics, and ease of synthesis.6-8 PLA/drug NPs (also called nanoencapsulates) can 
be readily prepared via co-precipitation of PLA and hydrophobic drug.9 However, this easy-access 
method tends to have various NP formulation challenges.4 For example, NPs formulated by this 
method typically show “burst” drug release profiles in aqueous solution with as much as 80-90% 
of the encapsulated drug being released during the first few to ten hours, which often leads to 
severe systemic toxicities. In addition, drug loading in these PLA/drug nanoencapsulates can be 
notoriously low, typically within the range of 1-5 wt% for most systems reported.5 Thus, a large 
amount of NPs are needed to encapsulate the therapeutic amount of the drug. It will be extremely 
challenging when using for in vivo studies. Due to the limited body weight and blood volume of 
mouse, the administration volume is usually fixed. Taking a 20~30 g mouse as an example, the 
i.v. injection volume should be controlled to 100~200 µL. At the 1% drug loading of NPs, the 
administration dose of 50 mg drug/kg (20 g mouse), and the injection volume of 100 µL, a very 
concentrated formulation of 1 g/mL NP solution is required. In practice, it is almost impossible to 
formulate such concentrated solutions and inject them intravenously. Furthermore, there is lack of 
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a general strategy to achieve quantitative drug loading in PLA/drug NPs. Depending on the amount 
and the intrinsic property of the drug and its compatibility with the polymer, the encapsulation 
efficiencies can vary drastically in a range of 10 to 90%. Non-encapsulated drugs may self-
aggregate and can be very difficult to be removed from the NPs, resulting in large heterogeneities 
in NP size and size distributions. These formulation challenges significantly impact the 
processability and the clinical translation of PLA NP-based drug delivery vehicles for cancer 
therapy.  
To address these challenges, our group has developed a novel strategy to prepare drug-
PLA nanoconjugates (NCs) through drug-initiated ring-opening polymerization (ROP) of lactide 
(LA) followed by nanoprecipitation of the resulting drug-PLA conjugates. 10-13 This method 
renders drug-PLA NCs with nearly 100% loading efficiency, negligible “burst” drug release 
profiles, and narrowly distributed particle sizes. In these NCs, the release of drug is attributed to 
the cleavage of a lactate ester bond between drug molecules and polymer through hydrolysis at 
physiological conditions. Because PLA is hydrophobic, the entanglement of polymer chain forms 
rigid core of NCs. Water and ions (e.g., H+ and OH-) were not able to access to the ester linkage 
easily and therefore results in slow release kinetics of drug. For example, only 50% of 20(S)-
camptothecin (CPT) is released from CPT-PLA conjugates in PBS after two weeks at 37 oC.12 
Such slow release profile can significantly diminish the side effects of free CPT in circulation, 
brings difficulties to achieve the active drug concentration within short time in tumors. To improve 
the efficacy of CPT-PLA NCs, an improved rapid release of CPT from NC, while still avoiding 
burst release, is desired. As reported, amine could accelerate the hydrolysis of esters by facilitating 
to form a destabilized intermediate during the hydrolysis process.14 Thus, I report a simple 
chemistry in this chapter that allows for facile conjugation of CPT to the terminal carboxylate 
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group of polylactide (PLA) via a hydrolysis-labile amino ester linker. Instead of using poorly 
controlled coupling chemistry, I developed a ring-opening polymerization (ROP) method to 
facilitate the incorporation of hydrophilic amino ester linker between CPT and PLA. The obtained 
CPT-N-PLA conjugates were able to be co-precipitated with methoxy-poly(ethylene glycol)-PLA 
(mPEG-PLA) to self-assemble into NCs with well-controlled physicochemical properties, such as 
sub-100 nm size, narrow size distribution and controlled release kinetics. The formulated NCs with 
rapid drug release kinetic profile were also demonstrated to potentially enhance the in vivo 
therapeutic efficacy against lewis lung carcinoma (LLC) induced in C57BL/6 mice. 
 
2.2 Materials and Methods 
2.2.1 General 
20(S)-camptothecin (CPT) was purchased from LC Laboratories (Woburn, MA, USA) and stored 
at 30 oC in a glovebox prior to use. β-Diimine (BDI) ligands and the corresponding metal complex 
(BDI-EI)ZnN(TMS)2 were prepared by following the published procedure
15 and stored at 30 oC 
in a glovebox. All other chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA) and 
used as received unless otherwise noted. Anhydrous tetrahydrofuran (THF), dimethylformamide 
(DMF), and dichloromethane (DCM) were purified by alumina columns and kept anhydrous by 
using molecular sieves. The molecular weights (MWs) of PLAn were determined by gel 
permeation chromatography (GPC, also known as size exclusion chromatography (SEC)) 
equipped with an isocratic pump (Model 1100, Agilent Technology, Santa Clara, CA, USA), a 
DAWN HELEOS 18-angle laser light scattering detector and an Optilab rEX refractive index 
detector (Wyatt Technology, Santa Barbara, CA, USA). The wavelength of the HELEOS detector 
was set at 658 nm. The size exclusion columns (Phenogel columns 100, 500, 103 and 104 Å, 5 μm, 
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300 × 7.8 mm, Phenomenex, Torrance, CA, USA) used for the analysis of polymer-drug 
conjugates was serially connected on the GPC. The GPC columns were eluted with DMF (HPLC 
grade) containing 0.1 M LiBr at 65 °C at 1 mL/min. Data processing was performed with ASTRA 
V software (Version 5.1.7.3, Wyatt Technology, Santa Barbara, CA, USA). HPLC analyses were 
performed on a System Gold system equipped with a 126P solvent module and a System Gold 128 
UV detector (Beckman Coulter, Fullerton, CA, USA) equipped with a 126P solvent module, a 
System Gold 128 UV detector and an analytical C18 column (Luna C18, 250 × 4.6 mm, 5 μ, 
Phenomenex, Torrance, CA, USA). The NMR studies were conducted on a Varian UI500NB 
system (500 MHz) or a Varian U400 (400 MHz). Infrared spectra were recorded on a PerkinElmer 
100 serial FTIR spectrophotometer (PerkinElmer, Waltham, MA, USA). The sizes and the size 
distributions of the PLAn NCs were determined on a ZetaPALS dynamic light scattering (DLS) 
detector (15 mW laser, incident beam = 676 nm, Brookhaven Instruments, Holtsville, NY, USA). 
Lyophilization of the NCs was carried out on a benchtop lyophilizer (FreeZone 2.5, Fisher 
Scientific, USA).  
 
2.2.2 Synthesis of CPT-Br.  
 
CPT (104 mg, 0.30 mmol) was suspended in anhydrous dichloromethane (5 mL) followed by the 
addition of 4-dimethylaminopyridine (4 mg, 0.03 mmol), bromoacetic acid (300 mg, 1.8 mmol) 
and diisopropylcarbodiimide (260 L, 1.8 mmol). The mixture was stirred at rt for 24 h. The 
reaction was monitored by HPLC. After the solvent was evaporated in vacuum, the crude product 
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was purified by silica column (CH2Cl2/EtOAc=4/1) to give CPT-Br (370 mg, 91% yield).16 1H 
NMR (CDCl3, 500 MHz): δ 8.40 (s, 1H, ArH), 8.23 (d, 1H, ArH), 7.93 (d, 1H, ArH), 7.84 (t, 1H, 
ArH), 7.69 (t, 1H, ArH), 7.27 (s, 1H, –N–C=CH–C–), 5.71 (d, 1H, –N–CO–C–CH2–O–), 5.43 (d, 
1H, –N–CO–C–CH2–O–), 5.30 (s, 2H, Ar–CH2–N–), 3.83 (m, 2H, –O–CO–CH2Br), 2.32 (q, 1H, 
–CH2–CH3), 2.20 (q, 1H, –CH2–CH3), 1.00 (t, 3H, –CH2–CH3). 13C NMR (CDCl3, 500 MHz): δ 
167.0, 166.2, 157.5, 152.5, 149.2, 146.8, 145.1, 131.4, 130.9, 130.0, 128.7, 128.5, 128.4, 128.3, 
120.6, 96.0, 67.5, 50.2, 42.4, 32.1, 25.2, 7.8. HPLC purity: >95%. MALDI (m/z): calcd for 
C22H17BrN2O5, 470.3, [M]; found, 471.0 [M+H]+.  
 
2.2.3 Synthesis of CPT-N-OH. 
 
In a glovebox, Cpt (3.5 mg, 0.01 mmol) was dissolved in anhydrous tetrahydrofuran (THF, 300 
L) and mixed with a THF solution (500 L) containing (BDI-EI)ZnN(TMS)2 (6.5 mg, 0.01 
mmol). The mixture was stirred for 15 min. Phe-OCA (192.4 mg, 100 equiv) was dissolved in 
THF (2 mL) and added to the stirred (BDI-EI)ZnN(TMS)2 and Cpt solution. The reaction 
proceeded in the glovebox overnight. The conversion of Phe-OCA was determined by FT-IR by 
monitoring the disappearance of Phe-OCA anhydride band at 1812 cm-1. After Phe-OCA was 
completely consumed, the reaction was stopped by quenching the polymerization solution with 
cold methanol solution (300 L). The polymer was precipitated with ether (50 mL), collected by 
centrifugation and dried by vacuum.  The molecular weight and molecular weight distribution 
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(MWD = Mw/Mn) of Cpt-PheLAn were accessed by GPC.  
 
2.2.4. Synthesis of CPT-N-PLAn.  
CPT-N-OH was utilized as the initiator for the polymerization of lactide (LA), in the presence of 
(BDI-EI)ZnN(TMS)2. A typical procedure is given here. In a glovebox, CPT-N-OH (4.49 mg, 0.01 
mmol) solution in anhydrous tetrahydrofuran (THF, 300 L) was mixed with a 100 L THF 
solution (BDI-EI)ZnN(TMS)2 (6.5 mg, 0.01 mmol). The mixture was stirred for 15 min. LA (144.1 
mg, 100 equiv) was dissolved in THF at 50 mg/mL concentration and added to above solution 
under stirring. The reaction proceeded in the glovebox overnight. The conversion of LA was 
determined by FT-IR (by monitoring the disappearance of anhydride band at 1772 cm-1) (Figure 
S1). After LA was completely consumed, the reaction was stopped by quenched with cold 
methanol solution (300 L). The polymer was then precipitated with ether (20 mL) and dried by 
vacuum line. Molecular weight and PDI was accessed by GPC according to general experimental 
condition. 
 
2.2.5. Synthesis of mPEG5k-PLA.  
mPEG5k-OH was utilized as the initiator for the polymerization of LA, in the presence of (BDI-
EI)ZnN(TMS)2. A typical procedure is given here. In a glovebox, mPEG5k-OH (50 mg, 0.01 mmol) 
solution in anhydrous dichloromethane (DCM, 3 mL) was mixed with a 100 L DCM solution 
(BDI-EI)ZnN(TMS)2 (6.5 mg, 0.01 mmol). The mixture was stirred for 15 min. LA (144.1 mg, 
100 equiv) was dissolved in DCM at 50 mg/mL concentration and added to above solution under 
stirring. The reaction proceeded in the glovebox overnight. The conversion of LA was determined 
by FT-IR (by monitoring the disappearance of anhydride band at 1772 cm-1). After LA was 
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completely consumed, the reaction was stopped by quenched with cold methanol solution (300 
L). The polymer was then precipitated with ether (50 mL) and dried by vacuum line. Molecular 
weight and PDI was accessed by GPC according to general experimental condition.  
 
2.2.6. CPT-N-polylactide nanoconjugatess (NCs) formulation.  
CPT-N-PLAn conjugate were prepared by following the procedures as described above. A DMF 
solution of the CPT-N-PLAn conjugate (100 μL, 10 mg/mL) was added dropwise to nanopure 
water (2 mL). The resulting NCs were collected by ultrafiltration (5 min, 3000 × g, Ultracel 
membrane with 10,000 NMWL, Millipore, Billerica, MA, USA), washed with water and then 
characterized by DLS for particle sizes and size distributions.  
 
2.2.7. PEGylated CPT-N-polylactide nanoconjugatess (NCs) formulation.  
A DMF solution of the mixture of CPT-N-PLAn conjugate (100 μL, 20 mg/mL) and mPEG5k-PLA 
(100 μL, 20 mg/mL) was added dropwise to fast stirring nanopure water (4 mL). The resulting 
NCs were collected by ultrafiltration (5 min, 3000 × g, Ultracel membrane with 10,000 NMWL, 
Millipore, Billerica, MA, USA), washed with water and then characterized by DLS for particle 
sizes and size distributions.  
 
2.2.8. Extraction of CPT from NCs.  
PEGylated CPT-N-PLA10 NCs (1 mg) in water (1 mL) was treated with the NaOH solution (1 M, 
1 mL) for 12 h at rt. The pH value of CPT-N-PLA10 suspension was then tuned to 2 by phosphoric 
acid. The solution color turned yellow. The resulting solution was concentrated, and the released 
CPT was collected and purified through semi-prep HPLC column (Jupitor, 250 × 21.20 mm, 10 μ, 
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Phenomenex, Torrance, CA, USA). The mobile phase of HPLC was acetonitrile:water:TFA 
(25:75:0.75, v/v/v). The collected yellow oily compound after removal of the solvents was 
dissolved in trace of phosphoric acid:methanol (1:1, v/v) solution (500 μL). The pH of the solution 
was tuned to 3-4 by NaOH (0.1 M). The resulting solution was extracted with chloroform (5 × 10 
mL). The organic phase was then dried by magnesium sulfate. After the organic solvent was 
evaporated, a slight yellow solid was obtained. The solid was analyzed by HPLC and its spectrum 
was compared with the authentic CPT, showing that the released compound has identical elution 
time as to the authentic CPT. 
 
2.2.9. Stability of PEGylated CPT-N-PLA10 NCs.  
PEGylated CPT-N-PLAn NCs were prepared by following the procedures as described above. The 
obtained NCs were dispersed in PBS, cell culture medium, and human serum buffer (human 
serum:PBS = 1:1, v/v), respectively. The particle sizes were measured by DLS and followed over 
60 min. 
 
2.2.10. Lyophilization of NCs with bovine serum albumin (BSA).  
PEGylated CPT-N-PLAn NCs were prepared by following the procedures as described above. The 
resulting NCs were analyzed by DLS. Bovine serum albumin (BSA) was then added into the NC 
solution. The mixture was lyophilized for 16 h at -50 °C to obtain a white powder.  The white 
powder was reconstituted in nanopure water (2 mL) and the solution was stirred for 5 min at rt. 
The resulting NC solution was analyzed by DLS to assess NC size and size distribution. 
 
2.2.11. Release kinetic study of NCs.  
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PEGylated CPT-N-PLA10 NCs and PEGylated CPT-PLA10 NCs were prepared by following the 
procedures as described above. The NCs were collected and purified by ultrafiltration (5 min, 3000 
× g, ultracel membrane with 10,000 NMWL, Millipore, Billerica, MA, USA). The collected NCs 
were dispersed in human serum buffer (human serum:PBS=1:1, v/v, 5 mL), divided into 10 equal-
volume portions, and added to 10 eppendorf microcentrifuge tubes (500 μL NC solution in each 
tube). The tubes were incubated at 37°C. Complete release of CPT from NC was predetermined 
by the hydrolysis mentioned above. At scheduled time points, two tubes were taken out, to which 
methanol (500 μL) was added to precipitate proteins. The precipitates were removed by 
centrifugation (5 min, 15000 × g). The supernatant then was injected into HPLC for analysis of 
the released CPT. For the HPLC analysis, acetonitrile:water (containing 1% TFA) was used as 
mobile phase. The gradient for acetonitrile:water (containing 1% TFA) was changed linearly from 
25:75 to 75:25 over 30 min and then kept at 75:25 for 30 min and changed back to 25:75 over 5 
min. the flow rate was 1.0 mL/min. Analytical C18 column (Luna C18, 250 × 4.6 mm, 5 μ, 
Phenomenex, Torrance, CA, USA) was used to perform the analysis. The integrated area of the 
CPT peak was documented and compared with that of 100% released CPT to determine the 
released CPT.  
 
2.2.12. Cytotoxicity evaluation.  
MCF-7 cells (ATCC, Manassas, VA, USA) used in the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay were cultured in Dulbecco’s modified Eagle medium 
(DMEM) containing 10% fetal bovine serum, 1000 units/mL aqueous penicillin G, and 100 μg/mL 
streptomycin. MCF-7 cells were placed in a 96-well plate for 24 h (10 000 cells per well). Cells 
were washed with 100 μL of prewarmed PBS. Freshly prepared PEGylated CPT-PLA10 NCs, 
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PEGylated CPT-N-PLA10 NCs, and free CPT (prepared in 1× PBS, 100 μL) were added to the 
cells. CPT was used as a positive control. Untreated cells without CPT were used as negative 
controls in this MTT assay. The cells were incubated for 72 h in a 5% CO2 incubator at 37 °C. The 
standard MTT assay protocols were followed thereafter.  
 
2.2.13. Tumor reduction study.  
C57BL/6 mice (female, 6-8 weeks) were purchased from Charles River (Wilmington, MA, USA). 
Ad libitum feeding was provided. Light was provided in a 12/12-hour light/dark cycle. The study 
protocol was reviewed and approved by the Illinois Institutional Animal Care and Use Committee 
(IACUC) of University of Illinois at Urbana‒Champaign. These mice were anesthetized, shaved, 
and prepared for implantation of the tumor cells.  Lewis lung carcinoma (LLC) cells were collected 
from culture, and 1 × 105 cells suspended in a 1:1 mixture of hank’s balanced salt solution (HBSS) 
buffer and matrigel were then injected subcutaneously into left and right flank of a mouse. After 
two weeks when tumors had reached ~200 mm3, mice were divided into five groups of six mice, 
minimizing weight and tumor size differences. Four groups of mice were treated by intravenous 
injection of PBS (1×), mPEG-PLA NC, PEGylated CPT-PLA NC (50 mg/kg), and PEGylated 
CPT-N-PLA NC (50 mg/kg). The remaining on group mice was treated with free irinotecan (100 
mg/kg) intraperitoneally. After dosing, the animals were monitored closely, and measurements of 
the tumor size for each animal were performed at regular intervals using calipers without 
knowledge of which injection each animal had received. The tumor volume for each time point 
was calculated according to the formula (length) × (width)2/2, where the long axis is the length, 
the short axis is the width.  If body weight loss is beyond 20% of predosing weight, the animals 
were euthanized. When the tumor load reached 1200 mm3 or the animal had become moribund, 
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the mouse was sacrificed. The statistical analysis was undertaken using Mann-Whitney U test and 
p-values < 0.05 were considered statistically significant. When an animal exited the study due to 
tumor size or treatment related death, the final tumor size recorded for the animal was included 
with the data used to calculate the mean size at subsequent time point. At the end of study, the mice 
were euthanized, and the LLC tumors were collected and freshly frozen with optimum cutting 
temperature (O.C.T.) compound (Sakura Finetek USA, Torrance, CA, USA). Tumor sections of 5 
µm thickness were collected by cryostat (Leica CM3050S). Cell apoptosis in tumors was analyzed 
using in situ cell death detection kit (Roche Diagnostics GmbH, Mennheim, Germany) and 
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end (TUNEL) staining was 
performed following the manufacture’s procedure. Positive cells were red fluorescent and 
background cells were blue fluorescent (stained with 4’,6-diamidino-2-phenylindole (DAPI)). The 
tumor sections were imaged with the confocal laser scanning microscopy (LSM 700, Zeiss) at 20 
× magnification. The total number of cells (blue) and apoptotic cells (red) was counted in multiple 
sections (> 10) per tumor  by ImageJ to quantify the apoptotic index (ratio of apoptotic cell number 
(TUNEL, red) to the total cell number (DAPI, blue).  
 
Statistical analysis. Student’s t-test comparisons at 95% confidence interval were used for 
statistical analysis of release kinetics and cell viability. The results were deemed significant at 0.01 
< *p  0.05, highly significant at 0.001 < **p  0.01, and extremely significant at ***p  0.001.  
 
2.3 Results and Discussion 
2.3.1 Synthesis and characterization of CPT-N-LAn conjugates 
 
It has been suggested that the release of conjugated anticancer drug should occur in a 
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controlled manner within the tumor stroma to maximize its therapeutic efficacy and the drug-
oligomer conjugates formed by the hydrolysis of polymer chains during the circulation should be 
inhibited to minimize the systemic toxicity.17,18 Thus, distinctive differences of hydrolysis rates 
between drug-polymer and polymer backbones are desirable. To achieve this aim, the CPT 
derivative was first synthesized by condensation of bromoacetic acid with CPT’s C20-hydroxyl 
group to yield CPT-bromide (CPT-Br). Then, CPT-Br was reacted with ethanolamine to obtain N-
substituted CPT-ester containing primary hydroxyl group, termed CPT-N-OH. As previously 
reported, the pendent hydroxyl group of the therapeutic agent allows for one-step drug conjugation 
to the terminal carboxylate group of PLA via a ROP method facilitated by BDI-Zn catalyst. 
Through such living polymerization, both the initiation (CPT-N-OH incorporation) and the chain 
propagation can proceed in a well-controlled manner and result in materials with pre-defined drug 
loadings and narrow molecular weight distributions (MWDs) (Scheme 2.1). Controlled ROP were 
performed over a broad range of LA/CPT-N-OH ratios from 10 to 200 when the LA 
polymerizations were mediated by (BDI-EI)ZnN(TMS)2/CPT-N-OH with quantitative CPT-N-OH 
incorporation efficiencies and narrow MWDs (Mw/Mn = 1.09-1.23) (Table 2.1). The obtained 
MWs of the CPT-N-PLAn conjugates were in excellent agreement with the expected MWs, which 
followed a linear correlation with the LA/CPT-N-OH ratios (Figure 2.1b).  Monomodal GPC MW 
distribution curves were observed in all CPT-N-PLAn conjugates prepared with various LA/CPT-
N-OH ratios (Figure 2.1a). The well-controlled polymerization mediated by (BDI-
EI)ZnN(TMS)2/CPT-N-OH presumably proceeded through the insertion-coordination mechanism 
as reported.29 
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Scheme 2.1. Preparation of PEGylated CPT-N-PLA NCs via CPT-N-OH initiated LA 
polymerization in the presence of (BDI-EI)ZnN(TMS)2, followed by nanoprecipitation and non-
covalent surface modification. 
 
 
 
Figure 2.1. (A) Overlay of GPC traces of CPT-N-PLAn (n = 50, 100 and 200). (B) (BDI-
EI)ZnN(TMS)2/CPT mediated controlled ring-opening polymerization (ROP) of LA at various 
ratio of LA/CPT (MWD = Molecular Weight Distribution.  
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Table 2.1.  Polymerization of LA mediated by CPT-N-OH and (BDI-EI)ZnN(TMS)2 
 
 
 
a All reactions were performed in the glovebox. Abbreviation:  Conv. (%) = conversion of 
monomer %, MWD = Molecular weight distribution. bDetermined by FT-IR by monitoring the 
disappearance of the LA peak at 1772 cm-1. cDetermined by gel permeation chromatography 
(GPC) and MALDI-TOF MS analysis.  
 
 
2.3.2 Preparation and characterization of CPT-N-LA10 NC 
Nanoprecipitation, representing a facile, non-extensive and low-energy consuming 
technique has been widely used for the preparation of versatile polymeric NPs.8,11,19 In this study, 
the CPT-N-PLA conjugate was dissolved in water-miscible organic solvent (DMF) and then 
dropwise added into fast stirring water, resulting in formation of CPT-N-PLA10 NCs with CPT 
embedded in the hydrophobic PLA matrices (Table 2.2). This method allows for a rapid 
production of NC with sub-100 nm size and very narrow size distribution in a large quantity (gram 
scale), which confirmed with dynamic light scattering (DLS) (Figure 2.2a). Furthermore, the sizes 
of these NCs prepared by nanoprecipitation can be easily controlled by tuning the concentration 
of polymer.32 When the DMF/water ratio is fixed at 1/20 (v/v), the size of CPT-N-PLA10 NCs 
showed a linear correlation with the concentration of CPT-N-PLA10 conjugate and can be precisely 
tuned from 50 nm to 75 nm (Figure 2.2b). 
 
 
 
 
 
Entry a Name [M]/[Cat.]
Conv
(%) b
Mn cal
(×103g/mol) 
Mn
(×103g/mol) c
MWD 
(Mw/Mn) 
c
1 CPT-N-PLA200 200/1 >98 29.2 28.9 1.09
2 CPT-N-PLA100 100/1 >98 14.9 15.7 1.13
3 CPT-N-PLA50 50/1 >98 7.6 7.9 1.17
4 CPT-N-PLA10 10/1 >98 1.9 1.4 1.23
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Table 2.2.  Characterization of CPT-N-PLA NC prepared by LA polymerization mediated by 
(BDI-EI)ZnN(TMS)2 catalyst
a 
   
 
 
 
 
 
aAbbreviation: NC = Nanoconjugates; M/I = monomer/initiator ratio; Eff = incorporation 
efficiency, the percent of initiator utilized in the initiation of LA polymerization; PDI = 
polydispersity derived from particle sizing using DLS. NCs are named as CPT-N-PLAM/I. 
b, c the 
data was based on the reversed-phase HPLC analysis of unincorporated drug. d, e characterized by 
DLS. 
 
 
 
To achieve favorable in vivo performance, the NCs are expected to have prolonged 
circulation time to maximize their therapeutic efficacy.20 However, surface-unmodified NC are 
usually found to have non-specific binding with proteins in blood to form large aggregates, 
subsequently resulting in rapid clearance from the blood stream due to uptake by the 
reticularendothelial systems (RES).3 Modification of NC surfaces with PEG, termed 
“PEGylation”, is the most widely used approach to reduce recognition by RES and prolong 
systemic circulation.21-24 To minimize efforts for complicated chemical synthesis, we applied a 
facile strategy to coat the surface of NCs with PEG. By mixing mPEG5k-PLA10 (PLA block of 1.4 
kDa and mPEG segment of 5 kDa) copolymer with CPT-N-PLA10 conjugate followed by 
nanoprecipitation technique, it yields PEGylated NCs via the hydrophobic interaction of PLA 
segments of mPEG5k-PLA10 and CPT-N-PLA10. As shown in Figure 2.3, the nanoparticle size in 
water increased from 73 to 93 nm after PEGylation, indicating that PEGylation only partly 
contributed to the increased particle diameter. When dispersed in PBS, cell culture medium 
(DMEM) and human serum, the particle size was further augmented by 20-40 nm, which was 
Entrya Name M/I ratio Eff (%)b Loading (%)c Size (nm)d PDIe
1 CPT-N-PLA100 NC 100 >95 2.3 82 0.06
2 CPT-N-PLA50 NC 50 >95 4.6 89 0.09
3 CPT-N-PLA10 NC 10 >95 18.5 73 0.12
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presumably attributed to the salt-induced screening of the repulsive force.37 No aggregation was 
noted according to the DLS histogram, which demonstrated the desired stability of the PEGylated 
CPT-N-PLA10 NC (Figure 2.3). For further clinical applications, it is desirable that NCs 
formulated in solid form that bear with their original well-controlled properties, feasible for the 
long-term storage and transport prior to their use in clinic. As shown in Figure 2.4, bovine serum 
albumin (BSA), a ubiquitous protein in the blood, could be used to stabilize CPT-N-PLA10 NC and 
effectively prevent the severe aggregation of NCs during lyophilization process. 
                                     
                 
 
Figure 2.2. Formulation and characterization of CPT-N-PLA10 NCs. (A) DLS analysis of CPT-N-
PLA10 NC in water (0.5 mg/mL). (B) Precipitation of CPT-N-PLA10 from DMF solution into water 
at various CPT-N-PLA10 concentrations.  
 
 
Figure 2.3. Stability of PEGylated CPT-N-PLA10 NCs in PBS, cell culture medium, and human 
serum buffer (human serum:PBS=1:1, v/v). 
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Figure 2.4. DLS analysis of NCs reconstitution: Monodispersed PEGylated CPT-N-PLA10 NCs 
mixed with bovine serum albumin (BSA) in water before lyophilization (upper panel). The 
reconstituted NC after lyophilization in the presence of BSA (BSA:NC=10:1, wt/wt) (bottom 
panel).  
 
 
 
2.3.3 Drug release kinetics and cytotoxicity 
I performed the release kinetic study of CPT from PEGylated CPT-N-LA10 NC and 
PEGylated CPT-LA10 NC respectively in the 50% human serum buffer, which better mimics the 
release in physiological conditions. Since the release kinetics of CPT is determined by the 
hydrolysis of ester linkage between CPT and NCs, the release kinetics of CPT from NCs are more 
sustainable as compared to the burst release profile often observed in the polymeric encapsulates. 
As shown in Figure 2.5a, CPT-LA10 NC with the hydrophobic ester linker between CPT and 
polymeric NC exhibited sustained drug release with 18% CPT released over 48 h. In comparison, 
when the linker changed to hydrolysis-labile amino ester linker, the release kinetics of CPT from 
CPT-N-LA10 NC could be significantly accelerated with nearly 50% CPT being released within 
the same period of time. In vitro toxicity of NCs is highly correlated with the amount of drug 
released from NCs, we therefore evaluated the cytotoxicity of PEGylated CPT-LA NCs with two 
different linkers in MCF-7 cells using MTT assay (Figure 2.5b). The IC50 of PEGylated CPT-
LA10 NC (1435 nM) is nearly three times higher than PEGylated CPT-N-LA10 NC (454 nM).  As 
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a result, the toxicity of PEGylated CPT-NCs against cancer cell proliferation could be improved 
simply by controlling the linker. 
 
Figure 2.5. (A) Release kinetics of CPT from PEGylated CPT-PLA10 NC and PEGylated CPT-N-
PLA10 NC in human serum buffer (human serum:PBS=1:1, v/v) at 37 
oC. (B) Cytotoxicity of free 
CPT, PEGylated CPT-LA10 NC and PEGylated CPT-N-PLA10 in MCF-7 cells as determined by 
MTT assay (37 oC, 72 h). Statistical differences between the groups were assessed with Student’s 
t-test. * P< 0.05 is considered statistically significant. 
 
 
 
 
 
2.3.4 In vivo efficacy of CPT-N-LA NCs 
I infer that the NC formulation with rapid drug release kinetic profile will potentially 
enhance the efficacy. For proof of concept, I then investigated the in vivo therapeutic efficacy of 
NCs against Lewis lung carcinoma (LLC) induced by subcutaneous injection of LLC cells into the 
C57BL/6 mice. When the size of tumors reached around 200 mm3, the mice were divided to five 
groups to minimize the differences of body weights and tumor sizes among groups (N=6). Two 
groups of mice received the single intravenous injection of PEGylated CPT-N-LA10 NC and 
PEGylated CPT-LA10 NC at the dose of 50 mg CPT per kg mice body weight (50 mg/kg), 
respectively. Irinotecan, a CPT analogue with improved solubility, was administrated as clinically 
suggested at the single dose of 100 mg/kg intravenously. The other two groups were administrated 
intravenously with PBS and mPEG-PLA NC as negative controls (Figure 2.6a). The tumor sizes 
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and body weights of mice in each group were monitored continuously for 8 days post injection. 
We found the group of mice treated with PEGylated CPT-N-LA10 NCs significantly delayed of 
tumor growth and more effective than groups treated with CPT-LA10 NCs, and other control 
groups (P<0.05, Mann-Whitney U test, Figure 2.6b and c). Our efficacy result is further 
confirmed by TUNEL staining of tumor sections obtained from above five groups of mice at day 
8. As shown in Figure 2.6e, tumors treated with CPT-N-LA10 NCs had substantially increased the 
apoptotic cell numbers compared with those treated with CPT-LA10 NCs. The apoptotic index 
(TUNEL/DAPI, day 8) indicates that CPT-N-LA10 NC (12.29%) showed dramatically improved 
efficacy compared to the CPT-LA10 NC (9.23%) (Figure 2.6e). When evaluating the body weight 
changes of all the mice received treatments, none significant (<20%) body weight drop was 
observed (Figure 2.6d), which indicated minimal acute toxicities of CPT-loaded polymeric NCs. 
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Figure 2.6. In vivo tumor reduction study. (A) Experimental procedures of the study. (B) Delay 
and inhibition of LLC (Lewis lung carcinoma) tumor growth in C57BL/6 mice with different 
treatments (PEGylated CPT-LA10 NC, PEGylated CPT-N-LA10 NC, irinotecan, mPEG-PLA NC, 
and PBS), N=6. Data are presented as relative median tumor size (V/V0, compare to the tumor 
volume at day 0). (C) Box plot of LLC tumor growth in C57BL/6 mice at day 8, after treated with 
PEGylated CPT-LA NC, PEGylated CPT-N-LA NC, irinotecan, mPEG-PLA NC, and PBS at day 
0. Statistical properties of relative tumor volume ratio (V/V0, compare to the tumor volume at day 
0) shown in box plot are as follows: box (median with 25/75% percentile), whisker (5/95% 
percentile), and asterisks (maximum/minimum). Univariate differences between the groups were 
assessed with Mann-Whitney U test. P< 0.05 is considered statistically significant. (D) Relative 
body weight (M/M0) monitoring over the study (M: body weight monitored during the study; M0: 
body weight monitored at day 0). (E) Representative deoxynucleotidyl transferase-mediated 
deoxyuridine triphosphate nick end (TUNEL) staining sections of LLC tumors with all treatments 
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(PEGylated CPT-LA10 NC, PEGylated CPT-N-LA10 NC, irinotecan, mPEG-PLA NC, and PBS). 
Scale bar: 40 μm.  
 
2.4. Conclusions 
Overall, by taking advantage of the controlled ROP method, I successfully designed and 
incorporate a hydrolysis-labile amino ester linker to conjugated CPT to PLA with via a fully 
controlled manner. The resulting CPT-N-PLA conjugates were able to self-assemble into sub-
100nm-sized NCs with desired physicochemical properties, with accelerated release kinetics 
compared with our previous CPT-PLA NCs. I also demonstrated such improvement could 
contribute to the enhanced in vivo efficacy: the growth of Lewis lung carcinomas (LLCs) induced 
in C57BL/6 mice was significantly delayed compared with CPT-PLA NCs, without acute systemic 
toxicity. 
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CHAPTER 3 
SYNTHESIS AND FORMULATION OF DRUG-POLY(O-CARBOXYANHYDRIDES) 
NANOCONJUGATES  
 
 
3.1 Introduction 
I have reported the study in chapter 2 by using hydroxyl-containing therapeutic agents 
initiated ROP of LA to prepare drug-PLA NCs. However, this strategy has a few limitations and 
fail to meet the demand of wide spread utilities when applied to broad biomedical applications. 
One drawback of these drug-PLA conjugates is their lack of side-chain functionalities, which 
makes it difficult to conjugate active moieties to polymers or to tune the physicochemical 
properties of PLA-derived materials through side-chain modifications.1-4 In addition, to achieve 
high drug loading, it is essential to prepare drug-PLA conjugate with very short, low molecular 
weight (MW) PLA chain.5,6 However, nanoprecipitation of drug-PLA with lower MW results in 
enlarged size and reduced NC stability because of the decreased inter-chain interactions within the 
drug-PLA conjugates.7-9 Similar phenomenon is also observed when in vivo applicable NCs with 
stably surface-coated PEG are prepared via the co-precipitation of drug-PLA conjugate and 
mPEG-PLA.8,10,11 The low hydrophobic interactions between the low-MW drug-PLA and mPEG-
PLA lead to NCs with reduced stability of PEG shell, increased tendency of particle disassembly 
upon dilution post-injection, and increased possibility of particle aggregation because of depletion 
of the PEG shell. To prepare structurally stable NCs with low MW drug-polymer conjugates (thus 
high drug-loading), one possible solution is to increase the hydrophobic interactions between the 
polymer chains. However, the methyl groups on the side chains of PLA cannot be further modified, 
which makes it difficult to modulate the hydrophobicity/hydrophilicity. 
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Natural amino acids serve as a rich renewable resource for the preparation of biomaterials. 
Given the structural similarity between amino acids and α-hydroxyl acids, the attempt to synthesize 
1,3-dioxolane-2,5-dione (also called O-carboxyanhydrides (OCA)), a class of five-membered ring 
compounds derived from amino acids, has attracted tremendous interests.12-15 By utilizing this 
method, a handful of OCA monomers with considerable chemical functionalities could be easily 
synthesized in large scale and high purity, and can be polymerized to obtain side-chain functional 
polymers in a controlled manner. Thus, OCA derived from phenylalanine (Phe-OCA) was 
developed to generate new polymers bearing hydrophobic phenyl side chains which were further 
used to prepare in vivo stable anticancer camptothecin (Cpt)-Poly(Phe-OCA) NCs.16 I also 
anticipated that increased hydrophobicity of the polymer chain could result in enhanced non-
covalent chain-chain interactions of the drug-polymer conjugates and substantially improve the 
corresponding NC stability, which would allow formation of high drug-loading NCs, and 
tremendously improve their pharmacological properties. 
 
3.2 Materials and Methods 
3.2.1 General 
β-Diimine (BDI) ligands and the corresponding metal complex (BDI-EI)ZnN(TMS)2 were 
prepared by following the published procedure17 and stored at 30 oC in a glovebox. Anhydrous 
solvents were purified by alumina columns and kept anhydrous by using molecular sieves. 
Paclitaxel (Ptxl), docetaxel (Dtxl) and 20(S)-camptothecin (Cpt) were purchased from LC 
Laboratories (Woburn, MA, USA) and stored at 30 oC in a glovebox prior to use. Doxo·HCl was 
purchased from Bosche Scientific (New Brunswick, NJ, USA) and used as received.  Removal of 
HCl of Doxo·HCl was achieved by following the procedure reported in the literature.18 All other 
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chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA) and used as received unless 
otherwise noted. The molecular weights (MWs) of PheLAn were determined by gel permeation 
chromatography (GPC, also known as size exclusion chromatography (SEC)) equipped with an 
isocratic pump (Model 1100, Agilent Technology, Santa Clara, CA, USA), a DAWN HELEOS 
18-angle laser light scattering detector and an Optilab rEX refractive index detector (Wyatt 
Technology, Santa Barbara, CA, USA). The wavelength of the HELEOS detector was set at 658 
nm. The size exclusion columns (Phenogel columns 100, 500, 103 and 104 Å, 5 μm, 300 × 7.8 mm, 
Phenomenex, Torrance, CA, USA) used for the analysis of polymers or polymer-drug conjugates 
were serially connected on the GPC. The GPC columns were eluted with THF (HPLC grade) at 
40 °C at 1 mL/min. HPLC analyses were performed on a System Gold system equipped with a 
126P solvent module and a System Gold 128 UV detector (Beckman Coulter, Fullerton, CA, USA) 
equipped with a 126P solvent module, a System Gold 128 UV detector and an analytical C18 
column (Luna C18, 250 × 4.6 mm, 5 μ, Phenomenex, Torrance, CA, USA). The NMR studies were 
conducted on a Varian UI500NB system (500 MHz). The critical micelle concentration (CMC) 
was determined by a fluorescence spectrometer (Perkin Elmer LS55 fluorescence spectrometer, 
Wellesley, USA) with Nile Red as the fluorescence probe. The sizes and the size distributions of 
the PheLAn NCs were determined on a ZetaPALS dynamic light scattering (DLS) detector (15 mW 
laser, incident beam = 676 nm, Brookhaven Instruments, Holtsville, NY, USA).  Lyophilization 
of the NCs was carried out on a benchtop lyophilizer (FreeZone 2.5, Fisher Scientific, USA). The 
MCF-7 cells (ATCC, Manassas, VA, USA) used in the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay were cultured in Dulbecco’s modified Eagle medium (DMEM) 
containing 10% fetal bovine serum, 1000 units/mL aqueous penicillin G, and 100 μg/mL 
streptomycin. Female athymic nude mice (6-8 weeks) were purchased from National Cancer 
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Institute (NCI, Frederick, MD, USA). Ad libitum feeding was provided. Light was provided in a 
12/12-hour light/dark cycle. The study protocol was reviewed and approved by the Illinois 
Institutional Animal Care and Use Committee (IACUC) of University of Illinois at Urbana‒
Champaign. 
 
3.2.2 Preparation and characterization of Phe-OCA monomer.  
 L-Phenylalanine (4.1 g, 25 mmol) was diazotized with sodium nitrite (1.5 equiv, 37 mmol) in 
sulfuric acid efficiently provides pure 2-hydroxyl-3-pheynylpropanoic acid with satisfied yield 
(>75%). Condensation of the resulted α-hydroxyl acid with phosgene produced corresponding 1,3-
dioxolane-2,4-diones, so-called phenyl O-carboxyanhydrides (Phe-OCA). The produced Phe-
OCA is white crystal after recrystallization from THF:hexane (6:25, v/v) in glovebox with 
reasonable yield (>50%). 1H NMR (CDCl3, 500 MHz): δ 7.40 (t, 2H, Ar-H), 7.29 (d, 2H, Ar-H), 
7.27 (t, 1H, Ar-H), 5.18 (t, 1H, alpha-H), 2.93-3.19  (m, 2H,  -CH2-Ar). 13C NMR (CDCl3, 400 
MHz): δ 166.5, 148.0, 131.7, 129.9, 129.4, 128.6, 80.1, 36.6. ESI-MS (m/z): Calcd C10H8O4  192.0 
(M); found 193.1 (M+H)+. 
 
3.2.3. Preparation and characterization of Cpt-PheLAn conjugates 
In a glovebox, Cpt (3.5 mg, 0.01 mmol) was dissolved in anhydrous tetrahydrofuran (THF, 300 
L) and mixed with a THF solution (500 L) containing (BDI-EI)ZnN(TMS)2 (6.5 mg, 0.01 
mmol). The mixture was stirred for 15 min. Phe-OCA (192.4 mg, 100 equiv) was dissolved in 
THF (2 mL) and added to the stirred (BDI-EI)ZnN(TMS)2 and Cpt solution. The reaction 
proceeded in the glovebox overnight. The conversion of Phe-OCA was determined by FT-IR by 
monitoring the disappearance of Phe-OCA anhydride band at 1812 cm-1. After Phe-OCA was 
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completely consumed, the reaction was stopped by quenching the polymerization solution with 
cold methanol solution (300 L). The polymer was precipitated with ether (50 mL), collected by 
centrifugation and dried by vacuum.  The molecular weight and molecular weight distribution 
(MWD = Mw/Mn) of Cpt-PheLAn were accessed by GPC.  
 
3.2.4. Synthesis of mPEG5k-PheLAn diblock polymer 
A diblock polymer of mPEG5k-PheLAn was synthesized by following similar procedures as 
described in the Section 2.2 by using mPEG5k-OH as the initiator. In a glovebox, mPEG5k-OH (50 
mg, 0.01 mmol) solution in anhydrous dichloromethane (DCM, 800 L) was mixed with a DCM 
solution (500 L) containing  (BDI-EI)ZnN(TMS)2 (6.5 mg, 0.01 mmol). The mixture was stirred 
for 15 min. Phe-OCA (192.4 mg, 100 equiv) was dissolved in DCM at 50 mg/mL concentration 
and added to the stirred solution of mPEG5k-OH and (BDI-EI)ZnN(TMS)2. The reaction proceeded 
in the glovebox overnight. The conversion of Phe-OCA was determined by FT-IR by monitoring 
the disappearance of the Phe-OCA anhydride band at 1812 cm-1. After Phe-OCA was completely 
consumed, the reaction was stopped by quenching the polymerization reaction with cold methanol 
solution (300 L). The polymer was precipitated with ether (50 mL) collected by centrifugation 
and dried by vacuum. The molecular weight and MWD of the obtained mPEG5k-PheLAn were 
accessed by GPC (Mn = 26.0 kDa, MWD = 1.19).  
 
3.2.5. Synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-
PheLA25 NCs 
The NH2-PheLA25 conjugate was synthesized by following a similar procedure as described in the 
Section 2.3 by using ethanolamine as the initiator. In a reaction vial containing NH2-PheLA25 
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conjugates (23.5 mg, 0.004 mmol) was added an anhydrous dimethylformamide (DMF) solution 
(0.5 mL) of DOTA-NCS (2.2 mg, 0.018 mmol) and triethylamine (3.6 mg, 0.036 mmol). The 
reaction mixture was stirred for 4 h under nitrogen at rt. The solvent and triethylamine were 
removed under vacuum to give DOTA-PheLA25, which was used directly without further 
purification.  
 
3.2.6. General procedure for the preparation and characterization of drug-PheLAn 
nanoconjugates (NCs) 
Ptxl-PheLAn (Doxo-PheLAn or Dtxl-PheLAn) conjugate were prepared by following the similar 
procedure as described in the Section 2.2 by using the corresponding drug as the initiator for the 
polymerization of Phe-OCA in the presence of (BDI-EI)ZnN(TMS)2. A DMF solution of the drug-
PheLAn conjugate (100 μL, 10 mg/mL) was added dropwise to nanopure water (2 mL). The 
resulting drug-PheLAn NCs were collected by ultrafiltration (5 min, 3000 × g, Ultracel membrane 
with 10,000 NMWL, Millipore, Billerica, MA, USA), washed with water and then characterized 
by DLS for particle sizes and size distributions, and by HPLC for drug loadings by following the 
reported procedures.10,11 
 
3.2.7. Extraction of Cpt from NCs 
Cpt-PheLA25 NCs (1 mg) in water (1 mL) was treated with the NaOH solution (1 M, 1 mL) for 12 
h at rt. The pH value of Cpt-PheLA25 suspension was then tuned to 2 by phosphoric acid. The 
solution color turned yellow. The resulting solution was concentrated, and the released Cpt was 
collected and purified through semi-prep HPLC column (Jupitor, 250 × 21.20 mm, 10 μ, 
Phenomenex, Torrance, CA, USA). The mobile phase of HPLC was acetonitrile:water:TFA 
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(25:75:0.75, v/v/v). The collected yellow oily compound after removal of the solvents was 
dissolved in trace of phosphoric acid:methanol (1:1, v/v) solution (500 μL). The pH of the solution 
was tuned to 3-4 by NaOH (0.1 M). The resulting solution was extracted with chloroform (5 × 10 
mL). The organic phase was then dried by magnesium sulfate. After the organic solvent was 
evaporated, a slight yellow solid was obtained. The solid was analyzed by HPLC and its spectrum 
was compared with the authentic Cpt, showing that the released compound has identical elution 
time as to the authentic Cpt. 
 
3.2.8. Release kinetic study of Cpt-PheLAn NCs 
Cpt-PheLA25 NCs were prepared by nanoprecipitation as previously described. Cpt-PheLA25 (10 
mg, 0.002 mmol) was dissolved in DMF (1 mL) to prepare a stock solution of 10 mg/mL. The 
DMF solution of Cpt-PheLA25 (200 L) was dropwise added to a vigorously stirred water solution 
(4 mL). The NCs were collected and purified by ultrafiltration (5 min, 3000 × g, Ultracel 
membrane with 10,000 NMWL, Millipore, Billerica, MA, USA). The collected NCs were 
dispersed in human serum buffer (human serum:PBS=1:1, v/v, 5 mL), divided into 10 equal-
volume portions, and added to 10 eppendorf microcentrifuge tubes (500 μL NC solution in each 
tube). The tubes were incubated at 37°C. Complete release of Cpt from NC was predetermined by 
the hydrolysis mentioned above in the Section 2.6. At scheduled time points, two tubes were taken 
out, to which methanol (500 μL) was added to precipitate proteins. The precipitates were removed 
by centrifugation (5 min, 15000 × g). The supernatant then was injected into HPLC for analysis of 
the released Cpt. For the HPLC analysis, acetonitrile:water (containing 1% TFA) was used as 
mobile phase. The gradient for acetonitrile:water (containing 1% TFA) was changed linearly from 
25:75 to 75:25 over 30 min and then kept at 75:25 for 30 min and changed back to 25:75 over 5 
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min. the flow rate was 1.0 mL/min. Analytical C18 column (Luna C18, 250 × 4.6 mm, 5 μ, 
Phenomenex, Torrance, CA, USA) was used to perform the analysis. The integrated area of the 
Cpt peak was documented and compared with that of 100% released Cpt to determine the released 
Cpt.  
 
3.2.9. Formation and characterization of Cpt-PheLA100 NCs in human serum (50%) 
A Cpt-PheLA100 DMF solution (100 L, 10 mg/mL) was dropwise added into nanopure water (2 
mL) (DMF:water = 1:20, v/v). The obtained NCs were dispersed in human serum buffer (human 
serum:PBS = 1:1, v/v). The particle sizes were measured by DLS and followed over 60 min. 
 
3.2.10. Lyophilization of Cpt-PheLA100 NCs with human serum albumin (HSA) 
A Cpt-PheLA100 DMF solution (100 L, 10 mg/mL) was dropwise added to vigorously stirred 
nanopure water (2 mL). The resulting NCs were analyzed by DLS.  Human serum albumin (HSA) 
was then added into the NC solution.  The mixture was lyophilized for 16 h at -50 °C to obtain a 
white powder.  The white powder was reconstituted in nanopure water (2 mL) and the solution 
was stirred for 5 min at rt. The resulting NC solution was analyzed by DLS to assess NC size and 
size distribution. 
 
3.2.11. Determination of the critical micelle concentration (CMC) of mPEG5k-PheLA100 and 
mPEG5k-PLA100 
CMC of mPEG5k-PheLA100 and mPEG5k-PLA100 were determined using Nile Red (Sigma, St Louis, 
MO, USA) as an extrinsic probe. Serial solutions with fixed Nile Red concentration of 6 × 10-7 M 
and various concentrations of mPEG5k-PheLA100 and mPEG5k-PLA100 between 3.9 × 10
-5 and 0.5 
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mg/mL were prepared. Fluorescence spectra were obtained at rt. Fluorescence measurements were 
taken at an excitation wavelength of 557 nm and the emission monitored from 580 to750 nm. 
Excitation and emission slit widths were both maintained at 10.0 nm and spectra were accumulated 
with a scan speed of 500 nm/min.   
 
3.2.12. Determination of the cytotoxicity of Cpt-PheLAn NCs 
MCF-7 cells were placed in a 96-well plate for 24 h (10,000 cells per well). Cells were washed 
with prewarmed PBS (100 μL). Freshly prepared Cpt-PheLA25, Cpt-PheLA50, and Cpt-PheLA100 
NCs (prepared in 1 × PBS, 100 μL) were added to the cells. Cpt was used as a positive control. 
Untreated cells and PheLA NPs without Cpt were used as negative controls in this MTT assay. The 
Cpt-PheLAn NCs (n = 25, 50 and 100) were applied to MCF-7 cells at a concentration up to 0.5 
μg/mL. The cells were incubated for 72 h in a 5% CO2 incubator at 37 °C. The standard MTT 
assay protocols were followed thereafter.  
 
3.2.13. 64Cu labeled PheLA25 NCs 
The 64Cu chloride (300 µCi, obtained from Washington University at St. Louis, MO, USA) was 
mixed with PEGylated DOTA-PheLA25 NCs (20 mg) in NH4OAc buffer (pH = 5.5, 0.1 M, 0.5 
mL).  The mixture was incubated for 1 h at 60 °C. To determine the labeling efficiency, the NPs 
were washed by ultrafiltration (10 min, 3000 × g, Ultracel membrane with 10 000 NMWL, 
Millipore, Billerica, MA, USA), and the radioactivity in the supernatant and the NP solution was 
measured at different time points respectively . The purified 64Cu-labelled PheLA25 NCs were used 
for injection.      
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3.2.14. In vivo biodistribution study of 64Cu-labelled PheLA25 NCs 
Six female athymic nude mice bearing MCF-7 human breast cancer xenografts (6-8 weeks) were 
divided into two groups (n = 3), minimizing the weight differences. The two groups of mice were 
treated with 64Cu-labelled mPEG5k-PLA100 NPs and 
64Cu-labelled mPEG5k-PheLA100 NPs at a dose 
of 35 µCi intravenously, respectively. Mice were euthanized 24 h post injection. The major organs 
(liver, spleen, kidney, heart, and lung), as well as MCF-7 subcutaneous tumors were collected, 
weighed and measured for radioactivity (64Cu) with a γ-counter (Wizard2, Perkin-Elmer, USA) 
using appropriate energy window centered at photo peak of 511 keV.  Raw counts were corrected 
for background, decay, and weight. Corrected counts were converted to microcurie per gram of 
tissue (μCi/g) with a previously determined calibration curve by counting the 64Cu standards 
(Figure S6b). The activity in each collected tissue sample was calculated as percentage of the 
injected dose per gram of tissue (% I.D./g).  For this calculation, the tissue radioactivity was 
corrected for the 64Cu decay (T(1/2)=12.7 h)  to the time of γ-well counting. 
 
3.2.15. Pharmacokinetic Study of 64Cu labeled PheLA25 NCs 
Six female athymic nude mice (6-8 weeks) were divided into two groups (n = 3), minimizing the 
weight differences. The two groups of mice were treated with 64Cu-labelled mPEG5k-PLA100 NPs 
and 64Cu-labelled mPEG5k-PheLA100 NPs intravenously at a dose of 35 µCi, respectively. Blood 
was collected intraorbitally from mice at scheduled time points (0 h, 0.5 h, 1 h, 2 h, 5 h, 10 h and 
22 h) for pharmacokinetic profiling. The collected blood samples were weighed and measured for 
radioactivity (64Cu) with a γ-counter (Wizard2, Perkin-Elmer, USA) using appropriate energy 
window centered at photo peak of 511 keV. Raw counts were corrected for background, decay, and 
weight. Corrected counts were converted to microcurie per gram of tissue (μCi/g) with a previously 
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determined calibration curve by counting the 64Cu standards (Figure S6b). The activity in each 
collected blood sample was calculated as percentage of injected dose per gram of blood (% I.D./g). 
For this calculation, the blood radioactivity was corrected for the 64Cu decay to the time of γ-well 
counting. 
 
3.2.16. In vivo biocompatibility study of Cpt-PheLA25 NCs 
Six female athymic nude mice (6-8 weeks) were divided into two groups (n = 3), minimizing the 
weight differences. In 3 mice, mPEG5k-PheLA100 NPs were administered intravenously (200 L, 
25 mg/mL) via lateral tail vein at a dose of 250 mg NC/kg. The other 3 mice received intravenous 
PBS, and served as a sham control group. The animals were euthanized 24 h later by carbon 
dioxide. Organs including heart, lung, liver, spleen, kidney, and intestine were collected following 
by flash freezing in optimum cutting temperature (O.C.T.) compound (Sakura Finetek USA, 
Torrance, CA, USA). Tissues were sectioned using cryostat at the thickness of 10 m, stained with 
hematoxylin and eosin for microscopic examination. Characterization of all the collected tissues 
for inflammatory cell infiltrate including macrophages and neutrophils were performed by 
Nanozoomer Digital Pathology System (Hamamatsu) at 20 × magnification and analysed by an 
independent pathologist. 
 
Statistical Analyses 
Student’s t-test comparisons at 95% confidence interval were used for statistical analysis. The 
results were deemed significant at 0.01 < *p  0.05, highly significant at 0.001 < **p  0.01, and 
extremely significant at ***p  0.001.  
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3.3 Results and Discussion 
3.3.1 Synthesis and characterization of phenyl O-carboxyanhydrides (Phe-OCA) 
The OCA can be synthesized from L-phenylalanine in a large scale with high purity. The 
diazontization of L-phenylalanine with sodium nitrite provided pure 2-hydroxyl-3-
pheynylpropanoic acid with satisfactory yield (>75%). Condensation of the resulting α-hydroxyl 
acid with phosgene by following the reported procedures19 produced the corresponding 1,3-
dioxolane-2,4-diones, or phenyl O-carboxyanhydrides (Phe-OCA). Phe-OCA was obtained in high 
yield (>50%) as white crystalline solid after recrystallization in a glovebox (Scheme 2.1) and 
characterized by 1H NMR (Figure 3.1).  
 
 
                                 Scheme 3.1. Synthesis of PheOCA from L-phenylalanine.  
 
 
 
 
Figure 3.1. 1H NMR spectra of Phe-OCA in CDCl3. 
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Figure 3.2. 13C NMR spectrum of Phe-OCA in CDCl3. 
 
3.3.2 Organo- and metal catalysts for polymerization of Phe-OCA 
Previous studies regarding the polymerizations of OCAs have been entirely based on 
DMAP as the catalyst.13-15 However, no polymerization of Phe-OCA was observed when DMAP 
was used as the catalyst and Cpt was used as the initiator, presumably due to the low reactivity of 
the tertiary 20-OH of Cpt and increased steric encumbrance of the Phe-OCA compared to Ala-
OCA. Thus, I attempted to use more reactive metal catalysts as what we previously used in drug-
initiated lactide polymerization and functional group transformation.  
It is known that a metal alkoxide (MOR) can be prepared in situ by mixing a hydroxyl 
containing compound (R-OH) with a metal-amino complex and subsequently used to initiate ROP 
of cyclic esters.8,10,11,20 I first tested the feasibility of forming Cpt-metal complex. (BDI-
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EI)ZnN(TMS)2 (Scheme 3.2), an active catalyst developed by Coates and coworkers for the 
polymerization of LA, was dissolved in THF to give a colorless solution. When this solution was 
added to a vial containing Cpt powder (1 equiv relative to (BDI-EI)ZnN(TMS)2), and the mixture 
was stirred for 20 min, Cpt was completely dissolved and the color of the solution gradually turned 
to orange. In the absence of (BDI-EI)ZnN(TMS)2, however, Cpt remained insoluble in THF and 
there was no color change of the solution. The sharp contrast of the solubility of Cpt in the presence 
and absence of (BDI-EI)ZnN(TMS)2 and the color change after Cpt was mixed with (BDI-
EI)ZnN(TMS)2 suggested that there was a reaction between Cpt and (BDI-EI)ZnN(TMS)2 and 
(BDI-EI)Zn-Cpt alkoxide was possibly formed (Scheme 3.3). When 25-equiv Phe-OCA was 
added to the mixture of (BDI-EI)ZnN(TMS)2/Cpt, Phe-OCA polymerization was observed to 
proceed rapidly and completed in 12 h with >98% OCA conversion. The conversion of Phe-OCA 
was determined by FT-IR with monitoring the disappearance of anhydride band at 1812 cm-1 
(Figure 3.3). The Mn of the resulting Cpt-poly(Phe-OCA)25, or Cpt-PheLA25, was 4.3  103 g/mol, 
which was in excellent agreement with the expected MW (3.9  103 g/mol) (entry 1, Table 3.1).  
Controlled polymerizations were also observed for polymerization at Phe-OCA/Cpt ratios of 50 
and 100 (entry 2 and 3, Table 3.1).  The MWs followed a linear correlation with the Phe-OCA/Cpt 
ratios (Figure 3.4a). All three drug-polymer conjugates had narrow molecular weight distributions 
(MWDs) (Table 3.1), evidenced by their monomodal GPC curves (Figure 3.4b). In addition, in 
order to confirm the successful conjugation of Cpt to the polymer chain by the ROP strategy, we 
prepared Cpt-PheLA15 and analyzed its end group by MALDI-TOF MS (Figure 3.5). The result 
clearly showed that Cpt was convalently conjugated to the PheLAn. To study whether this strategy 
could be also applied to other hydroxyl group-containing therapeutic reagents, I selected paclitaxel 
(Ptxl), doxorubicin (Doxo) and docetaxel (Dtxl) (Scheme 3.4), and evaluated their capability of 
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initiating the ROP of Phe-OCA in the presence of (BDI-EI)ZnN(TMS)2 . When mixed with (BDI-
EI)ZnN(TMS)2, all these tested drugs could initiate controlled ROP of PheOCA with nearly 100% 
drug incorporation efficiency and 100% monomer conversion (Table 3.2).   
                                     
                                                            
Scheme 3.2. Schematic illustration of structure of (BDI-EI)ZnN(TMS)2 catalyst.     
 
 
           
 
Scheme 3.3. Schematic illustration of (BDI-EI)ZnN(TMS)2/Cpt  mediated ring-opening 
polymerization (ROP) of Phe-OCA followed by formulation of Cpt-PheLAn nanoconjugates (NCs, 
n = the feed ratio of Phe-OCA/Cpt) using nanoprecipitation. 
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        Figure 3.3. FT-IR spectra of Cpt initiated polymerization of Phe-OCA at 3 h, 5 h and 12 h. 
 
 
         
 Figure 3.4. (a) (BDI-EI)ZnN(TMS)2/Cpt mediated controlled ring-opening polymerization (ROP) 
of Phe-OCA at various Phe-OCA/Cpt ratios (MWD = molecular weight distribution). (b) Overlay 
of the GPC traces of Cpt-PheLAn (n = 25, 50 and 100). 
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Figure 3.5. MALDI-TOF MS analysis of Cpt-PheLAn. The obtained m/z is identical to the 
calculated m/z of (Cpt-PheLAn + Na) (348.11 + 148.06 × n + 23). 
 
 
 
Scheme 3.4. Chemical structures of hydroxyl-containing paclitaxel, doxorubicin and docetaxel.   
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Table 3.1.  Polymerization of Phe-OCA mediated by (BDI-EI)ZnN(TMS)
2
/Cpt. 
 
 
a
 All reactions were performed in glovebox. Abbreviation: Temp.= temperature,  Conv.% =  
conversion of monomer %,  MWD = Molecular weight distribution. 
b
Determined by FT-IR  by 
monitoring the disappearance of Phe-OCA anhydride peak at 1820-1800 cm
-1
. 
c
Determined by gel 
permeation chromatography (GPC). dn /dc = 0.63 based on the 100% mass recovery dn /dc 
program determination by GPC (ASTRA 5). 
 
Table 3.2. Characterization of drug-PheLAn NCs prepared by Phe-OCA polymerization 
mediated by (BDI-EI)ZnN(TMS)2 and other hydroxyl containing therapeutics. 
 
a
Abbreviation: NC = nanoconjugates, NP = nanoparticles, M/I = monomer/initiator ratio, Eff = 
incorporation efficiency, the percent of therapeutic agent utilized in the initiation of Phe-OCA 
polymerization, PDI = polydispersity derived from particle size using dynamic light-scattering; 
Ptxl=Paclitaxel; Doxo=Doxorubicin; Dtxl = Docetaxel. NCs are named as drug-PheLA
M/I
, [b] and 
[c] based on the reversed-phase HPLC analysis of unincorporated drug. [d] characterized using 
dynamic light-scattering. 
 
3.3.3 Physicochemical properties of Cpt-PheLA nanoconjugates 
Entry a R-OH [M]/[Cat.] Temp. Time(h) Conv (%) b
Mn cal
(×103g/mol) 
Mn
(×103g/mol) c
MWD 
(Mw/Mn) 
c
1 Cpt 25/1 rt 12 >98 3.9 4.3 1.19
2 Cpt 50/1 rt 12 >98 7.5 7.9 1.15
3 Cpt 100/1 rt 12 >98 15.1 15.4 1.17
4 mPEG5k 100/1 rt 12 >98 19.9 26.0 1.19
Entrya Name Drug M/I ratio Eff (%)b Loading (%)c Size (nm)d PDIe
1 Ptxl-PheLA100 NC Ptxl 100 >98 5.4 84 0.09
2 Ptxl-PheLA50 NC Ptxl 50 >98 10.3 65 0.13
3 Ptxl-PheLA25 NC Ptxl 25 >98 18.7 72 0.13
4 Doxo-PheLA25 NC Doxo 25 >98 10.3 75 0.10
5 Dtxl-PheLA25 NC Dtxl 25 >98 16.1 78 0.10
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Drug loading, particle size, and release kinetics are critical properties of a nanoparticulate 
drug delivery system.21-23 Polymeric NPs are typically prepared via co-precipitation of polymer 
and drugs.24,25 However, the drug loadings of polymeric NPs prepared from conventional co-
precipitation of polymer and drug can be very low.26 For instance, I used Cpt/mPEG-PheLA100 
(5:95, wt/wt) to prepare Cpt-containing NPs and obtained Cpt/mPEG-PheLA100 NP with diameter 
of 134 nm and a fairly large polydispersity of 0.27 (entry 4, Table 3.3).  The drug loading was 
only 1.4% with the loading efficiency as low as 28.1%.  When Cpt and mPEG-PheLA100 were 
mixed at a ratio of 25:75 (wt/wt) in attempts to increase drug loading, the drug loading of the 
resulting Cpt/mPEG-PheLA100 NP remained unchanged (1.4%, entry 5, Table 3.3); the loading 
efficiency further decreased the 5.5%, substantiating that it is impossible to increase drug loading 
of an encapsulated polymeric NP by simply mixing more drug with polymer. Furthermore, 
unencapsulated Cpt tends to be self-aggregated and resulted in heterogeneous compositions, 
evidenced by the observation of larger particles around 250-300 nm in addition to the Cpt-
encapsulated mPEG-PheLA100 NP at 100-125 nm (Figure 3.6). In contrast, NPs prepared from 
Cpt-PheLAn conjugates, termed nanoconjugates (NCs), successfully addressed all these issues. For 
the polymerization at PheLA-OCA/Cpt ratios of 25:1, 50:1 and 100:1, no free Cpt was detected in 
the polymer solution after the polymerization was complete (ii, Figure 3.7), indicating 100% drug 
incorporation efficiency. No Cpt release was observed during nanoprecipitation of Cpt-PheLAn 
conjugates, the drug loading efficiency of Cpt-PheLAn NCs were essentially 100% (entries 1-3, 
Table 3.3).  The drug loadings of NCs can be pre-determined by PheLA-OCA/Cpt ratios used for 
polymerization.  At the PheLA-OCA/Cpt ratio of 25, Cpt-PheLA25 NC drug loading is 8.5%, 6 
times higher than that of Cpt/PheLA NPs (entries 3 vs. 5, Table 3.3). NCs with sub-100 nm size 
and narrow size distributions were obtained (entry 1-3, Table 3.3; Figure 3.8). The narrow size 
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distributions of NCs were in sharp contrast to the multimodal particle distributions observed in the 
Cpt-encapsulated PheLA NPs (Figure 3.6), which could be attributed to the quantitative drug 
incorporation and well-defined structure of Cpt-PheLAn conjugates which excluded the possibility 
of self-aggregation of Cpt and consequently reduced heterogeneities (Figure 3.8; Figure 3.6). Cpt 
was conjugated to the PheLA polymer through ester linkage and could be released from NPs 
subjected to the hydrolysis of ester bond in the physiological conditions. To better mimic the 
physiological conditions, I performed the release kinetic study of Cpt from Cpt-PheLAn NCs in 
the 50% human serum buffer. The release kinetics of Cpt from Cpt-PheLAn NCs was correlated 
with the drug loading (polymer chain length) (Figure 3.9). The lower the drug loading (longer 
Cpt-PheLAn polymer chain), the slower the drug release, presumably because longer polymer 
chains resulted in stronger hydrophobic interactions which made it more difficult for the access of 
Cpt-PheLAn ester linkages to aqueous environment for Cpt release via hydrolysis.  In all three NCs 
tested, no burst release was observed while Cpt molecules were completely released from Cpt-
encapsulated mPEG-PheLA100 NP within 24 h (Figure 3.9). In order to facilitate potential clinical 
application and minimizing drug release prior to use, it is desirable to formulate NCs in solid 
form.26 Our group previously reported that albumin could function as lyoprotectants to prevent 
PLA-based NCs from aggregation during lyophilization.27  Therefore, I attempted to use human 
serum albumin (HSA) as lyoprotectants of Cpt-PheLAn NC solid formulation. Figure 3.10 
demonstrated that HSA could effectively protect solid form of Cpt-PheLAn NCs from aggregation; 
the lyophilized Cpt-PheLA NC100 NCs redispersed in aqueous solution maintained narrow particle 
size distribution and nearly identical size as the parental NCs. 
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Table 3.3. Characterization of Cpt-PheLA
n
 NCs prepared by Phe-OCA polymerization mediated 
by (BDI-EI)ZnN(TMS)
2 
versus NPs obtained by conventional Cpt/polymer encapsulation
a
 
 
a
Abbreviation: NC=Nanoconjugates; NP=Nanoparticles; Encap.=Encapsulation; 
Conj.=Polymerization and nanoprecipitation; M/I = monomer/initiator ratio; Wt feeding = weight 
feeding of Cpt/polymer; Eff = for nanoconjugates, which is incorporation efficiency, the percent 
of therapeutic agent utilized in the initiation of Phe-OCA polymerization and for NPs, which is 
encapsulation efficiency; PDI=polydispersity derived from particle size using dynamic light-
scattering; Cpt=Camptothecin. NCs are named as Cpt-PheLA
M/I
, NPs are named as drug
wt feeding% 
/ mPEG-PheLA100. [b] and [c] based on the reversed-phase HPLC analysis of unincorporated drug. 
[d] characterized using dynamic light-scattering. 
 
 
 
Figure 3.6. Dynamic light scattering (DLS) spectra of Cpt-PheLA
100
 NCs prepared by 
nanoprecipitation in water (0.5 mg/mL) and Cpt
5%
/mPEG-PheLA
100
 NPs prepared by 
encapsulation in water (0.5 mg/mL).  
 
Entrya Name Method
M/I ratio or Wt
feeding%
Eff (%)b
Loading 
(%)c
Size (nm)d PDIe
1 Cpt-PheLA100 NC Conj. 100 >95 2.3 94 0.09
2 Cpt-PheLA50 NC Conj. 50 >95 4.5 82 0.10
3 Cpt-PheLA25 NC Conj. 25 >95 8.5 93 0.12
4 Cpt5/ mPEG-PheLA100 NP Encap. 5 28.1 1.4 134 0.27
5 Cpt25/ mPEG-PheLA100 NP Encap. 25 5.5 1.4 176 0.38
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Figure 3.7. HPLC analysis of Cpt-initiated polymerization and release of Cpt from Cpt-PheLA100 
NCs. (i) authentic Cpt. (ii) the Phe-OCA polymerization solution (M/I = 100) mediated by (BDI-
EI)ZnNTMS and Cpt.  (iii) Cpt released from Cpt-PheLA100 NCs treated with 1 M NaOH for 12 
h. 
 
 
 
 
Figure 3.8. Dynamic light scattering (DLS) analysis of Cpt-PheLA100 NCs in water (0.5 mg/mL) 
and TEM image of Cpt-PheLA100 NCs (negative stained). 
 
 
(a)
(b)
25 30 35
Cpt-PheLA
50
Cpt-PheLA
25
Elution time (min)
Cpt-PheLA
100
0 50 100
0
5
10
15
0
5
10
15
M
W
D
 
 
 
 
 M
n
 MWD
Phe-OCA/Cpt
M
o
le
c
u
la
r 
W
e
ig
h
t 
(x
1
0
3
g
/m
o
l)
expected
obtained
i
ii
iii
Free Cpt
Released Cpt
Cpt-PheLA100
(c)
(a)
(c) (d)
50 100 150 200 250 300 350
 
D = 94 nm PDI = 0.086
Particle size (nm)
0 50 100 150 200 250 300
0 50 100 150 200 250 300
(ii) D = 120 nm 
PDI = 0.005
Particle size (nm)
D = 97 nm 
PDI = 0.126
(i)
100 nm
(b)
0
300
600
3000
3500
IC
5
0
 V
a
lu
e
  
(n
M
)
Fr
ee
 C
pt
 
C
pt
-P
he
LA
25
C
pt
-P
he
LA
50
C
pt
-P
he
LA
10
0
38 nM
116 nM
711 nM
3326 nM
0 1 2 3 4 5
0
20
40
60
80
100
C
p
t 
R
e
le
a
s
e
d
 (
%
)
Time (Day)
 Cpt-PheLA
100
 NCs
 Cpt-PheLA
50
 NCs
 Cpt-PheLA
25
 NCs
 Cpt/mPEG-PheLA NP
55 
 
 
Figure 3.9. Release kinetic profiles of Cpt-PheLAn NCs (n = 25, 50 and 100) versus Cpt/mPEG-
PheLA100 encapsulated NPs in human serum buffer (human serum:PBS = 1:1, v/v). 
 
 
 
 
 
 
Figure 3.10. DLS analysis of NC reconstitution.  (i) Cpt-PheLA100 NCs mixed with human serum 
albumin (HSA) in water before lyophilization. (ii) The reconstituted Cpt-PheLA100 NCs after 
lyophilization in the presence of HSA (HSA:NC = 10:1, w/w). 
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dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays in MCF-7 cells, are 116, 711, and 
3326 nM, respectively. The IC50 value of Cpt–PheLA25 NC is about 3 times higher than that of 
free Cpt (38 nM), while the IC50 value of the Cpt–PheLA100 NC is two orders of magnitude higher. 
As a result, the toxicity of the NCs can be tuned in a wide range simply by controlling NC drug 
loading.  
 
3.3.5 Stability evaluation of Cpt-PheLA NCs  
I next compared the difference of PheLA based NCs with PLA based NCs and first 
evaluated their stability in human serum. Surface modification of NPs with poly(ethylene glycol) 
(PEG) is widely used for prolonged systemic circulation, reduced aggregation of NPs in blood,28 
and suppressed nonspecific absorption of protein.29 To reduce the efforts of removing unreacted 
reagents and by-products, I attempted to use non-covalent approach to PEGylate NC surface 
instead of covalently conjugating PEG to NCs.30,31  I used mPEG-PheLA100, an amphiphilic 
copolymer that has a PheLA block of 21 kDa and mPEG segment of 5 kDa,32 to PEGylate Cpt-
PheLA25 NCs.  It is expected that the PheLA block of mPEG-PheLA100 could form strong 
interaction with NCs through hydrophobic interaction to create a stable PEG shell. Similar 
approach has been used previously in NP surface PEGylation.33 Dropwise addition of the mixture 
of mPEG-PheLA100 and Cpt-PheLA25 to fast stirring nanopure water resulted in rapid PEG coating 
of Cpt-PheLA25 NCs.  The resulting PEG coated NCs likely formed the core-shell nanostructure 
with hydrophobic Cpt-PheLA25 as the core and PEG as the shell, and the particle size remained 
unchanged in 50% human serum buffer for 5 days (Figure 3.11a) . In comparison, the size of 
PEGylated Cpt-LA25 NCs prepared by same strategy with mPEG-LA100 was found to increase from 
122 nm to 175 nm under the same condition (Figure 3.11a), presumably due to the slow depletion 
57 
 
of PEG shell from the mPEG-PLA/Cpt-LA25 NC surface.  This study suggests that increased 
polymer chain-chain interaction can indeed improve the surface PEGylation stability and 
facilitates NCs’ in vivo application.  Because PheLAn has stronger hydrophobic interaction than 
LAn, and the corresponding PheLAn NPs should be more stable against dilution and has a relatively 
low critical micelle concentration (CMC). The CMC of mPEG-LA100 NP was determined to be 
0.045 mg/mL.  As expected, the CMC of mPEG-PheLA100 NP was 50% lower (0.022 mg/mL) 
(Figure 3.11b).  Upon 100 time dilution the mPEG-LA100 NP size increased by 30% from 110 nm 
to 143 nm, while mPEG-PheLA100 NP size only increased by 10% from 108.8 nm to 119.9 nm 
(Figure 3.11c). Thus, under a dilute condition when mPEG-LA100 NP is completely dissembled, 
mPEG-PheLA100 NP might still keep its nanostructures as illustrated in Figure 3.11d. 
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Figure 3.11. (a) Stability of PEGylated Cpt-PheLA25 NCs versus PEGylated Cpt-PLA25 NCs in 
human serum buffer (human serum:PBS = 1:1, v/v). (b) CMC determination of mPEG5k-PheLA100 
and mPEG5k-LA100. Intensity of Nile Red versus concentrations of mPEG5k-PheLA100 and 
mPEG5k-PLA100. The CMC was determined by taking the midpoint in the plots, which was 2.2 × 
10-2 mg/mL and 4.5 × 10-2 mg/mL, respectively. (c) The particle size changes of PEGylated 
PheLA100 NPs and PEGylated LA100 NPs with/without dilution as determined by dynamic light 
scattering (DLS). The original concentration of NP was 0.5 mg/mL. (d) Proposed changes of core-
shell nanostructure of PEGylated PheLAn and PEGylated LAn NPs upon dilution after injection 
into the body: (i) PEGylated PheLAn NPs, stable micellar structure due to enhanced non-covalent 
interactions (hydrophobic interactions and π-π stacking) in the polymeric core preventing rapid 
dissolution of core-shell nanostructure in vivo. (ii) PEGylated LAn NPs, loosely packed polymeric 
core disrupted upon dilution. Orange star = drug cargos; blue line = PheLA/PLA polymer chain; 
green line = PEG.   
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I then evaluated whether increased stability of PheLA NP PEGylation would lead to 
prolonged in vivo circulation and enhanced pharmacological performance by comparing the 
pharmacokinetics (PK) and in vivo biodistribution of PEGylated PheLA NCs and PLA NCs. For 
the PK study, 64Cu-labeled PEGylated PheLA100 NPs and 
64Cu-labeled PEGylated LA100 NPs 
(Figure 3.12a) were injected into mice (n = 3) through tail vein intravenous (i.v.) injection, 
respectively. At predetermined time points, a small volume of blood was taken from orbital sinus 
and collected for quantitative measurements. Concentrations of PEGylated PheLA100 NPs in the 
blood within the first five hours post-injection were nearly twice as much as the PLA counterparts 
(p < 0.05 at t = 1 and 2 h and p < 0.01 at t = 5 h), showing that PEGylated PheLA NPs were cleared 
from blood much slower than PEGylated LA100 NPs (Figure 3.12b).  For the in vivo biodistribution 
study, 64Cu-labeled PEGylated PheLA100 NPs and 
64Cu-labeled PEGylated PLA NPs (50 mg/kg) 
were injected via lateral tail vein injection into MCF-7 human breast cancer bearing athymic nude 
mice (n = 3), respectively. Twenty four hours post injection, normal and tumor tissues were 
harvested and the 64Cu radioactivities in the liver, heart, spleen, kidney, lung, blood, and tumor 
tissues were assessed and normalized against the total injected dose and tissue mass (%I.D./g) 
(Figure 3.12c).  The majority of NPs accumulated in the liver and the spleen; while lesser 
concentrations of NPs were localized in the respiratory and the urinary systems. PEGylated 
PheLA100 NPs showed improved tumor accumulation by 50% compared to PEGylated LA100 NPs 
(Figure 3.12c).  
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Figure 3.12. (a) Schematic illustration of synthesis and formulation of 64Cu-labelled PEGylated 
PheLA NPs and PLA NPs. (b) Six athymic nude mice were divided into two groups (n = 3) and 
injected 64Cu-labelled PEGylated PheLA100 NPs and 64Cu-labeled PEGylated PLA100 NPs via i.v. 
injection, respectively. Mice were taken blood intraorbitally at different time points (0 h, 0.5 h, 1 
h, 2 h, 5 h, 10 h, and 22 h) and the radioactivity in blood was determined using γ-counter. 
Statistical significance analysis were assessed by Two-Sample Unpaired Student’s t-test; 0.01 < p 
≤ 0.05 and p ≤ 0.01 are considered statistically significant and highly significant and are denoted 
as “*” and “**” respectively, in the figure. (c) Six athymic nude mice were divided into two groups 
(n = 3) and injected 64Cu labelled PEGylated PheLA100 NPs and PLA100 NPs via i.v. injection, 
respectively.  Mice were euthanized after 24 h and the major organs were collected.  The 
radioactivity in each organ was determined using γ-counter. The fidelity of utilizing γ-counter 
for quantitative radioactivity analysis in biological tissues was verified in a series of control studies. 
All the organ distribution were presented as percentage of injected dose per gram of tissue (% 
I.D./g tissue). 
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3.3.6 Safety evaluation of Cpt-PheLA NCs  
The safety profile of PheLA NP is one of significant parameters to determine its potential 
for drug delivery applications.34 To evaluate it, I first used MCF-7 cells to perform the MTT assay 
to determine the toxicity of the PheLA NPs. Figure 3.13a showed cell viability results of PheLA100 
NPs and PEGylated PheLA100 NPs after 72-h incubation at 37 
oC. As expected, both NCs did not 
show noticeable toxicities at a concentration up to 10 mg/mL, which is much higher than in vivo 
used NP concentration. Acute in vivo toxicity experiments were also performed after i.v. 
administration of PEGylated PheLA100 NPs in athymic nude mice at very high dose of 250 mg/kg. 
Mice treated with PBS were set as a control group. There was no mortality observed in any group. 
In addition, there were no treatment related clinical signs and change of body weights of the mice. 
Representative sections of various organs taken 24 h post-injections from the control mice 
receiving PBS and the mice receiving PEGylated PheLA100 NPs were stained by hematoxylin and 
eosin, and evaluated by an independent pathologist (Figure 3.13b). The absence of immune or 
inflammatory reactions after NP administration supports their lack of toxicity.
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Figure 3.13. (a) Cytotoxicity of blank PheLA100 NPs and PEGylated PheLA100 NPs in MCF-7 
cells over 72 h at 37oC, determined by MTT assays. (b) Histopathology analysis of mouse tissues 
following an i.v. injection of PEGylated PheLA100 NPs via tail vein. Representative sections of 
various organs taken from the control mice receiving PBS and the treatment mice receiving 250 
mg/kg PEGylated PheLA100 NPs 24 h post injection were stained by hematoxylin and eosin. No 
organs of the mice given PEGylated PheLA100 NPs showed acute inflammations.   
 
 
3.4 Conclusions 
In conclusion, I developed a strategy of using Cpt-initiated controlled ROP of Phe-OCA 
followed by nanoprecipitation to prepare Cpt-PheLA NCs, a class of PLA-like NPs with enhanced 
polymer hydrophobicity and drug covalently conjugated to the polymers via ester linkages. NCs 
with well-controlled properties such as predefined drug loadings, quantitative loading efficiencies, 
controlled release kinetics without “burst” release, and narrow size distributions are readily 
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obtainable.   This strategy can be applied to the conjugation of numerous other hydroxyl-containing 
drugs to polyester NPs, among which include paclitaxel, doxorubicin and docetaxel demonstrated 
in this study. The PEGylated PheLA NPs exhibited enhanced stability in human serum and dilute 
solution compared to PLA based NPs, and thereby efficiently reduced premature disassembly in 
circulation. Enhanced surface PEGylation facilitated protracted in vivo circulation of PheLA NPs 
and subsequently increased their accumulation in tumors. The PheLA NCs are novel, 
biocompatible nanoparticlulate delivery vehicles that can potentially be used for drug delivery 
applications. 
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CHAPTER 4 
TARGETED DRUG-POLY(O-CARBOXYANHYDRIDE) NANOCONJUGATES 
THROUGH ALBUMIN BINDING 
 
4.1 Introduction 
Nanoparticle (NP) based therapeutics holds great promise for cancer treatment due to the 
fact that the multiple functions can be built onto the single entity.1-3 One of these functions is 
including the specific tumor targeting in the body.4-6 However, irregular blood flow in tumors 
contributes to heterogeneous delivery and biodistribution, thus complicating the effectiveness of 
NP-based therapies. To efficiently targeting the tumors, one of widely accepted strategy is that the 
NP extravasate from the leaky tumor blood vessels and preferentially accumulate in the tumor 
tissues by enhanced permeability and retention (EPR) effect. 2,7,8 
To fully take advantage of EPR effect, the NPs with elongated circulation the bloodstream 
are desirable.9-11 However, the NPs always get eliminated from circulation rapidly after being 
systemically administrated because the uptake by the reticuloendothelial system (RES).12 To 
overcome this drawback, using poly(ethylene glycol) as surface modification of NPs, known as 
PEGylation, has been widely applied to reduce non-specific protein binding and avoid 
opsonization because of a combination of steric hindrance related to the polymer flexibility and 
hydrophilicity.9,11,13-15 While PEG has been successfully used for surface protection of NPs, more 
and more recent studies have reported that the PEGylation largely reduced the interaction of 
nanomaterials and living organism, thus leads to the low accumulation in the tumor tissues, 
sometimes even less than 1% of totally injected NPs reach the tumor target, which significantly 
diminishes the efficacy of therapeutics. Moreover, PEGylated NPs were rapidly cleared from 
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blood upon repeated injections by producing PEG-specific IgM and subsequent activation of the 
complement system.15-17 Thus, to be most effective with minimal side effects, NPs need a portal 
into cells.  
Serum albumin, a ubiquitous protein in the blood, has been reported to efficiently 
accumulate in the tumor tissues due to the fact that the tumors catabolize excessive quantities of 
albumin.18-20 Several attempts to use albumin as carriers for chemotherapeutic agents have been 
extensively reported.21-24 One of representative examples is Abraxane, which uses albumin to 
solubilize Taxol, and showed favorable biodistribution profile and reduced toxicities.25,26 However, 
using albumin as surface modification of NPs to facilitate their tumor targeting has yet been studied. 
Herein, I set out to create a drug-poly(O-carboxyanhydride) nanoparticulate platform designed to 
“hitchhike” on albumin to get across the tumor endothelium barrier and avidly accumulate in the 
tumor tissues.  
 
4.2 Materials and Methods  
4.2.1 General 
β-Diimine (BDI) ligands and the corresponding metal complex (BDI-EI)ZnN(TMS)2 were 
prepared by following the published procedure27 and stored at 30 oC in a glovebox. Anhydrous 
solvents were purified by alumina columns and kept anhydrous by using molecular sieves. 
Doxo·HCl was purchased from Bosche Scientific (New Brunswick, NJ, USA). D,L-Lactide (LA) 
was purchased from TCI America (Portland, OR, USA). (S)-2,2',2'',2'''-(2-(4-
isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (p-SCN-
Bn-DOTA) was purchased from Macrocyclics, Inc. (Dallas, TX, USA). Anhydrous 
tetrahydrofuran (THF), dimethylformamide (DMF), and dichloromethane (DCM) were purified 
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by alumina columns and kept anhydrous by using molecular sieves. D-luciferin potassium was 
purchased from Regis Technologies (Morton Grove, IL, USA). All other chemicals were 
purchased from Sigma-Aldrich (St Louis, MO, USA) and used as received unless otherwise noted. 
The molecular weights (MWs) of PheLA were determined by gel permeation chromatography 
(GPC, also known as size exclusion chromatography (SEC)) equipped with an isocratic pump 
(Model 1100, Agilent Technology, Santa Clara, CA, USA), a DAWN HELEOS 18-angle laser 
light scattering detector and an Optilab rEX refractive index detector (Wyatt Technology, Santa 
Barbara, CA, USA). The wavelength of the HELEOS detector was set at 658 nm. The size 
exclusion columns (Phenogel columns 100, 500, 103 and 104 Å, 5 μm, 300 ×  7.8 mm, 
Phenomenex, Torrance, CA, USA) used for the analysis of polymer-drug conjugates was serially 
connected on the GPC. The GPC columns were eluted with DMF (HPLC grade) containing 0.1 M 
LiBr at 65 °C at 1 mL/min. Data processing was performed with ASTRA V software (Version 
5.1.7.3, Wyatt Technology, Santa Barbara, CA, USA). HPLC analyses were performed on a 
System Gold system equipped with a 126P solvent module and a System Gold 128 UV detector 
(Beckman Coulter, Fullerton, CA, USA) equipped with a 126P solvent module, a System Gold 
128 UV detector and an analytical C18 column (Luna C18, 250 × 4.6 mm, 5 μ, Phenomenex, 
Torrance, CA, USA). Infrared spectra were recorded on a PerkinElmer 100 serial FT-IR 
spectrophotometer (PerkinElmer, Waltham, MA, USA). The sizes and the size distributions of the 
nanoconjugates (NCs) were determined on a ZetaPALS dynamic light scattering (DLS) detector 
(15 mW laser, incident beam = 676 nm, Brookhaven Instruments, Holtsville, NY, USA). The ζ-
potential of freshly prepared NCs was evaluated by Malvern Zetasizer (Herrenberg, Germany). 
Lyophilization of the NCs was carried out on a benchtop lyophilizer (FreeZone 2.5, Fisher 
Scientific, USA). Ex vivo measurement of the radioactivity was conducted with 2480 Wizard2 
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Automatic γ-counter (Perkin-Elmer, USA). The flash frozen organs were embedded with optimum 
cutting temperature (O.C.T.) compound (Sakura Finetek USA, Torrance, CA, USA) and sectioned 
with a Leica CM3050S cryostat and mounted on glass slides for histological analysis. MCF-7 cells 
were obtained from ATCC (Manassas, VA, USA). Cells were cultured in DMEM medium 
containing 10% fetal bovine serum (FBS), 100 units/mL aqueous Penicillin G and 1 nM estrogen 
(Sigma-Aldrich Inc., St. Louis, MO, USA). Human umbilical vein endothelial cells (HUVEC) 
were purchased from ATCC (Manassas, VA, USA) and cultured in Vasculife Basal Medium 
(ATCC). Both of the cells were grown at 37 °C in 5% CO2 humidified air. The confocal 
microscopy images for cellular internalization S6 tumor penetration studies were taken on a Zeiss 
LSM700 Confocal Microscope (Carl Zeiss, Thornwood, NY, USA) using a 63×/1.4 oil lens with 
excitation wavelength set at 405, 488 and 555 nm. Female athymic nude mice were purchased 
from the National Cancer Institute (NCI, Frederick, MD, USA) and ovariectomized at the age of 
21 days by the vendor. After arrival, mice were single-cage housed and had free access to food 
and water. Food and water were available ad libitum. Artificial light was provided in a 12/12 hour 
cycle. The study protocol was reviewed and approved by The Illinois Institutional Animal Care 
and Use Committee (IACUC) of the University of Illinois at Urbana Champaign. 
 
4.2.2 Preparation and characterization of Phe-OCA monomer.  
 L-Phenylalanine (4.1 g, 25 mmol) was diazotized with sodium nitrite (1.5 equiv, 37 mmol) in 
sulfuric acid efficiently provides pure 2-hydroxyl-3-pheynylpropanoic acid with satisfied yield 
(>75%). Condensation of the resulted α-hydroxyl acid with phosgene produced corresponding 1,3-
dioxolane-2,4-diones, so-called phenyl O-carboxyanhydrides (Phe-OCA). The produced Phe-
OCA is white crystal after recrystallization from THF:hexane (6:25, v/v) in glovebox with 
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reasonable yield (>50%). 1H NMR (CDCl3, 500 MHz): δ 7.40 (t, 2H, Ar-H), 7.29 (d, 2H, Ar-H), 
7.27 (t, 1H, Ar-H), 5.18 (t, 1H, alpha-H), 2.93-3.19  (m, 2H,  -CH2-Ar). 13C NMR (CDCl3, 400 
MHz): δ 166.5, 148.0, 131.7, 129.9, 129.4, 128.6, 80.1, 36.6. ESI-MS (m/z): Calcd C10H8O4  192.0 
(M); found 193.1 (M+H)+. 
 
4.2.3. Preparation and characterization of Doxo-PheLA25 conjugate 
In a glovebox, Doxo (12.5 mg, 0.02 mmol) was dissolved in anhydrous tetrahydrofuran (THF, 600 
L) and mixed with a 900 L THF solution containing (BDI-EI)ZnN(TMS)2 (13.0 mg, 0.02 mmol). 
The mixture was stirred for 15 min. Phe-OCA (96.0 mg, 25 equiv.) was dissolved in THF (2 mL) 
and added to above solution under stirring. The reaction proceeded in the glovebox overnight. The 
conversion of Phe-OCA was determined by FT-IR (by monitoring the disappearance of anhydride 
band at 1812 cm-1). After Phe-OCA was completely consumed, the reaction was stopped by 
quenched with cold methanol solution (300 L). Then, the polymer was precipitated with ether 
(50 mL) and dried by vacuum. 
 
4.2.4. Synthesis of mPEG5k-PheLA100 diblock polymer 
A diblock polymer of mPEG5k-PheLAn was synthesized by following similar procedures as 
previously published by using mPEG5k-OH as the initiator. In a glovebox, mPEG5k-OH (50 mg, 
0.01 mmol) solution in anhydrous dichloromethane (DCM, 800 mL) was mixed with a DCM 
solution (500 mL) containing  (BDI-EI)ZnN(TMS)2 (6.5 mg, 0.01 mmol). The mixture was stirred 
for 15 min. Phe-OCA (192.4 mg, 100 equiv) was dissolved in DCM at 50 mg/mL concentration 
and added to the stirred solution of mPEG5k-OH and (BDI-EI)ZnN(TMS)2. The reaction proceeded 
in the glovebox overnight. The conversion of Phe-OCA was determined by FT-IR by monitoring 
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the disappearance of the Phe-OCA anhydride band at 1812 cm-1. After Phe-OCA was completely 
consumed, the reaction was stopped by quenching the polymerization reaction with cold methanol 
solution (300 mL). The polymer was precipitated with ether (50 mL) collected by centrifugation 
and dried by vacuum. The molecular weight and MWD of the obtained mPEG5k-PheLAn were 
accessed by GPC (Mn = 26.0 kDa, MWD = 1.19). 
 
4.2.5. Synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-
PheLA25 conjugate 
The NH2-PheLA25 conjugate was synthesized by following a similar procedure as previously 
published by using ethanolamine as the initiator. In a reaction vial containing NH2-PheLA25 
conjugates (23.5 mg, 0.004 mmol) was added an anhydrous dimethylformamide (DMF) solution 
(0.5 mL) of DOTA-NCS (2.2 mg, 0.018 mmol) and triethylamine (3.6 mg, 0.036 mmol). The 
reaction mixture was stirred for 4 h under nitrogen at rt. The solvent and triethylamine were 
removed under vacuum to give DOTA-PheLA25, which was used directly without further 
purification.  
 
4.2.6. General procedure for the preparation and characterization of Doxo-PheLAn 
nanoconjugates (NCs) 
A DMF solution of the Doxo-PheLA25 conjugate (100 μL, 10 mg/mL) was added dropwise to 
nanopure water (2 mL). The resulting Doxo-PheLA25 NCs were collected by ultrafiltration (5 min, 
3000 × g, Ultracel membrane with 100,000 NMWL, Millipore, Billerica, MA, USA), washed with 
water and then characterized by DLS for particle sizes and size distributions. 
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4.2.7. Preparation and characterization of albumin-bound Doxo-PheLAn nanoconjugates 
(Alb-NCs) 
The obtained Doxo-PheLA25 NCs were dispersed in nanopure water (2 mL, 0.5 mg/mL).  Human 
serum albumin (HSA) (5 mg) was added into the NC solution and stirred for 30 min at rt. The 
resulting HAS-bound Doxo-PheLA25 NCs (Alb-NCs) were collected and washed with nanopure 
water by ultrafiltration (5 min, 3000 × g, Ultracel membrane with 100,000 NMWL, Millipore, 
Billerica, MA, USA), and then characterized by DLS for particle sizes and size distributions.  
 
4.2.8. Preparation and characterization of PEGylated Doxo-PheLA25 nanoconjugates (PEG-
NCs) 
A DMF solution of the mixture of Doxo-PheLA25 conjugate (50 μL, 20 mg/mL) and mPEG5k-
PheLA100 (50 μL, 20 mg/mL) was added dropwise to nanopure water (2 mL). The resulting 
PEGylated Doxo-PheLA25 (ALb-NCs) were collected by ultrafiltration (5 min, 3000 × g, Ultracel 
membrane with 100,000 NMWL, Millipore, Billerica, MA, USA), washed with water and then 
characterized by DLS for particle sizes and size distributions. 
 
4.2.9. DLS and ξ-potential measurements  
The hydrodynamic size was measured with 90Plus Particle Size Analyser by dispersing the NPs 
in DI water at concentration of 0.5 mg/mL. Measurements were taken at a 90° scattering angle. 
The ξ-potential of the NPs was determined with a Malvern Zetasizer. The freshly prepared NPs 
were dispersed in DI water to a concentration of 0.5 mg/mL.  
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4.2.10. Preparation of  64Cu labeled Alb-NCs or PEG-NCs 
The 64Cu chloride (300 µCi, obtained from Washington University at St. Louis, MO, USA) was 
mixed with Alb-NCs or PEG-NCs (20 mg) in NH4OAc buffer (pH = 5.5, 0.1 M, 0.5 mL).  The 
mixture was incubated for 1 h at 60 °C. To determine the labeling efficiency, the NCs were washed 
by ultrafiltration (10 min, 3000 × g, Ultracel membrane with 10 000 NMWL, Millipore, Billerica, 
MA, USA), and the radioactivity in the supernatant and the NC solution was measured at different 
time points respectively. The purified 64Cu-labelled NCs were used for injection.      
 
4.2.11. Micro-PET/CT imaging evaluation 
Six female athymic nude mice were prepared for the implantation of MCF-7 breast cancer cells. 
MCF-7 cells (1 × 106) were suspended in a 1:1 mixture of Hank's Balanced Salt (HBS) buffer and 
matrigel, and then injected subcutaneously into the flank of a mouse. When tumors reached ~100 
mm3, mice were divided into 2 groups (n=3), minimizing weight and tumor size difference among 
the groups. The two groups of mice were treated with 64Cu-Alb-NCs or 64Cu-PEG-NCs at a dose 
of 40 µCi and 43 µCi intravenously, respectively. Mice were placed on the micro-CT imaging bed 
and kept anaesthetized with a constant isoflurane flow. A dynamic PET scan was acquired for 1 h 
(60 min acquisition time, reconstructed as 60 frames at 60 seconds/frame). The micro-CT scan (80 
keV/500 µA X-rays energy, 360 projections, 360 degrees, 75 µm pixel size) was used for 
determining the anatomical localization of the tumor. Static micro-PET scans were acquired at two 
selected time points (6 h and 24 h p.i.) together with micro-CT scans for anatomical co-registration. 
The obtained micro-PET and micro-CT images were constructed using ordered subset expectation 
maximization and cone-beam algorithms with existing commercial software (Inveon Acquisition 
Workspace and Cobra Exxim, respectively). To quantify the radioactivity of 64Cu in the tumors, 
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complex irregular volumes of interest (VOIs) were drawn on the micro-CT images and registered 
with micro-PET images to determine mean counts in each VOI. The radiotracer activity from each 
VOI was normalized by injected dose and expressed at percent of the decay-corrected injected 
activity per cm3 of tissue, which can be approximated as percentage % I.D. g-1 assuming the density 
of the tissue is around 1g/cm3. The initial total injected activity was determined by dose calibrator 
before injection. 
 
4.2.12. In vivo biodistribution evaluation with γ-counter 
After Micro-PET/CT imaging acquisition, mice were euthanized 24 h p.i. The blood and major 
organs (liver, spleen, kidney, heart, lung, intestine, bladder and muscle), as well as MCF-7 tumor 
were collected, weighed and measured for radioactivity (64Cu) with a γ-counter (Wizard2, Perkin-
Elmer, USA) using appropriate energy window centered at photo peak of 511 keV.  Raw counts 
were corrected for background, decay, and weight. Corrected counts were converted to microcurie 
per gram of tissue (μCi g-1) with a previously determined calibration curve by counting the 64Cu 
standards. The activity in blood and each collected tissue sample was calculated as percentage of 
the injected dose per gram of tissue (% I.D. g-1).  For this calculation, the tissue radioactivity was 
corrected for the 64Cu decay (T(1/2)=12.7 h)  to the time of γ-well counting. 
 
4.2.13. Long-term in vivo efficacy study 
Twelve female athymic nude mice were prepared for the implantation of MCF-7 breast cancer 
cells. MCF-7 cells (1 × 106) were suspended in a 1:1 mixture of Hank's Balanced Salt (HBS) buffer 
and matrigel, and then injected subcutaneously into the flanks of a mouse (four injection sites per 
mouse). When tumors reached ~110 mm3, mice were divided into 3 groups (n=4), minimizing 
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weight and tumor size difference among the groups. Tumor-bearing mice of the corresponding 
group were treated three times (every four days) through iv injection of PBS (1×, 200 μL), PEG-
NCs (40 mg Doxo/kg) and Alb-NCs (40 mg Doxo/kg), respectively. The body weight and tumor 
sizes of animals were monitored closely. The tumor size for each animal were monitored by using 
calipers without knowledge of which injection each animal had received. The tumor volume for 
each time point was calculated according to the formula (length) × (width)2 /2. If body weight loss 
is beyond 20% of predosing weight, the animals were euthanized. When the tumor load reached 
700 mm3 (as predetermined endpoint) or the animal had become moribund, the mouse was 
sacrificed. When an animal exited the study due to tumor size or treatment related death, the final 
tumor size recorded for the animal was included with the data used to calculate the mean size at 
subsequent time point. Curves were truncated after two or more deaths occurred.  
 
Statistical Analyses 
Student’s t-test comparisons at 95% confidence interval were used for statistical analysis. The 
results were deemed significant at 0.01 < *p  0.05, highly significant at 0.001 < **p  0.01, and 
extremely significant at ***p  0.001.  
 
4.3 Results and Discussion 
4.3.1 Preparation of albumin-bound drug-poly(O-carboxyanhydride)  nanoconjugates 
In an early work of Dawson,28 an important observation was made that hydrophobic 
nanoparticles tend to adsorb more albumin molecules than hydrophilic nanoparticles, even though 
the affinity of the protein to both nanoparticle types is roughly the same. This suggests that 
hydrophobic copolymer nanoparticles have more albumin-binding sites. Thus, the previously 
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developed poly(O-carboxyanhydrides) (Phe-OCA) with enhanced hydrophobicity served as a 
good candidate for preparing albumin-bound nanoconjugates (NCs).29 Followed by the similar 
strategy we reported before, doxorubicin (Doxo) was used as a hydroxyl-containing drug to initiate 
the polymerization of Phe-OCA to prepare Doxo-poly(Phe-OCA) conjugates, termed Doxo-
PheLAn, where n is the degree of polymerization. Followed by nanoprecipitation, Doxo-PheLAn 
self-assembled in water and formed NCs with well controlled physicochemical properties such as 
high drug loading, quantitative loading efficiency, sub-100 nanometer size and narrow size 
distributions (Scheme 4.1). As expected, these formed NCs tend to tightly bind with albumin after 
incubation with albumin for 30 mins and followed an extensive wash to get rid of non-specific 
binding of albumin (Scheme 4.2). The increase of the hydrodynamic diameter (from 75 nm to 81 
nm) (Figure 4.1) and the drop of surface charge (from -2mV to -13mV) indicated the successful 
binding of albumin to the surfaces of NCs. The binding of albumin onto the surfaces of NCs was 
quantitatively monitored in situ by fluorescence correlation spectroscopy (FCS), a technique that 
measures the bursts of fluorescence emitted by the dye-labeled particles diffusing through a tiny 
spot volume formed by tight focusing of excitation beam. Autocorrelation analysis of the 
fluorescence emission time traces yields relaxation time, τD, from which the diffusion constant, D, 
and, by means of the Stokes–Einstein relation, the hydrodynamic radius rh can be extracted. Thus, 
the radius of NPs as a function of albumin concentration could be directly observed. As Figure 
4.2 showed, hydrodynamic radius of Doxo-PheLA NCs increased as a result of albumin adsorption. 
At a protein concentration ranging from 10-1000 µM, the increase in hydrodynamic radius of 
Doxo-PheLA NCs is from 17 to 116 nm. The saturation of the NP radius increase at high albumin 
concentration at 1000 µM indicated the formation of a protein monolayer. To further confirm the 
binding affinity between PheLA NCs and albumin due to the increased hydrophobicity, both 
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PheLA NCs and less hydrophobic PLA NCs were dispersed into FITC-labeled albumin solution 
and incubated for 1h. Then NCs were pelleted and removed. The fluorescence intensity of 
supernatant was monitored by fluorescence spectrometer to demine the amount of albumin bound 
with NCs. The results showed the fluorescence intensity of FITC-albumin incubated with PheLA 
NCs largely dropped after the removal of PheLA NCs, owing to the large percentage of albumin 
bound with PheLA NCs. However, PLA NCs showed minimal binding, demonstrating the 
hydrophobicity contribute to the strong binding between albumin and NCs (Figure 4.3). The 
binding was demonstrated stable when Alb-bound PheLA NCs (Alb-NCs) were internalized into 
the human umbilical vein endothelial cells (HUVEC) as evidenced by the co-localization of NCs 
(red fluorescence) and FITC-labeled albumin (green fluorescence) under confocal laser scanning 
microscopy (CLSM) (Figure 4.4).  
 
Scheme 4.1. Schematic illustration of preparation of Doxo-PheLA conjugates via Doxo-initiated 
ring opening polymerization of Phenyl O-carboxylanhydrides (PheOCA). 
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Scheme 4.2. Schematic illustration of preparation of human serum albumin (HSA)-coated Doxo-
PheLA conjugates. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Dynamic light scattering spectra of Doxo-PheLA NCs and human serum albumin 
(HSA)-coated Doxo-PheLA NCs.  
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Figure 4.2. Adsorption of human serum albumin (HSA) onto Doxo-PheLA NCs. Hydrodynamic 
radius of Doxo-PheLA NCs plotted as a function of the concentration of HSA. 
 
 
 
 
 
 
Figure 4.3. Percentage of fluorescence intensity of FITC-labeled HSA change after binding with 
PLA NCs and PheLA NCs. 
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Figure 4.4. Co-localization of Doxo-PheLA NCs (red fluorescence) with FITC-labeled HSA 
(green fluorescence) in the HUVEC cells. 
 
 
4.3.2 In vivo tumor accumulation and penetration of Albumin-coated PheLA NCs (Alb-NCs) 
in human breast cancer MCF-7 xenograft 
To explore the effect of the modification of NCs with albumin on their tumor accumulation, 
we first investigated the in vivo targeting capability of Alb-NCs for MCF-7 human breast cancer 
xenograft and PEGylated NCs used as control. Alb-NCs and PEG-NCs were radio labeled with 
isotope 64Cu (denoted as 64Cu-Alb-NC and 64Cu-PEG-NC respectively), and then administered 
into athymic nude mice bearing subcutaneous (s.c.) MCF-7 human breast cancer xenograft through 
tail vein injection. Their biodistribution were closely monitored by non-invasive whole body 
micro-positron emission tomography/X-ray computed tomography (micro-PET/CT) images after 
intravenous injection.  As Figure 4.5A shown, 64Cu-Alb-NCs started to accumulated in the MCF-
7 tumor (yellow arrow, 0.5 % injected dose per gram of tissue (% I.D.g-1)) as early as 1 h post 
injection (p.i.) and gradually increased to 1.3 % I.D.g-1 6 h p.i.. The high radioactivity detected in 
the tumor area was maintained as long as 24 h (1.3 % I.D.g-1). In contrast, 4Cu-PEG-NCs showed 
comparable tumor accumulation (0.6 % I.D.g-1) 1 h p.i., but significantly lower tumor 
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accumulation (0.9 versus 1.3 % I.D.g-1 6 h p.i. and 0.6 versus 1.4 % I.D.g-1 24 h p.i.). This sharp 
contrast was further confirmed by ex vivo measurement of the radioactivity in the excised tumors 
24 h p. i. with the γ-counter, which showed that the accumulation of 64Cu-Alb-NCs in tumors were 
1.7 % injected dose per gram of tissue (% I.D. g-1), approximately 1.7 fold increase compared with  
64Cu-PEG-NCs (0.98 % I.D. g-1 ) (Figure 4.5B).  
To further evaluate the distribution of accumulated Alb-NCs in the tumor tissues, a 
subcutaneous MCF-7 tumor model was established on both flanks of athymic nude mice. 
Fluorescently labeled Alb-NCs and PEG-NCs were injected into the mice through intravenous 
injection, respectively. The tumors were dissected 6 h p.i., stained, and analyzed with CLSM. 
Much brighter red fluorescence (NCs) close to the blood vessels (green fluorescence, stained with 
CD31) was observed in the tumor tissue sections of the mice treated with Alb-NCs (Figure 4.6A). 
Further quantification with Image J indicated a 1.8 fold increase in tumor accumulation of Alb-
NCs compared with PEG-NCs, demonstrating that surface modification with albumin could 
significantly facilitated NCs to transport across tumor blood vessels and enhance their tumor 
accumulation (Figure 4.6B).  
I also compared the passive diffusion capability of Alb-NC and PEG-NC by carrying out 
an ex vivo experiment to compare their penetration in tumor tissues. MCF-7 tumors collected from 
athymic nude mice were incubated in the cell culture medium containing Alb-NCs or PEG-NCs 
for 48 h. The tumors were then collected, sectioned, stained with DAPI and imaged via CLSM. 
The representative imaging in (Figure 4.7A) suggested that ALb-NCs can penetrate deeper in 
tumor tissues than PEG-NCs. To quantify it, the fluorescence intensity of tumor tissues were 
analyzed by Image J, as shown in Figure 4.7B. The tumor tissue penetration depth was defined as 
the distance from the periphery of the tumor to the site where the fluorescence intensity decreases 
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by 95 % as compared to the tumor periphery fluorescent intensity. As a result, the penetration 
depth of Alb-NCs was 2380 µm, which is 2 fold higher than PEG-NCs (1410 µm). All together, 
these results demonstrated that Alb-NCs could better accumulate and penetrate MCF-7 tumor 
tissue, thus facilitating the efficient delivery of anticancer drugs more deeply into tumor tissues 
than PEG-NCs.  
 
 
Figure 4.5. In vivo tumor accumulation study. (A) In vivo whole-body dynamic PET/CT imaging 
of mice treated with 64Cu-Alb-NCs (upper) and 64Cu-PEG-NCs (bottom). Images were taken at 1, 
6 and 24 h post intravenous injection of 64Cu-Alb-NCs and 64Cu-PEG-NCs, respectively. The 
tumor areas were indicated by yellow circle and arrows. (B) In vivo tumor accumulation of 64Cu 
labeled Alb-NC (red bar) and PEG-NC (blue bar) in MCF-7 xenografts bearing athymic nude mice, 
assessed by γ-counter. All the data was presented as percentage of injected dose per gram of tissues 
(% I.D. /g). 
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Figure 4.6. (A) Athymic nude mice bearing MCF-7 tumors (size: ~7.0 mm × 8.0 mm) were 
injected with Alb-NC and PEG-NC through intravenous injection. Mice were euthanized and 
dissected 6 h post injection. Tumor sections (intersections, 5 µm in thickness) were collected and 
mounted on glass slides. Fluorescence images were taken by Zeiss LSM700 confocal microscopy. 
Representative images showing the perivascular distribution of Alb-NC and PEG-NC (red, Rhd 
channel) in relation to blood vessels (green fluorescence, FITC channel) in tissue sections of MCF-
7 tumors. (B) Quantification of the accumulation of Alb-NCs (red bar) and PEG-NCs (blue bar) 
in the tumor tissues, evaluated by the average fluorescence intensity per area. 
 
 
 
 
 
 
 
 
 
Figure 4.7. MCF-7 tumors (size: ~7.0 mm × 8.0 mm) was ex vivo cultured with Alb-NC and PEG-
NC in cell medium for 48 h. Tumors without any treatment serve as control. Tumor sections 
(intersections, 5 µm in thickness) were collected by cryostat and mounted on glass slides. 
Fluorescence images were taken by Zeiss LSM700 confocal microscopy (A). (B) Plot profile of 
fluorescence in tumor section analyzed by Image J, showing the depth of NC penetration. To 
quantify the penetration, we defined the tumor tissue penetration depth as the distance from the 
periphery of the tumor to the site where the fluorescence intensity decreases by 95% as compared 
to the fluorescent intensity at tumor periphery. The penetration depths of Alb-NC and PEG-NC 
were found to be 2380 µm, and 1410 µm, respectively. 
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4.3.3 In vivo anti-tumor efficacy studies. 
To determine the impact of enhanced tumor targeting of Alb-NCs on their anticancer 
potential, I next evaluated the antitumor efficacy of Alb-NCs against the inhibition of growth of 
MCF-7 breast cancer xenografts, which were induced by subcutaneous injection of 1, 000, 000 
MCF-7 cancer cells into athymic nude mice. Human breast cancer MCF-7 cells are hormone-
dependent cells, requiring estrogen to maintain the growth of primary tumors in mice. Therefore, 
the engraftment and growth of MCF-7 tumors was supported by estrogen pellets subcutaneously 
implanted in the interscapular region of the mice prior to cell injection. When the size of tumors 
reached around 110 mm3, the mice were divided to three groups to minimize the differences of 
body weights and tumor sizes among groups (N=4). Two groups of mice received the intravenous 
injection of Doxo-loaded Alb-NCs and PEG-NCs at the dose of 40 mg Doxo per kg mice body 
weight (40 mg/kg) every four days for three times, respectively. The one remaining group was 
administrated intravenously with PBS as negative controls (Figure 4.8A). The tumor sizes in each 
group (N=16) were monitored continuously for 56 days post injection. Compared with the PBS 
negative control group, both of treatment groups (Alb-NCs and PEG-NCs) showed effective 
inhibition against the growth of MCF-7 tumor. Treatment of Alb-NCs resulted in markedly smaller 
average tumor size (568 ± 87 mm3 ) at day 56 in comparison with PEG-NCs (961 ± 62 mm3) and 
PBS (1533 ± 198 mm3) (Figure 4.8B), demonstrating that Alb-NCs is much more efficacious than 
PEG-NCs in reducing tumor burden (P<0.05, Student T test, Figure 4.8B). Importantly, the 
survival rate of mice treated with Alb-NCs were also markedly higher than mice treated with PEG-
NCs and untreated mice (Figure 4.8C). The efficacy result is further confirmed by TUNEL 
staining of tumor sections obtained from above three groups of mice. As shown in Figure 4.8D, 
tumors treated with Alb-NCs had substantially increased the apoptotic cell numbers compared with 
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those treated with PEG-NCs. These results strongly suggested that Alb-NCs inhibited estrogen-
induced MCF-7 tumor growth more effectively compared to the PEG-NCs.  
 
 
Figure 4.8. In vivo antitumor efficacy studies. (A) Experimental procedures. (B) Delay and 
inhibition of MCF-7 tumor growth for athymic nude mice with treatment of Doxo-loaded Alb-
NCs (40 mg Doxo/kg) and PEG-NCs (40mg Doxo/kg). PBS was used as negative control. Three 
doses were administrated on Day 0 and Day 4 and Day 8. End point was set up as the tumor size 
reached 900 mm3. All of the data are represented as average ± SEM (n=16). (C) Kaplan–Meier 
plots for all groups are shown. Loss of mice was because of treatment-related death, 
nontreatment-related death, or euthanasia after the end point (900 mm3) had been reached (n = 
4). (D) Representative immunohistochemical analysis of MCF-7 xenografts using 
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end (TUNEL) staining 
with the treatments of Alb-NCs and PEG-NCs. 
 
4.3.4 Mechanism of surface modification with albumin for tumor targeting  
Albumin with plasma concentration ranging from 400 to 675 µM constitutes more than 60% 
of plasma protein in human blood.18,30 Studies has shown that albumin binds to albumin-binding 
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proteins (ABPs) activates caveolin-1 resulting in the formation of caveolae, non-clathrin-coated 
pits in endothelial cells, which are responsible for the transport albumin and other plasma 
constituents across the endothelial cell to the interstitial space.31 To identify the potential 
mechanisms for the increased intratumoral concentrations that occurred with Alb-NCs, I carried 
out the mechanistic study to address the possible role of caveolae as the carriers responsible for 
Alb-NC tumor targeting. Human umbilical vein endothelial cells (HUVEC) were chose for all the 
mechanistic studies. For studies of transendothelial Alb-NC transport in the apical-to-basolateral 
direction, HUVEC were grown to confluence on transwell filter inserts. Experimental began when 
the opti-MEM medium in the upper wells was replaced by an aqueous solution containing Alb-
NC and PEG-NC, respectively. During the 24 h incubation period, aliquots of media (0.1 mL) in 
the lower well were taken out and analyzed by fluorescence intensity. The concentration of Alb-
NC or PEG-NC in the lower well could be calculated based on the fluorescence intensity by pre-
determined working curve. As compared with PEG-NC, Alb-NC showed more rapidly and 
significantly increased transendothelial transport, demonstrating the profound capability of 
crossing endothelial barrier (Figure 4.9A).  The differences of endocytosis of these two NCs in 
the endothelial cells could also been visualized by taking advantage of confocal laser scanning 
microscopy (CLSM), which demonstrated that Alb-NC were internalized by endothelial cells more 
efficiently than the NCs with PEGylation  (Figure 4.9B). To determine whether caveolae is 
responsible for the transport of both NCs (Alb-bound or PEGylated), both Alb-NCs and PEG-NCs 
were incubated with HUVEC for 4 h at 37 oC in the presence of FITC labeled cholera toxin B 
(FITC-CTB, green), a specific caveolae marker for it labels the caveolae-specific ganglioside GM1. 
CLSM images clearly suggested the differences of the internalization processes between Alb-NC 
and PEG-NC. As Figure 4.9C showed, the internalized Alb-NC (red fluorescence) notably co-
87 
 
localized with CTB (green fluorescence), suggesting the caveolae is responsible for the uptake and 
transport of Alb-NCs in the endothelial cells. Compared to the cells treated with PEG-NC, inside 
which red and green fluorescence are largely separated, thus clearly indicating that the uptake of 
PEG-NCs follow the different mechanism from caveolae mediated transport (Figure 4.9C). To 
further address the role of caveolae for the observed transendothelial transport of Alb-NCs, we 
disturbed the organization of caveolae by treating endothelial cells with methyl-β-CD and 
measured the uptake of Alb-NC in endothelial cells. As shown in Figure 4.9D, methyl-β-CD 
largely prevented the internalization of Alb-NC in endothelial cells. Thus, our results suggested 
that a model of Alb-NCs transporting across the endothelial barrier: albumin interaction with the 
ABPs such as gp 60 localized in caveolae induces the vesicles trafficking across endothelium 
(Figure 4.9E). The accumulation of Alb-NCs in the sub-endothelial space may further penetrate 
the tumor tissues and thus substantially enhance their efficacy.  
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Figure 4.9. Albumin induces the transendothelial transport of NCs. (A) Transcytosis kinetics of 
Alb-NC and PEG-NC across the HUVEC monolayer. (B) Uptake of Alb-NC (red, left panel) and 
PEG-NC (red, right panel) in the HUVEC cells, visualized by Zeiss LSM 700 confocal microscopy. 
The nucleus was stained with DAPI (blue), and the cell skeleton was stained with Alexa Fluor® 
488 Phalloidin (green). (C) Confocal images of Doxo-loaded Alb-NC (red, left, upper panel) and 
PEG-NC (red, left, bottom panel) and CTB (green, center) in HUVEC cells are shown. Overlay of 
NC staining and FITC-CTB uptake shows marked co-localization in the merged images (right). 
(D) Cyclodextrin prevents albumin-induced endocytosis of NCs, analyzed by Zeiss LSM 700 
confocal microscopy. Alb-NC was loaded with Doxo (red). The nucleus was stained with DAPI 
(blue), and the cell skeleton was stained with Alexa Fluor® 488 Phalloidin (green). (E) Schematic 
illustration of albumin-induced transcytosis of NCs in endothelial cells. Binding of hydrophobic 
domain of NC to albumin in plasma promotes NC-albumin interaction and binding to endothelial 
plasmalemma in caveolae by ABP (e.g., gp 60). Albumin plays an essential role in the mechanism 
of NC transcytosis. 
 
 
4.4 Conclusions 
In conclusion, I constructed an albumin-bound, Doxo-loaded, polymeric NCs with well-
controlled physicochemical properties, in which albumin acted as a novel surface modifier for 
Doxo-PheLA NCs to transport NCs across the endothelial-cell barrier through caveolae-mediated 
transcytosis pathway and subsequently, lead to the significantly improved tumor accumulation and 
markedly enhanced efficacy against MCF-7 primary tumors. This design may serve as a general 
strategy to enhance the tumor accumulation and antitumor efficacy of nanomedicine, an approach 
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that may be applicable to a broad range of nanoparticulate therapeutics and imaging agents. Further 
work will be needed to determine whether albumin binding is functionally critical, or alternatively 
whether other rare serum components may have a role in the observed tumor targeting.  
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CHAPTER 5 
TARGETED DOXORUBICIN-POLYLACTIDE NANOCONJUGATES THROUGH 
PAMIDRONATE FUNCTIONALIZATION 
 
 
5.1 Introduction 
Osteosarcoma, the most common primary malignant bone tumor occurring in children and 
adolescents, accounts for approximately 60% of primary malignant bone tumors diagnosed in the 
first two decades of life.1,2 The tumor causes altered balances of anabolic and catabolic pathway 
in bone marrow environment, leading to enhanced activity of osteoclasts and decreased bone 
strength.3-5 In addition, cancer cells residing in bone further enhance the osteoclastic activity by 
secretion of calcium and several cytokines such as parathyroid hormone-related protein (PTHrP), 
receptor activator of nuclear factor kappa-B ligand (RANKL), and interleukin-6 (IL-6).6 The 
release of calcium and other cytokines by osteoclast cells during bone resorption, in turn, activates 
growth of cancer cells residing in bone marrow via vicious cycle.7 In current clinical settings, the 
standard treatment for osteosarcoma is a combination of surgery and chemotherapy.8-11 The cure 
rate of patients with localized osteosarcoma ranges from 15 to 20% with surgery alone, but 
improves to approximately 70% when combined with chemotherapy. Unfortunately, for the 40% 
of patients with progression of osteosarcoma after frontline therapy, further therapy with additional 
chemotherapy is palliative and toxic.12 It is estimated that less than 30% of patients with recurrent 
disease will be cured.13,14 As such, novel approaches to deliver chemotherapeutic agents to the 
sites of cancer to overcome cancer induced bone resorption, decrease cancer growth and increase 
overall quality of life of cancer patients is of utmost importance. 
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Nanomedicine that is able to deliver therapeutic agents to diseased sites could be an 
effective and complementary adjuvant treatment for inoperable focal and multifocal skeletal 
malignancies.15-17 NPs can be engineered to carry various therapeutic agents, extravasate leaky 
blood vessels, reach and accumulate at tumor tissues, target malignant cancer cells, and release 
cargos in a controlled manner.16,18-21 Although promising, the successful clinical translation of NPs 
has proven very difficult mainly because there are two major hurdles are hard to overcome. First, 
to efficiently deliver the therapeutic agents to the tumor tissues, the site specificity for the desired 
target is highly important. There has been growing interests in using biological molecules such as 
peptides, aptamers, and antibodies for targeted cancer therapy.17,22,23 However, those frequently 
used targeting agents showed minimized affinity for mineralized tissues. Since the bone is 
composed of a mineralized matrix, the molecules possessed strong affinity with hydroxyapatite 
needs to be considered as potential candidate. Parmidronate, one of bisphosphonates, has been 
commonly used as the treatment for disease characterized by osteolysis, for its high affinity 
towards hydroxyapatite, fast distribution and accumulation in bones. Those characteristics of 
parmidronate led to explore its utility for targeting bone tissues.24 Second, to achieve better 
performances in the physiological conditions, NPs are required to possess controlled 
physicochemical and pharmacological properties.25 Specifically, the clinically applicable NPs 
should have controlled sizes, narrow size distribution, high drug loading and loading efficiency, 
and controlled drug release profile. However, the NPs formulated via the traditional method by 
nanoprecipitaion of the mixture of polymer and drug is hard to meet those requirements.  
The clinical translation of nanomedicine for improving the treatment of osteosarcoma 
might be accelerated through the use of appropriate large mammalian tumor models which 
faithfully recapitulate the processes involved in malignant osteolysis. Enigmatically, dogs 
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spontaneously develop OS with the highest frequency of all mammal species, commonly affecting 
older dogs of large or giant skeletal size. Biological, histological and genomic features of OS in 
humans and dogs are highly similar and have provided a basis to evaluate novel therapeutics in 
dogs with OS.26-32 In addition, given the comparable anatomic size of humans and dogs (50 
kilograms or greater) afflicted with OS, dogs might serve as highly predictive models for 
comparable human pathologies based upon allometric scale similarities. Given these desirable 
modeling attributes and as part of the broader field of comparative oncology, translational drug 
development studies in dogs with OS have been used successfully to define dose and schedule for 
investigational therapeutic agents intended for development and clinical application in humans.33  
To address the issues abovementioned, I report in this chapter a pamidronate (Pam) 
functionalized, biocompatible polylactide (PLA) based NP for the targeted treatment of focal 
malignant osteolysis by delivering doxorubicin (Doxo) specifically to the bone tumor 
microenvironment. The combination of active bone targeting mediated by Pam and passive tumor 
targeting through enhanced permeation and retention (EPR) effect of NPs resulted in markedly 
enhanced accumulation of Doxo loaded NPs within bone tumors in both mice and dogs bearing 
OS. Improved efficacy of Pam-functionalized, Doxo-loaded NPs (Pam-Doxo-NPs) were 
demonstrated in a preclinical orthotopic mouse model of OS. Most importantly, through the 
inclusion of dogs with naturally-developing OS, clinically relevant dosages of Pam-Doxo-NPs 
could be evaluated for biocompatibility, biodistribution, and anticancer activities in a large 
mammalian modeling system. 
 
5.2 Materials and Methods 
5.2.1 General 
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Doxo·HCl was purchased from Bosche Scientific (New Brunswick, NJ, USA). D,L-Lactide (LA) 
was purchased from TCI America (Portland, OR, USA). (S)-2,2',2'',2'''-(2-(4-
isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (p-SCN-
Bn-DOTA) was purchased from Macrocyclics, Inc. (Dallas, TX, USA). All the other chemicals 
were purchased from Sigma–Aldrich (St Louis, MO, USA). Anhydrous tetrahydrofuran (THF), 
dimethylformamide (DMF), and dichloromethane (DCM) were purified by alumina columns and 
kept anhydrous by using molecular sieves. D-luciferin potassium was purchased from Regis 
Technologies (Morton Grove, IL, USA). The molecular weights (MWs) of PLA were determined 
by gel permeation chromatography (GPC, also known as size exclusion chromatography (SEC)) 
equipped with an isocratic pump (Model 1100, Agilent Technology, Santa Clara, CA, USA), a 
DAWN HELEOS 18-angle laser light scattering detector and an Optilab rEX refractive index 
detector (Wyatt Technology, Santa Barbara, CA, USA). The wavelength of the HELEOS detector 
was set at 658 nm. The size exclusion columns (Phenogel columns 100, 500, 103 and 104 Å, 5 μm, 
300 × 7.8 mm, Phenomenex, Torrance, CA, USA) used for the analysis of polymer-drug 
conjugates was serially connected on the GPC. The GPC columns were eluted with DMF (HPLC 
grade) containing 0.1 M LiBr at 65 °C at 1 mL/min. Data processing was performed with ASTRA 
V software (Version 5.1.7.3, Wyatt Technology, Santa Barbara, CA, USA). HPLC analyses were 
performed on a System Gold system equipped with a 126P solvent module and a System Gold 128 
UV detector (Beckman Coulter, Fullerton, CA, USA) equipped with a 126P solvent module, a 
System Gold 128 UV detector and an analytical C18 column (Luna C18, 250 × 4.6 mm, 5 μ, 
Phenomenex, Torrance, CA, USA). The NMR studies were conducted on a Varian UI500NB 
system (500 MHz). Infrared spectra were recorded on a PerkinElmer 100 serial FTIR 
spectrophotometer (PerkinElmer, Waltham, MA, USA). The sizes and the size distributions of the 
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NPs were determined on a ZetaPALS dynamic light scattering (DLS) detector (15 mW laser, 
incident beam = 676 nm, Brookhaven Instruments, Holtsville, NY, USA). The ζ-potential of 
freshly prepared MPs was evaluated by Malvern Zetasizer (Herrenberg, Germany). Lyophilization 
of the NPs was carried out on a benchtop lyophilizer (FreeZone 2.5, Fisher Scientific, USA). 
Murine OS K7M2 cells transfected with GFP were provided by Chand Khanna, from National 
Cancer Institute (Bethesda, MD, USA). Murine OS K7M3 cells engineered with firefly luciferase 
were provided by Su Young Kim from National Cancer Institute (Bethesda, MD, USA). Both of 
cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS) and 100 units/mL 
aqueous Penicillin G at 37 °C in 5% CO2 humidified air. 8-week old female BABL/c mice were 
purchased from the National Cancer Institute (NCI, Frederick, MD, USA). Feed and water were 
available ad libitum. Artificial light was provided in a 12/12 hour cycle. The study protocol was 
reviewed and approved by The Illinois Institutional Animal Care and Use Committee (IACUC) of 
the University of Illinois at Urbana Champaign. Dogs with spontaneously-occurring appendicular 
osteosarcoma were recruited to participate in the present investigational trial conducted at the 
University of Illinois Veterinary Teaching Hospital to evaluate the biodistribution, safety, and 
anticancer activity of Pam-Doxo-NP. The median age and weight of pet dogs was 8 years (range; 
6-11 years) and 40.1 kilograms (range; 21.8-63.3 kilograms), respectively. Pet owners were 
informed of all treatment options available for their pet dogs and required to sign client consent 
forms prior to their dogs being treated with Pam-Doxo-NP. The study protocol was reviewed and 
approved by The Illinois Institutional Animal Care and Use Committee (IACUC) of the University 
of Illinois at Urbana Champaign. 
 
5.2.2 Preparation of Doxo-PLA polymer conjugate. 
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Doxo-PLA conjugates were synthesized by following similar procedures as published 34. In a 
glovebox, Doxo (5.4 mg, 0.01 mmol) was dissolved in anhydrous tetrahydrofuran (THF, 500 µL) 
and mixed with a THF solution (500 µL) containing (BDI-EI)ZnN(TMS)2 [(BDI)=2-((2,6-
diethylphenyl) amido)-4-((2,6-diisopropylphenyl)-imino)-2-pentene] (6.5 mg, 0.01 mmol). The 
mixture was stirred for 15 min. Lactide (LA) (14.4 mg, 10 equiv.) was dissolved in THF (500 µL) 
and added to the stirred (BDI-EI)ZnN(TMS)2 and Doxo mixture. The reaction proceeded in the 
glovebox overnight. After LA was completely consumed, the reaction was stopped by quenching 
the polymerization solution with cold methanol solution (30 µL). The polymer was precipitated 
with ether (10 mL), collected by centrifugation and dried by vacuum.  
 
5.2.3 Synthesis of PLA-PEG-COOH conjugate. 
A diblock polymer of PLA-PEG-COOH was synthesized by following similar procedures as 
described above by using HO-PEG-COOH (Mw of PEG: 5k Da) as the initiator. In a glovebox, 
HO-PEG-COOH (50 mg, 0.01 mmol) solution in anhydrous dichloromethane (DCM, 800 µL) was 
mixed with a DCM solution (500 µL) containing (BDI-EI)ZnN(TMS)2 (6.5 mg, 0.01 mmol). The 
mixture was stirred for 15 min. LA (144.1 mg, 100 equiv) was dissolved in DCM at 50 mg/mL 
concentration and added to the stirred solution of HO-PEG-COOH and (BDI-EI)ZnN(TMS)2. The 
reaction proceeded in the glovebox overnight. After LA was completely consumed, the reaction 
was stopped by quenching the polymerization reaction with cold methanol solution (300 µL). The 
polymer was precipitated with ether (50 mL) collected by centrifugation and dried by vacuum. 
 
5.2.4 Synthesis of PLA-PEG-Pam conjugate 
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To a DMF solution (2 mL) of PLA100-PEG5k-COOH (40.0 mg, 2.1 µmol) was added 1-(3-
dimethylaminopropyl)-3-ethylcarbodimide hydrochloride (EDC) (1.0 mg, 6.4 µmol) and N-
hydroxysuccinimide (NHS) (0.8 mg, 6.9 µmol). After the solution was stirred at room temperature 
for 30 mins, pamidronate (1.0 mg, 4.3 µmol) was added and the mixture was stirred overnight. 
The polymer conjugate was precipitated with ether (12 mL) collected by centrifugation and dried 
by vacuum. The resulting polymer conjugate is characterized by 1H NMR. 
 
5.2.5 Synthesis of PLA-PEG diblock polymer 
A diblock polymer of PLA-PEG was synthesized by following similar procedures as described 
above by using mPEG-OH (Mw of PEG: 5k Da) as the initiator. In a glovebox, mPEG-OH (50 mg, 
0.01 mmol) solution in anhydrous dichloromethane (DCM, 800 µL) was mixed with a DCM 
solution (500 µL) containing (BDI-EI)ZnN(TMS)2 (6.5 mg, 0.01 mmol). The mixture was stirred 
for 15 min. LA (144.1 mg, 100 equiv) was dissolved in DCM at 50 mg/mL concentration and 
added to the stirred solution of mPEG-OH and (BDI-EI)ZnN(TMS)2. The reaction proceeded in 
the glovebox overnight. After LA was completely consumed, the reaction was stopped by 
quenching the polymerization reaction with cold methanol solution (300 µL). The polymer was 
precipitated with ether (50 mL) collected by centrifugation and dried by vacuum. 
 
5.2.6 Preparation and characterization of Pam-Doxo-NPs 
Doxo-PLA conjugates were synthesized by following similar procedures as published 34. PLA-
PEG-Pam conjugate was synthesized by covalently conjugating pamidronate to PLA-PEG-COOH 
polymer via stable amide bond (fig. S1). A DMF solution of the mixture of Doxo-PLA10 (100 μL, 
10 mg/mL) and PLA-PEG-Pam conjugate (100 μL, 10 mg/mL) was added dropwise to rapid 
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stirring nanopure water (4 mL). The resulting Doxo-loaded PLA-PEG-Pam NPs (Pam-Doxo-NPs) 
were collected by ultrafiltration (5 min, 3000 × g, Ultracel membrane with 10,000 NMWL, 
Millipore, Billerica, MA, USA), washed with water and then characterized by DLS for particle 
sizes and size distributions, and by HPLC for drug loadings by following the reported procedures.34 
 
5.2.7 DLS and ξ-potential measurements 
The hydrodynamic size was measured with 90Plus Particle Size Analyser by dispersing the NPs 
in DI water at concentration of 0.5 mg/mL. Measurements were taken at a 90° scattering angle. 
The ξ-potential of the NPs was determined with a Malvern Zetasizer. The freshly prepared NPs 
were dispersed in DI water to a concentration of 0.5 mg/mL. 
 
5.2.8 Release kinetic study of Pam-Doxo-NPs 
Pam-Doxo-NPs were prepared by nanoprecipitation as previously described. The collected NPs 
(10 mg) were dispersed in human serum buffer (human serum:PBS=1:1, v/v, 5 mL), divided into 
10 equal-volume portions, and added to 10 eppendorf microcentrifuge tubes (500 μL NP solution 
in each tube). The tubes were incubated at 37°C. At scheduled time points, two tubes were taken 
out, to which methanol (500 μL) was added to precipitate proteins. The precipitates were removed 
by centrifugation (5 min, 15000 × g). The supernatant then was injected into HPLC for analysis of 
the released Doxo. For the HPLC analysis, acetonitrile:water (containing 1% TFA) was used as 
mobile phase. The gradient for acetonitrile:water (containing 1% TFA) was changed linearly from 
25:75 to 75:25 over 30 min and then kept at 75:25 for 30 min and changed back to 25:75 over 5 
min. the flow rate was 1.0 mL/min. Analytical C18 column (Luna C18, 250 × 4.6 mm, 5 μ, 
Phenomenex, Torrance, CA, USA) was used to perform the analysis. The integrated area of the 
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Doxo peak was documented and calculated according to the standard curve to determine the 
released Doxo. 
 
5.2.9 Stability study of Pam-Doxo-NPs in human serum (50%). 
Pam-Doxo-NPs were prepared by nanoprecipitation as previously described. The obtained NPs 
were dispersed in human serum buffer (human serum:PBS = 1:1, v/v). The particle sizes were 
measured by DLS and followed over 60 min.  
 
5.2.10 Lyophilization of Pam-Doxo-NPs with human serum albumin (HSA). 
Pam-Doxo-NPs were prepared by nanoprecipitation as previously described.  Human serum 
albumin (HSA) was then added into the NP solution.  The mixture was lyophilized for 16 h at -50 
°C to obtain a white powder.  The white powder was reconstituted in nanopure water (2 mL) and 
the solution was stirred for 5 min at room temperature. The resulting NP solution was analyzed by 
DLS to assess NP size and size distribution. 
 
5.2.11 Synthesis of cyanine 5 (Cy5)-PLA conjugates.  
Cy5-PLA conjugates were synthesized by following similar procedures as published 35. In a 
glovebox, Cy5 (5.0 mg, 0.01 mmol) was dissolved in anhydrous tetrahydrofuran (THF, 900 µL) 
and mixed with a THF solution (500 µL) containing (BDI-EI)ZnN(TMS)2 (6.5 mg, 0.01 mmol). 
The mixture was stirred for 15 min. Lactide (LA) (72.0 mg, 50 equiv.) was dissolved in THF (1 
mL) and added to the stirred (BDI-EI)ZnN(TMS)2 and Cy5 mixture. The reaction proceeded in the 
glovebox overnight. After LA was completely consumed, the reaction was stopped by quenching 
the polymerization solution with cold methanol solution (300 µL). The polymer was precipitated 
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with ether (50 mL), collected by centrifugation and dried by vacuum.  
 
5.2.12 Preparation and characterization of Cy5 labeled Pam-NPs 
A DMF solution of the mixture of Cy5-PLA (100 μL, 10 mg/mL) and PLA-PEG-Pam conjugate 
(100 μL, 10 mg/mL) was added dropwise to rapid stirring nanopure water (4 mL). The resulting 
Cy5 labeled Pam-NPs (Pam-Cy5-NPs) were collected by ultrafiltration (5 min, 3000 × g, Ultracel 
membrane with 10,000 NMWL, Millipore, Billerica, MA, USA), washed with water and then 
characterized by DLS for particle sizes and size distributions, and by HPLC for drug loadings by 
following the reported procedures 36. 
 
5.2.13 Synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-PLA 
conjugate 
 
 
The NH2-PLA conjugate was synthesized by following a similar procedure as described above by 
using ethanolamine as the initiator. In a reaction vial containing NH2-PLA conjugates (6.0 mg, 
0.004 mmol) was added an anhydrous dimethylformamide (DMF) solution (0.5 mL) of DOTA-
NCS (2.2 mg, 0.018 mmol) and triethylamine (3.6 mg, 0.036 mmol). The reaction mixture was 
stirred for 4 h under nitrogen at room temperature. The solvent and triethylamine were removed 
under vacuum to give DOTA-PLA conjugate, which was used directly without further purification. 
 
5.2.14 Preparation of 64Cu labeled Pam-NPs 
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The 64Cu chloride (300 µCi, obtained from Washington University at St. Louis, MO, USA) was 
mixed with Pam-NPs (20 mg) in NH4OAc buffer (pH = 5.5, 0.1 M, 0.5 mL). The mixture was 
incubated for 1 h at 60 °C. To determine the labeling efficiency, the NPs were washed by 
ultrafiltration (10 min, 3000 × g, Ultracel membrane with 10 000 NMWL, Millipore, Billerica, 
MA, USA), and the radioactivity in the supernatant and the NP solution was measured at different 
time points respectively. The purified 64Cu-labeled Pam-NPs (Pam-64Cu-NPs) were used for in 
vivo biodistribution study.    
 
5.2.15 In vitro HA binding evaluation 
To evaluate the binding kinetics of HA with NPs, 25 µg/mL Pam-Cy5-NPs or Cy5-NPs in 10-mL 
DI water containing HA (1.5 mg/mL) was continuously vortexed at 37 oC. Unbounded NPs were 
separated by 0.45 µm filter (Millipore, Billerica, MA, USA), and the concentration of filtrate was 
determined by measuring the Cy5 fluorescence intensity and calculated by standard curve (fig. 
S3). Bound NPs were calculated by subtracting unbound NPs from the total NPs. To measure the 
steady-state binding, the indicated concentrations of NPs were incubated in 10-mL DI water 
containing HA (1.5 mg/mL). Suspensions were continuously vortexed at 37 oC for 3 h and the 
bounded NPs were calculated following the same procedure. For direct visualization of NPs 
binding with HA crystals, 25 µg/mL Pam-Cy5-NPs or Cy5-NPs in 10-mL DI water containing HA 
(1.5 mg/mL) was incubated at 37 oC for 30 min with continuous vortexing. Crystals were collected 
and washed with DI water for three times, amounted on glass slides and evaluated using a Zeiss 
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Axiovert 40 CFL fluorescence microscope equipped with a 20 × objective. 
 
5.2.16 In vitro cytotoxicity evaluation 
To evaluate if prolonged retention of NPs on HA matrix could impact cytotoxicity, K7M2 
transfected with GFP (provided by Chand Khanna, National Cancer Institute) were seeded in BD 
Biocoat Osteologic 24-well plates at 10,000 cells per 3 ml of complete media. Upon K7M2 
adhesion, cells were exposed to a 15-minute pulse of saline (control), Pam-NP, Doxo-NP, or Pam-
Doxo-NP with gentle rocking. Following treatment exposure, residual media was removed and 
replaced with fresh complete media, and K7M2 GPF cells were allowed to grow for an additional 
7 days, prior to being lysed and resultant supernatant fluorescent intensities determined with a 
fluorometric plate reader.   
 
5.2.17 Establishment of Orthotopic OS tumor model 
The tumor model was established in 8 week-old female balb/c mice by injection of 1 × 106 of 
firefly luciferase transfected murine OS K7M3 cells (provided by Su Young Kim, National Cancer 
Institute) suspended in 10 µL Hank’s Balanced Salt Solution (HBSS) into the right proximal tibia 
using an insulin syringe with ½ inch, 29 gauge, non-detachable needle. Tumor progression was 
evaluated using a BLI system (Stanford Photonics, Palo Alto, CA, USA) with a dual micro-channel 
plate ICCD camera. Each mouse was intraperitoneally injected with a D-luciferin potassium salt 
solution (0.15 g/kg body weight) 3 minutes prior to imaging and then anesthetized with a constant 
flow of isoflurane-containing oxygen. A grey-scale image of the mouse was first recorded with 
dimmed light. Photon emission was then integrated for 10 seconds using the imaging software 
Piper Control (Stanford Photonics, Palo Alto, CA, USA) and visualized in pseudo-color. To 
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localize bioluminescent signals that indicated luciferase-engineered K7M3 tumors, grey-scale 
images of mouse body and bioluminescent signals of primary tumors were merged using Image J 
(NIH) and Photoshop Elements (Adobe, San Jose, CA, USA).  
 
5.2.18 Micro-PET/CT imaging evaluation 
Female BALB/c mice inoculated with K7M3-luciferase murine OS cells and allowed for primary 
tumors to develop over a course of 21 days. Mice were divided into 2 groups (n = 4) and were 
treated with Pam-64Cu-NPs or 64Cu-NPs at a dose of 75 µCi intravenously, respectively. Mice were 
placed on the micro-CT imaging bed and kept anaesthetized with a constant isoflurane flow. A 
dynamic PET scan was acquired for 1 h (60 min acquisition time, reconstructed as 60 frames at 60 
seconds/frame). The micro-CT scan (80 keV/500 µA X-rays energy, 360 projections, 360 degrees, 
75 µm pixel size) was used for determining the anatomical localization of the tumor. Static micro-
PET scans were acquired at two selected time points (5 h and 24 h p.i.) together with micro-CT 
scans for anatomical co-registration. The obtained micro-PET and micro-CT images were 
constructed using ordered subset expectation maximization and cone-beam algorithms with 
existing commercial software (Inveon Acquisition Workspace and Cobra Exxim, respectively). 
Micro-PET images were processed using 3-D median filtering and fused with micro-CT images. 
To quantify the radioactivity of 64Cu in the tumors, complex irregular volumes of interest (VOIs) 
were drawn on the micro-CT images and registered with micro-PET images to determine mean 
counts in each VOI. The radiotracer activity from each VOI was normalized by injected dose and 
expressed at percent of the decay-corrected injected activity per cm3 of tissue, which can be 
approximated as percentage % I.D. g-1 assuming the density of the tissue is around 1g/cm3. The 
initial total injected activity was determined by dose calibrator before injection. 
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5.2.19 In vivo biodistribution evaluation with γ-counter 
Female BALB/c mice bearing K7M3-luciferase murine OS cells were allowed to develop primary 
bone tumors over 21 days and then were divided into two groups (n = 4), minimizing the weight 
differences. The two groups of mice were treated with Pam-64Cu-NPs or 64Cu-NPs at a dose of 75 
µCi intravenously, respectively. Mice were euthanized 24 h p.i. The blood and major organs (liver, 
spleen, kidney, heart, lung, intestine, and bladder), as well as K7M3 tumors containing right leg 
and normal left leg were collected, weighed and measured for radioactivity (64Cu) with a γ-counter 
(Wizard2, Perkin-Elmer, USA) using appropriate energy window centered at photo peak of 511 
keV.  Raw counts were corrected for background, decay, and weight. Corrected counts were 
converted to microcurie per gram of tissue (μCi g-1) with a previously determined calibration curve 
by counting the 64Cu standards. The activity in blood and each collected tissue sample was 
calculated as percentage of the injected dose per gram of tissue (% I.D. g-1).  For this calculation, 
the tissue radioactivity was corrected for the 64Cu decay (T(1/2)=12.7 h)  to the time of γ-well 
counting. 
 
5.2.20 In vivo anticancer efficacy evaluation using murine orthotropic OS tumor model 
Female BALB/c mice inoculated with K7M3-luciferase murine OS cells were divided into four 
equivalent groups (n = 7) based upon primary tumor burden (BLI) and body weight. Two groups 
of mice were treated with Pam-Doxo-NPs and Doxo-NPs at a dose of 50 mg/kg (Doxo equivalent) 
intravenously for 2 consecutive treatments 1 week apart, respectively. The other two groups of 
mice were treated with blank NPs (no Doxorubicin) and saline as controls. Tumor progression was 
evaluated using a BLI system (Stanford Photonics, Palo Alto, CA, USA) as mentioned above. At 
the end of the study, mice were sacrificed by CO2. To ensure complete collection off the right tibia 
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and fibula, the distal femur and talus were incubated in the dissected samples, as well as the 
surrounding soft tissues. Tissues were placed in 10% formalin and scanned with micro-CT (80 
keV/500 µA X-rays energy, 360 projections, 360 degrees, 75 µm pixel size) to determine the bone 
destruction. After 48 h in 10 % formalin, bind limbs were placed in 10 % EDTA for 7 days to 
decalcify. All tissues was processed into paraffin and stained with hematoxylin and eosin and then 
evaluated by an experienced pathologist and tumor surface area quantified by ImageJ software. 
 
5.2.21 In vivo biodistribution, biocompatibility, and anticancer efficacy evaluation using 
spontaneous canine OS tumor model 
 
Treatment naïve dogs with confirmed appendicular OS were recruited to participate in a rapid 
dose-escalation study evaluating the biodistribution, biocompatibility, and anticancer activities of 
Pam-Doxo-NPs. For biodistribution studies, Pam-Doxo-NPs were labeled with 99mTc using a 
previously reported method 37, and subsequently infused intravenously as a 30-minute constant 
rate infusion into dogs sedated with intramuscular butorphanol and medetomidine. At the time of 
infusing 99mTc labeled Pam-Doxo-NPs, sequential images were acquired every second for 180 
seconds, every 5 minutes for 1 hour, and at 2-hours post-infusion. Studies determining the 
radiochemical purity of 99mTc labeled Pam-Doxo-NPs pre- and post-infusion (urine) were 
performed using a previously described protocol 38. Upon the completion of infusion, the 
biocompatibilities of Pam-Doxo-NPs in treated pet dogs were characterized weekly for 3 
consecutive weeks through the conductance of serial physical examination, complete blood count, 
serum chemistry profiles, and cardiac troponin concentrations. The direct anticancer activities of 
a
b
Intravenous NP Solution
Pre-infusion
Urine
Post-infusion
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Pam-Doxo-NPs were evaluated in pet dogs by amputating the OS-affected leg with consequent 
percent tumor necrosis assessment by histopathologic methods 32. Briefly, the bone and associated 
tumor were sectioned longitudinally either proximal to distal or lateral to medial dependent on the 
orientation of the mass lesion.  Sections were fixed in formalin for 24-48 hours followed by 
decalcification in an EDTA/HCL decalcifying solution (Richard Allen Scientific). Following 
decalcification, transverse sections of the longitudinal section were made to allow for placement 
into large tissue cassettes and sectioning onto glass slides. The sections were processed with an 
extended protocol, paraffin-embedded, sectioned at 4 microns and stained with hematoxylin-eosin 
(H&E). All slides (microscopic specimens), which cumulatively represent the entire plane in 
which the gross specimen was sectioned, were scanned in their entirety using an AxioCam HRc 
Carl Zeiss camera coupled to a Carl Zeiss Axioplan 2 microscope with a mechanical stage and 
utilizing Carl Zeiss KS 400 analysis software.  The scanned images were viewed in Adobe 
Photoshop CS3 (Adobe Systems Inc., San Jose CA 95110), to allow image analysis of tumor 
necrosis, while the original glass slides of the corresponding section were simultaneously viewed 
via light microscopy (Olympus BX41) providing detailed assessment of regions isolated on the 
digitally scanned images.  Utilizing Adobe Photoshop software and the scanned images, the total 
tumor area and regions of tumor necrosis were outlined in two different outlining colors. Regions 
outlined on the images were analyzed with the Carl Zeiss KS 400 image analysis software to 
quantitate total tumor area and the area of tumor necrosis. Ultimately, the overall total tumor area 
and total area of tumor necrosis for a given tumor were determined by adding the results (values) 
of each respective section. Percent necrosis for individual tumors was calculated as total area of 
necrosis/total tumor area. 
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5.3 Results and Discussion 
5.3.1 Synthesis and characterization of Pam-Doxo- nanoparticles (NPs) 
The Pam-Doxo-NPs were constructed through co-nanoprecipitation of doxorubicin-
polylactide (Doxo-PLA) polymer conjugates and pamidronate-conjugated poly(ethylene glycol)-
b-polylactide (PLA-PEG-Pam) (Figure. 5.1a). Doxo-PLA polymer conjugates were synthesized 
by utilizing the Doxo-initiated ring-opening polymerization (ROP) strategy as described 
previously 34. This method allows for quantitative incorporation of Doxo into PLA polymers, and 
results in Doxo-PLA conjugates with precisely controlled composition and molecular weights 
(Figure. 5.1A). At a monomer/initiator (LA/Doxo) ratio of 10, drug loading could be achieved as 
high as 27.4% (wt% of Doxo) with nearly 100% incorporation efficiency. Pamidronate was 
covalently conjugated to PLA-PEG-COOH polymer via stable amide bond as evidenced by 1H 
NMR (Figure. 5.2). The resultant Doxo-PLA polymer conjugate was mixed with PLA-PEG-Pam 
at 1/1 (wt/wt) ratio in dimethylformamide (DMF) followed by nanoprecipitation into rapidly 
stirred water as non-solvent to prepare NPs of 106 nm in hydrodynamic size and relatively narrow 
size distribution (polydispersity index (PDI) = 0.071) as measured by dynamic light scattering 
(DLS) (Figure. 5.1B).  NPs with ~ 100 nm size and narrow size distribution were also evidenced 
by transmission electron microscopy analysis (TEM) (Figure. 5.1C).  
Doxorubicin was conjugated to PLA polymer through ester linkages and could be released 
from NPs subjected to hydrolysis of ester bonds in the physiological condition. We conducted 
release kinetic studies of Pam-Doxo-NPs in 50% (vol.%) human serum to mimic the physiological 
parameters. The release kinetics of Doxo from NPs was controllable in a sustained manner without 
burst release effect (Figure. 5.3). The Pam-Doxo-NP maintained its size without aggregation in 
serum-containing buffer (Figure. 5.4) and could be formulated as solid form upon lyophilization 
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with human serum albumin as a lyoprotectant. The lyophilized Pam-Doxo-NPs, when 
reconstituted in buffer solution, maintained original size and narrow particle size distribution 
(Figure. 5.5). 
 
 
Figure 5.1. Preparation and characterization of pamidronate (Pam) modified doxorubicin (Doxo)-
polylactide nanoparticles (Pam-Doxo-NPs). (A) Schematic illustration of formulating Pam-Doxo-
NPs. (B) Dynamic light scattering (DLS) analysis of Pam-Doxo-NPs and Doxo-NPs. (C) 
Transmission electron microscopy (TEM) image of Pam-Doxo-NPs (Scale bar: 100 nm). (D) 
Formulation parameters and physicochemical properties of Pam-Doxo-NPs and Doxo-NPs (Mw of 
PEG: molecular weight of poly(ethylene glycol)). 
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Figure 5.2. 1H NMR characterization of PLA-PEG-Pam conjugate. 
 
 
 
Figure 5.3. Release kinetic profile of Pam-Doxo-NPs in human serum buffer (human serum:PBS 
=1:1, v/v). 
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Figure 5.4. The stability of Pam-Doxo-NPs in human serum buffer (human serum:PBS =1:1, 
v/v). 
 
 
 
 
Figure 5.5. DLS analysis of NP reconstitution. Pam-Doxo-NPs in water (upper panel) and 
reconstituted Pam-Doxo-NPs after lyophilization in the presence of human serum albumin (HSA) 
(HSA:NP =10:1, m/m) (bottom panel). 
 
 
 
5.3.2 In vitro hydroxyapatite binding capability and cytotoxicity of Pam-Doxo-NPs 
To characterize the potential bone-binding affinity of Pam-modified NPs, I first performed 
an in vitro hydroxyapatite (HA) adsorption assay using Cy5 labeled NPs (Cy5-NPs). 
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Hydroxyapatite was considered as an ideal model substrate because it constitutes the major 
inorganic component of bone and undergoes erosive osteolysis secondary to the growth of invasive 
osteotropic solid malignancies. As shown in Figure. 5.6A, Pam-modified Cy5-NPs (Pam-Cy5-
NPs) exhibited rapid binding with HA, with 3.9 mg NP bound per gram of HA during the first 15 
minutes of incubation and gradually reached the equilibrium by 24 hours. In contrast, non-targeted 
Cy5-NPs exhibited approximately 10-fold reduced binding capability with HA compared with the 
Pam-Cy5-NPs over 24 hours of incubation. To determine whether the binding of Pam-Cy5-NPs to 
HA exhibits similar adsorptive characteristics as free aminobisphosphonate, I measured the steady-
state binding affinity by titrating the concentrations of NPs. The results showed that the binding 
capacity was proportional to the concentrations of Pam-Cy5-NPs, while the Cy5-NPs had a non-
specific adsorption to HA (Figure.  5.6B); results indicated that Pam was principally responsible 
for HA binding. To further characterize the binding of NPs to HA, tandem bright field and 
fluorescence microscopy were utilized. With Cy5 fluorescence intensity confirmed to linearly 
correlate with NP concentration (Figure. 5.7), Pam-Cy5-NPs consistently adsorbed to exposed 
surface and edges of the HA crystals, while Cy5-NPs only minimally adhered to HA crystals 
(Figure.  5.8). 
Given the increased binding capacity of Pam-NPs to HA, I reasoned that Pam-NPs carrying 
chemotherapeutic agents may exert greater cytotoxicity to tumor cells residing within the bone 
microenvironment by virtue of its preferential deposition. To investigate this possibility, I 
evaluated the effect of Pam-Doxo-NPs against GFP labeled K7M2 OS cells grown on HA-coated 
culture plates, in which the numbers of viable K7M2 OS cells were directly proportional to GFP 
fluorescent intensities (Figure.  5.9). After 7 days of growth, GFP labeled K7M2 OS cells 
exhibited the greatest reduction in cell numbers following a 15-minute pulse exposure to Pam-
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Doxo-NPs (Figure.  5.10). The results were consistent with the preferential adherence of Pam-
Doxo-NPs to HA and consequent prolonged exposure of K7M2 cells to cytotoxic effects of Doxo 
in vitro. 
 
Figure 5.6. Binding affinity to hydroxyapatite (HA) and cytotoxicity of Pam-Doxo-NPs against 
GFP labeled osteosarcoma cells (K7M2). (A) The kinetics of binding to HA crystals was measured 
for Cy5-labeled Pam-NPs (Pam-Cy5-NPs, solid squares) and Cy5-labeled NPs (Cy5-NPs, solid 
circles). Measurements were acquired at 15 minute, 30 minute, 1 hour, 2 hour, 3 hour, 5 hour, and 
24 hour after mixing. (B) Steady-state binding to HA crystals was measured for Pam-Cy5-NPs  
(blue bar) and Cy5-NPs (green bar) at 3 hour.  
 
 
 
 
 
Figure 5.7. Validation studies of Cy5 fluorescence measurement. Calibration curve of Cy5 
fluorescence intensity with concentration of Pam-Cy5-NPs (left panel) and Cy5-NPs (right panel), 
measured by fluorescence spectrometer.  
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Figure 5.8. Direct visualization of Pam-Cy5-NPs and Cy5-NPs binding to HA using fluorescence 
microscopy. Bright field (top panel) and Cy5 fluorescence images (bottom panel) of HA crystals 
treated with Pam-Cy5-NPs (25 µg/mL) or Cy5-NPs (25 µg/mL) are shown. Scale bar: 10 µm. 
 
 
 
 
 
Figure 5.9. Validation studies of GFP fluorescence measurement. Linear relationship between 
K7M2 cell density and relative fluorescent units (GFP) upon cell lysis. 
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Figure 5.10. Differences in K7M2 GFP cell density after 7 days of incubation following 15-minute 
pulse exposure to blank NPs (no Doxo, Pam modified), Doxo-NPs and Pam-Doxo-NPs (Doxo 
equivalent dose: 3000 ng/mL). Untreated cells served as control. Data presented by average 
relative fluorescence units (RFU) of GFP, and analyzed with 1-way ANOVA and post hoc tukey 
test; significance defined as *p<0.05, **p<0.01, and ***p<0.001. 
 
 
5.3.3 In vivo OS targeting of Pam-Doxo-NPs in mice 
To investigate the in vivo targeting capability of Pam-NPs for osteotropic solid tumors like 
OS, we next labeled Pam-NPs and non-targeted NPs with 64Cu (denoted as Pam-64Cu-NP and 
64Cu-NP respectively), assessed 64Cu labeling stability of NPs in serum as a function of time 
(Figure 5.11), and monitored their biodistribution after intravenous administration into BALB/c 
mice bearing firefly luciferase transfected K7M3 OS tumors with non-invasive micro-positron 
emission tomography/X-ray computed tomography (micro-PET/CT) imaging (Figure. 5.12). In 
mice, the right hind leg was inoculated with K7M3 cells while the normal contralateral left hind 
leg served as an internal control. Established growth of K7M3 cells within the proximal tibial bone 
was confirmed using a bioluminescence imaging (BLI) taken at 14 days post-inoculation of the 
K7M3 cells. As shown in Figure. 5.12A, merged CT and PET images demonstrated noticeable 
radioactivity in the tumor-bearing right hind leg of mouse injected with Pam-64Cu-NP (3.0% 
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injected dose per gram of tissue (%I.D.g-1) as early as 1 hour post injection (p.i.) (Figure. 5.12B), 
while in comparison the radioactivity detected in the normal contralateral left hind leg was 
approximately 50% less (1.8 %I.D.g-1). The increased radioactivity detected in the tumor-bearing 
leg was maintained for as long as 24 hours p.i. (2.8 %I.D.g-1, Figure. 5.12B), suggesting the Pam-
64Cu-NPs were preferentially retained in the osteolytic tumor microenvironment presumably due 
to the high binding affinity with inorganic bone matrix. In contrast, the accumulation of non-
targeted 64Cu-NPs was much lower than Pam-64Cu-NP (1.8 versus 3.0 %I.D.g-1 1 hour p.i. and 1.9 
versus 2.8 %I.D.g-1 24 hour p.i.) and showed no difference between tumor-bearing right hind legs 
(1.9 %I.D.g-1) and normal contralateral left hind legs (1.7 %I.D.g-1), (Figure. 5.12B). Three 
dimensional reconstructed imaging and movie also provide evidence for the significantly enhanced 
accumulation of Pam-64Cu- NPs in the right leg at 5 hours p.i compared to 64Cu-NPs (Figure. 
5.12C). These results were further confirmed by ex vivo measurement of radioactivity 24 hours 
p.i. in surgically resected tumor-bearing right hind legs with a γ-counter (2.6 and 1.9 %I.D.g-1 for 
Pam-64Cu-NPs and 64Cu-NPs, respectively), (Figure. 5.12D). The accumulation of Pam-64Cu-NPs 
and 64Cu-NPs in the blood and other organs were also assessed by γ-counter, and demonstrated 
comparable soft tissue biodistribution profiles in other organs (Figure. 5.13). 
 
Figure 5.11. Stability of 64Cu labeling with Pam-64Cu-NPs and 64Cu-NPs in serum. 
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Figure. 5.12. Radio-labeled Pam-NP improves in vivo intratumoral accumulation and retention in 
murine orthotropic osteosarcoma after systemic administration. (A) In vivo whole-body dynamic 
micro-PET/CT imaging of mice was performed to assess the accumulation of Pam-64Cu-NPs) and 
64Cu-NPs in the tumor residing right hind leg (yellow box and arrow) at 1, 5 , and 24 hour p.i. 
(amplified, inset in yellow box). (B) The kinetics of the accumulation of Pam-64Cu-NPs and 64Cu-
NPs in tumor residing right hind leg and normal contralateral left hind leg at 1, 5, and 24 hour p.i., 
evaluated by micro-PET/CT imaging. (C) The corresponding three-dimensional micro-PET/CT 
imaging at 5 hour p.i. shows accumulation of Pam-64Cu-NPs or 64Cu-NPs in the tumor residing 
right hind leg (amplified, inset). (D) The accumulation of Pam-64Cu-NPs and 64Cu-NPs in bone 
tumor residing right hind leg, assessed by γ counter.  
 
 
 
 
 
Figure. 5.13. In vivo biodistribution of Pam-64Cu-NPs (blue bar) and 64Cu-NPs (green bar) in 
K7M3 OS bearing mice, assessed by γ-counter. All the data was presented as percentage of injected 
dose per gram of tissues (% I.D. g-1). 
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5.3.4 In vivo efficacy of Pam-Doxo-NPs in mice gainst OS in murine model 
 
Given the preferential accumulation of Pam-NPs to focal regions of skeletal osteolysis 
demonstrated by micro-PET/CT images, I reasoned that improved anti-tumor activity could be 
achieved with Pam-NPs loaded with Doxo. To investigate this therapeutic potential, I evaluated 
the efficacy of Pam-Doxo-NPs using the K7M3 OS model and a defined treatment protocol 
(Figure.  5.14A), in which in vivo tumor burden was demonstrated to be well correlated with the 
bioluminescent signal intensity. Fourteen days following K7M3 inoculation, mice were imaged 
and equally distributed based upon bioluminescent intensities into four intravenous therapeutic 
groups (n = 6), being saline, Pam functionalized blank vehicles (Pam-NPs), Doxo-NPs and Pam-
Doxo-NPs. Following randomization, mice received intravenously therapy once weekly for 2 
consecutive weeks and were then monitored for an additional week prior to sacrifice (Figure.  
5.14A). As expected, mice treated with Pam-Doxo-NPs showed a significant delay in the tumor 
growth compared to all other treatment groups (Figure.  5.14B, C, D). Importantly, only mice 
receiving Pam-Doxo-NPs had the possibility of achieving macroscopic tumor volume regression, 
while mice receiving other therapies (saline, Pam-NPs, or Doxo-NPs) uniformly demonstrated 
tumor progression at a rate of 100% of the treated mice (Figure.  5.14 B, C). The median fold 
increase of bioluminescent signal from Day 14 (pre-treatment) following 2 consecutively weekly 
treatments of intravenous Pam-Doxo-NPs was 1.8-fold, while treatment with saline, Pam-NPs, or 
Doxo-NPs produced markedly higher median fold increases of bioluminescent signal (13.9, 4.6, 
and 4.5-fold, respectively; Figure.  5.14C). In addition to bioluminescent signal changes, 
histologic analysis of tumor surface area post-mortem also supported increase anti-cancer activities 
exerted by Pam-Doxo-NPs above other treatment groups (Figure.  5.14B, D). For mice treated 
with Pam-Doxo-NPs, the median tumor surface area was 2.4 ×104 µm2 (p<0.05, compared to saline 
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control), however, no difference in tumor surface area was identified among remaining 3 treatment 
groups (Figure.  5.14D). To further confirm the enhanced efficacy achieved by Pam-Doxo-NPs, 
the extent and degree of bone destruction resultant from localized OS progression was evaluated 
by micro-CT. As illustrated in Figure.  5.14E, severe pathologic osteolysis associated with OS 
progression could be readily identified within the right proximal tibias of tumor-bearing mice 
receiving saline, Pam-NPs, and to a lesser extent with Doxo-NPs. In contrast, malignant osteolysis 
was attenuated in mice receiving Pam-Doxo-NPs, and resulted in a trend towards increased 
percentage of bone volume (leg with K7M3 tumor/normal leg × 100%) (Figure. 5.15). 
Collectively the observations of reduced bioluminescent signal change and tumor surface area, as 
well as the trend towards preserved bone volume, provide strong support for increased anti-tumor 
efficacy of Pam-Doxo-NPs compared with their non-targeted counterparts in an orthotopic murine 
model of OS. 
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Figure. 5.14. Pam-Doxo-NPs exert anticancer activities in murine orthotropic osteosarcoma after 
systemic administration. (A) Experimental procedure of in vivo bone tumor induction and 
treatment protocol. (B) Serial changes in K7M3 BLI as a function of time and treatment. 
Representative bioluminescent signal of mice before treatment and after different treatments: PBS 
as control, Pam-NP, Doxo-NP and Pam-Doxo-NP (Doxo equivalent dose: 50 mg/kg); and 
representative hematoxylin and eosin (H&E) images for pathology analysis. The relative tumor 
burden increase of four groups of mice after treatments, evaluated and quantified by (C) BLI and 
(D) histopathology. Data expressed as median and interquartile range and compared with Kruskal-
Wallis non-parametric ANOVA and post hoc Dunn’s test; significance defined as *p<0.05 
comparing with PBS as control.  (E) Micro-CT images of proximal tibias (tumor [T] versus control 
[C]) in 4 representative mice receiving different intravenous treatments of NPs. White circle 
indicated the leg with inoculated tumor. 
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Figure 5.15. In vivo efficacy of Pam-Doxo-NPs in orthotopic murine OS tumor model. Percentage 
of bone volume (leg with K7M3/normal leg × 100%) among mice receiving different intravenous 
treatments of NPs. 
 
 
 
 
5.3.5 Clinical evaluation of OS tumor targeting of Pam-Doxo-NPs in dogs 
Given the promising preclinical murine studies, I sought to further test the translational 
application of Pam-NPs in a large mammalian model system. For these purposes, I work with 
Professor Timothy Fan to choose to utilize dogs that naturally and spontaneously develop 
appendicular OS to serve as a physiologically-relevant model of focal malignant osteolysis similar 
to what occurs in human cancer patients. As part of a Phase I clinical trial in pet dogs diagnosed 
with OS, we studied the dynamic in vivo biodistribution profile of intravenously administered 
Pam-NPs labeled with 99mTc in dogs (Figure. 5.16). Upon intravenous infusion, Pam-NPs labeled 
with 99mTc were rapidly distributed to all major visceral organs including the heart, kidney, spleen, 
and liver, with eventually elimination into the urinary bladder (Figure. 5.16). Importantly, 
localization and accumulation of 99mTc labeled Pam-NPs was observed within the localized bone 
tumor microenvironment, indicating that Pam surface-modification can quickly target areas of 
malignant osteolysis in vivo within 1-2 hours after administration (Figure. 5.16). Furthermore, 
99mTc activity preferentially intensified in a time-dependent manner, suggesting the dynamic 
ba
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concentration and accumulation of Pam-NPs within the bone tumor microenvironment (Figure. 
5.16). To confirm that the detection of 99mTc radioactivit
indeed 99mTc labeled Pam-NPs and not simply free 99mTc as a consequence of spontaneous 
dissociation from Pam-NPs in vivo, we assessed the radiochemical purity of 99mTc labeled Pam-
NPs immediately before intravenous infusion and also the 99mTc signal which accumulated in the 
bladder (urine) 2 hours post-infusion (Figure. 5.17). The radiochemical purities of 99mTc labeled 
Pam-NPs immediately prior to intravenous infusion and 2-hours post infusion found within the 
urine were greater than 95%, providing evidence that the detected 99mTc radioactivity in pet dogs 
with OS was indeed associated with 99mTc labeled Pam-NPs. 
 
Figure. 5.16. Biodistribution of 99mTc-labeled Pam-Doxo-NPs in pet dogs with osteosarcoma. (A) 
Dynamic overlay of 180 gamma camera images acquired over 3 minutes (1 image/second) of 
99mTc-labeled Pam-Doxo-NPs infused intravenously into a pet dog with osteosacoma. Tracking of 
99mTc-labeled Pam-Doxo-NPs can be readily observed in highly perfused visceral tissues (1- site 
of intravenous infusion [lateral saphenous vein]; 2-descending caudal vena cava; 3-urinary 
bladder; 4-left kidney; 5-right kidney; 6-liver; and 7-heart). (B) Serial images from 5-60 minutes 
post infusion of 99mTc-labeled Pam-Doxo-NPs demonstrates prolonged dwell time in highly 
vascular visceral organs with ultimate renal elimination into the bladder. (C) In vivo perferential 
localization of 99mTc-labeled Pam-Doxo-NPs to regions of focal malignant osteolysis in 2 
representative dogs with OS (left- dog 1 with distal radial OS; right- dog 2 with distal femoral OS) 
confirmed by co-localization of pathologic radiographic changes and 99mTc activity. (D) 
Representative images of progressive 99mTc-labeled Pam-Doxo-NPs accumulation within focal 
areas of malignant osteolysis as a function of time (1-hour and 2-hour p.i.).  
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C D
1 hour
2 hour
122 
 
 
Figure. 5.17. Radiochemical purity assessment of 99mTc labeled Pam-Doxo-NPs immediately 
before intravenous infusion (left) and 2-hours post-infusion (right). 
 
 
5.3.6 Clinical evaluation of efficacy and toxicity of Pam-Doxo-NPs in dogs 
Upon confirming the osteotropic homing properties of Pam-NPs in dogs with OS, we next 
sought to explore the tolerability and anticancer activities of Pam-Doxo-NPs. Through a rapid 
dose-escalation protocol (Figure. 5.18), nine pet dogs with OS were treated with a single 
intravenous infusion of Pam-Doxo-NPs, with each subsequent pet dog recruited for study 
progressively receiving a greater dosage of Doxo equivalent (0-180 mg/m2 dose equivalent).  
Following intravenous infusion, pet dogs were monitored for hematologic and biochemical 
toxicity weekly for 3 weeks and then underwent amputation of the diseased limb to allow for 
histologic assessment of anticancer activity (percent tumor necrosis) within the primary OS lesion. 
Even at the highest Doxo dosage equivalent evaluated (180 mg/m2), Pam-Doxo-NPs were safe and 
did not cause any hematologic, renal, or persistent hepatic toxicity (Figure. 5.18). In 2 dogs, mild 
to moderate elevations in liver transaminases were identified 1 week post Pam-Doxo-NP 
administration, however, trended towards normalization upon subsequent reevaluations. In 
addition to hematologic and biochemical tolerability of Pam-Doxo-NP, no evidence of 
cardiotoxicity was identified in any dog as determined by circulating cardiac troponin-I 
a
b
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123 
 
concentrations (Figure. 5.19). Importantly, Pam-Doxo-NPs exerted moderate anticancer activity 
as determined by percent tumor necrosis, which was correlated (r2 = 0.61, p = 0.04) with 3 factors 
that dictated the concentrations of Doxo achieved within the bone tumor microenvironment being 
1) total dosage of Doxo, 2) magnitude of 99mTc labeled Pam-Doxo-NPs accumulation within tumor 
site, and 3) overall bone tumor volume of distribution (Figure. 5.20).  
 
Figure. 5.18. Exceptional biocompatibility of Pam-Doxo-NPs following single-dose intravenous 
infusion. (A) Clinical trial design for pet dogs receiving Pam-Doxo-NPs. (B) Hematologic and (C) 
biochemical safety profile of Pam-Doxo-NPs following single-dose, intravenous administration.  
Complete absence of grade I toxicity (dotted line) for total neutrophil and platelet counts 
throughout entirety of study. Mild and transient elevations in liver transaminases identified 1-week 
p.i. of Pam-Doxo-NPs administration in minority of pet dogs treated. 
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Figure. 5.19. Cardiac toxicity evaluation of Pam-Doxo-NPs. Serial cardiac troponin-I 
concentrations as a function of time post-infusion of Pam-Doxo-NPs in dogs receiving wide ranges 
of Doxo equivalent. Upper normal reference range (green dotted line) and lower reference range 
for cardiac insufficiency (red dotted line). 
 
 
 
Figure 5.20. Anticancer activities of Pam-Doxo-NPs following single-dose intravenous infusion 
in pet dogs. (A) Variables which influence anticancer activities exerted by Pam-Doxo-NPs include 
absolute Doxo dose, 99mTc-labeling intensity (red oval), and absolute tumor volume (calculated by 
ellipsoid formula 4/3π(length × width × depth). (B) Percent tumor necrosis of bone tumors from 
amputated dog legs evaluated by H&E staining and linear correlation with the ratio of three 
variables (Doxo dose × 99mTc-labeling intensity)/(absolute tumor volume). Data analyzed with 
Pearson correlation; signficance defined as p<0.05. 
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5.4 Conclusions 
In this chapter, I successfully demonstrated Pam surface-modified PLA NPs could 
significantly improve their accumulation and retention within the diseased bone tumor 
microenvironment. By virtue of preferential anatomic targeting, Pam-Doxo-NPs were capable of 
minimizing systemic off target toxicities and concurrently enhancing localized anti-tumor 
activities in not only a preclinical murine tumor model, but also a clinically relevant, large 
mammalian tumor model, being pet dogs with osteosarcoma.  
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CHAPTER 6 
TARGETED DRUG-POLYESTER NANOCONJUGATES THROUGH 
BIOORTHOGONAL OXIME LIGATION 
 
6.1 Introduction 
As introduced in precious chapters, nanoparticles (NPs) can be engineered to carry various 
therapeutic agents, extravasate leaky blood vessels, reach and accumulate at tumor tissues, target 
malignant cancer cells, and release cargos in a controlled manner.1-3 When combined with active 
targeting ligands, e.g., antibodies, peptides, aptamers, or small molecules, NPs could be selectively 
targeted to specific cancer cell surface receptors to treat certain types of cancer.4-8 Although 
moderate cancer targeting efficiency can be achieved, this active targeting strategy has its intrinsic 
limitations. First, it mainly relies on specific and strong biological interaction between a natural 
target and the corresponding biomacromolecule ligand, however, the biological interaction is 
generally weaker than covalent binding. For example, the typical dissociation constant Kd between 
antibody and its antigen is in the range of 10-6~10-8 M,9 while Kd in many highly robust 
bioorthogonal reactions is below 10-8 M.10-12 Second, different cancer cells always express 
heterogeneous receptors and the number of receptors per cell is always limited , which results in 
insufficient targeting or undesired off-targeting. Third, biomacromolecule binding ligands are 
generally more immunogenic and vulnerable than small molecule ligands and may be subjected to 
enzymatic degradation in vivo; the large size and undesired physiochemical properties of the 
biomacromolecule binding ligands may hinder their access to the target, in particular when they 
are conjugated onto the surface of NPs. Sophisticated technique is always involved in the 
incorporation such biomacromolecular ligands with NPs to maintain the binding site intact. 
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Bioorthogonal chemical conjugation, a reaction based on covalent binding between two 
bioorthogonal functional groups, has emerged as an attractive alternative to specific biological 
interaction in vivo due to its high specificity, efficiency and biocompatibility.13,14 Compared with 
abovementioned biological interactions, it has obvious benefits. First, extremely high affinity 
between an unnatural target and the ligand bearing a pair of bioorthogonal functional groups 
respectively could be achieved using highly specific and robust bioorthogonal chemistry. Second, 
unnatural target bearing one bioorthogonal functional group of the pair can be artificially 
introduced onto cancer cells in a controlled manner through various cell surface engineering 
methodologies.  For example, several bioorthogonal functional groups such as azide group or 
aldehyde group can be introduced to display on cell membrane through metabolic 
glycoengineering or liposome fusion technique.15-17  Third, small molecule ligand is generally easy 
to be synthesized in large scale, stable in physiological condition, facile for the incorporation into 
NPs with minimum impact on the NP properties due to the small size. Therefore, using 
bioorthogonal chemical conjugation could be a promising strategy for in vivo cancer targeting.18 
Among a variety of efficient click-type bioorthogonal condensation reactions,19 oxime 
ligation between an oxyamine and an aldehyde or a ketone is a highly specific and efficient.20 The 
formed oxime is highly stable toward hydrolysis (Kd ≤ 10-8 M) comparing to the corresponding 
imines or hydrazones.21 Oxime ligation is compatible with most biomolecule functionalities 
including amines and ideally suited for application in living system. Thus, I report in this chapter 
a novel strategy to improve the cancer targeting of PLA-based NPs through bioorthogonal oxime 
ligation. First, one bioorthogonal functional group (oxyamine) is introduced onto cancer cell 
surface by using liposome delivery and fusion through passive cancer targeting, i.e. enhanced 
permeation and retention (EPR) effect of nanomedicine. Second, the other bioorthogonal 
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functional group (aldehyde) functionalized NPs are guided to targeted tumor through oxime 
ligation reaction.  
 
6.2 Materials and Methods 
6.2.1 General 
Egg palmitoyl-oleoyl phosphatidylcholine (POPC) and 1,2-dioleoyl-3-
trimethylammoniumpropane (DOTAP) were purchased from Avanti Polar Lipids (Alabaster, AL, 
USA). D,L-Lactide (LA) was purchased from TCI America (Portland, OR, USA), recrystallized 
three times in toluene and stored at -30 °C in a glovebox prior to use. (S)-2,2',2'',2'''-(2-(4-
isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (p-SCN-
Bn-DOTA) was purchased from Macrocyclics, Inc. (Dallas, TX, USA). Butyraldehyde-PEG-
Valeric acid (bAld-PEG-VA, Mw=3400) was purchased from Laysan Bio, Inc. (Arab, Alabama, 
USA). All anhydrous solvents used in this study were purified by being passing through dry 
alumina columns and kept anhydrous by using molecular sieves. Other chemicals were purchased 
from Sigma-Aldrich (St Louis, MO, USA) and used as received unless otherwise noted. The NMR 
experiments were conducted on a Varian U400 (400 MHz), U500 or VXR500 (500 MHz) NMR 
spectrometer. Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry 
(MALDI-TOF MS) spectra was collected on an Applied Biosystems Voyager-DETM STR system. 
The size and the particle polydispersity of the liposome and the poly(ethylene glycol)-b-
polylactide nanoparticle (PEG-PLA NP) were determined on a ZetaPALS dynamic light scattering 
(DLS) instrument (15 mW laser, incident beam = 676 nm, Brookhaven Instruments, Holtsville, 
NY, USA) and a JEOL 2100 Transmission Electron Microscope (TEM). The ζ-potential of freshly 
prepared liposomes and PEG-PLA NPs were evaluated by Malvern Zetasizer (Herrenberg, 
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Germany). The 4T1 cells (ATCC, Manassas, VA, USA) used for in vitro and in vivo studies were 
cultured in DMEM medium containing 10% Fetal Bovine Serum (FBS), 100 units/mL aqueous 
Penicillin G and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA, USA). The confocal 
microscopy images were taken on a Zeiss LSM700 Confocal Microscope (Carl Zeiss, Thornwood, 
NY, USA) using a 63×/1.4 oil lens with excitation wavelength set at 405 nm, 555 nm and 633 nm. 
The flow cytometry analysis of cells was conducted with a BD FACSCanto 6 color flow cytometry 
analyzer (BD, Franklin Lakes, NJ, USA). Female BALB/c mice were purchased from National 
Cancer Institute (NCI, Frederick, MD, USA). Feed and water were available ad libitum. Artificial 
light was provided in a 12/12 hour cycle. The study protocol was reviewed and approved by The 
Illinois Institutional Animal Care and Use Committee (IACUC) of the University of Illinois at 
Urbana Champaign. Micro-PET/CT imaging was performed with small animal on a Siemens 
Inveon PET-CT system (Siemens Healthcare, USA). Ex vivo measurement of the radioactivity was 
conducted on a 2480 Wizard2 Automatic Gamma Counter (Perkin-Elmer). The flash frozen tumor 
tissue was embedded with optimum cutting temperature (OCT) compound (Sakura Finetek USA, 
Torrance, CA, USA) and sectioned with a Leica CM3050S cryostat and mounted on glass slides 
for histological analysis.  
 
6.2.2 Synthesis of O-dodecyloxyamine (Oa-C12) 
 
 
O-dodecyloxyamine (Oa-C12) was synthesized according to the published procedure. To a 
solution of N-hydroxyphthalimide (3.92 g, 24.0 mmol) and sodium bicarbonate (2.02 g, 24.0 mmol) 
Oa-C12
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in dimethylformamide (DMF) at 80°C was added 1-bromododecene (3.86 mL, 16.0 mmol). The 
mixture was stirred and refluxed for 12 h. the reaction was diluted with DCM and washed with 
H2O (6  × 100 mL), 1 M NaHCO3 (3 × 100 mL) and H2O (2 × 100 mL), dried over MgSO4, and 
concentrated to afford a white solid (4.77 g, 90%). 1H NMR (400 MHz, CDCl3) δ 7.85-7.83 (m, 
2H), 7.76-7.73 (m, 2H), 4.20 (t, J = 6.8 Hz, 2H), 1.83-1.75 (m, 2H), 1.51-1.43 (m, 2H), 1.31-1.26 
(m, 16 H), 0.88 (t, J = 6.8 Hz, 3H).  
 
To a solution of the above compound (995 mg, 30 mmol) in dry DCM (10 mL) under argon was 
slowly added hydrazine (0.57 mL, 18.0 mmol). Upon addition, a white precipitate was 
immediately formed. The mixture was stirred at room temperature (rt) for 12 h. The reaction 
mixture was diluted with DCM (50 mL) and washed with H2O (6  × 15 mL), dried over Na2SO4, 
and concentrated to afford a pale yellow oil (452 mg,  79%). 1H NMR (400 MHz, CDCl3) δ 5.33 
(bs, 2H), 3.64 (t, J = 6.8 Hz, 2H), 1.57-1.54 (m, 2H), 1.28-1.20 (m, 18H), 0.88 (t, J = 6.8 Hz, 3H).  
 
6.2.3 Synthesis of rhodamine labelled Oa-C12 (Rhd-C12)  
 
To a mixture of Rhodamine B isothiocyanate (Rhd, 28.4 mg, 0.053 mmol) and triethylamine (27 
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L, 0.27 mmol) in anhydrous DMF (0.5 mL), Oa-C12 (10.7 mg, 0.053 mmol) was added under 
nitrogen and stirred at 60 °C overnight. The product is then precipitated by ethyl ether. After the 
solvent was evaporated, the crude product was purified by preparative TLC 
(dichloromethane:methanol, 9:1 v/v) and used directly.   
 
6.2.4 Synthesis of Rhd bearing an aldehyde group (Ald-Rhd) 
 
To a mixture of Rhd (5 mg, 0.0093 mmol) and triethylamine (6 L, 0.059 mmol) in methanol (0.3 
mL), 2-(1,3-Dioxolan-2-yl)ethanamine (10 mg, 0.08 mmol) was added and stirred at 60 °C 
overnight. The product is then precipitated by ethyl ether. The dark purple precipitate is treated 
with acidic beads (Amberlyst® 15 hydrogen form) and stirred for 3 h at room temperature. 
Triethylamine was added until the solution reached pH=7. The reaction mixture was then 
concentrated to afford a dark purple powder and used without further purification. MALDI (m/z): 
calcd for C32H37N4O4S+, 573.7, [M]+; found, 573.0 [M]+.  
 
6.2.5 Syntheses of PEG-PLA polymer and aldehyde functionalized PEG-PLA (Ald-PEG-
PLA) 
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The PEG-PLA and NH2-PLA (25-mer) polymer conjugates were synthesized following a similar 
procedure as published before.22 In a reaction vial containing anhydrous DMF solution (4.2 mL) 
of bAld-PEG-VA (85 mg, 0.025 mmol) was added 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDC) (4.8 mg, 0.025 mmol) and N-hydroxysuccinimide (NHS) 
(2.9 mg, 0.025 mmol). The reaction mixture was stirred at rt for 15 min followed by the addition 
of NH2-PLA conjugate (146.9 mg, 0.025 mmol). The reaction mixture was stirred overnight under 
nitrogen at rt. The solvent was removed under vacuum to give Ald-PEG-PLA. The polymer was 
precipitated with ether (50 mL) collected by centrifugation, dried under vacuum and used directly. 
 
6.2.6 Synthesis of fluorescently labeled Cy5-PLA polymer conjugate 
Cy5-PLA (50-mer) polymer conjugate was synthesized following a similar procedure as published 
before.23,24 In a glove box, Cy5 (5.0 mg, 0.01 mmol) was dissolved in anhydrous tetrahydrofuran 
(THF, 900 µL) and mixed with a THF solution (500 µL) containing (BDI-EI)ZnN(TMS)2 (6.5 mg, 
0.01 mmol). The mixture was stirred for 15 min at rt. LA (72.0 mg, 0.5 mmol) was dissolved in 
THF (1 mL) and added to the stirred mixture of (BDI-EI)ZnN(TMS)2 and Cy5. The reaction 
proceeded in the glovebox overnight. After LA was completely consumed, the reaction was 
stopped by quenching the polymerization solution with cold methanol solution (300 µL). The 
polymer was precipitated with ether (50 mL), collected by centrifugation and dried under vacuum.  
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6.2.7 Synthesis of DOTA-PLA polymer conjugate 
The DOTA-PLA polymer conjugate was synthesized following the similar procedure as published 
before. In a reaction vial containing NH2-PLA (25-mer; 14.4 mg, 0.004 mmol) was added an 
anhydrous DMF solution (0.5 mL) of p-SCN-Bn-DOTA (5.6 mg, 0.008 mmol) and triethylamine 
(3.6 mg, 0.036 mmol). The reaction mixture was stirred for 4 h under nitrogen at rt. The solvent 
and triethylamine were removed under vacuum to give DOTA-PLA, which was used directly 
without further purification. 
 
6.2.8 General procedure for the preparation of liposome bearing Oa group (Oa-Lip)17 
Oa-C12 (120 μL of 10 mM solution in chloroform, 1.2 µmol) were dissolved with egg-POPC (424 
μL of 10 mg/mL in chloroform, 5.58 µmol) and DOTAP (10 μL of 10 mg/mL in chloroform, 0.14 
µmol) followed by nitrogen blow to evaporate all the solvent to form a lipid film in the glass vial.  
The lipid film was further dried under high vacuum for 4 h. The dried lipid film was then 
rehydrated with PBS buffer (3 mL) and sonicated (15 W) with a tip sonicator for 20 min at 50 °C 
until the clear solution was formed. The formed liposome solution was brought to a final volume 
of 3 mL in PBS and sterilized with filter (0.45 µm). 
 
For the preparation of fluorescent Oa-Lip (Rhd-Lip), Rhd-C12 (120 μL of 10 mM solution in 
chloroform, 1.2 µmol) were dissolved with the same amount of egg-POPC and DOTAP followed 
by the same preparing procedure. 
 
6.2.9 General procedure for the preparation of PEG-PLA NP (NP) and PEG-PLA NP with 
surface-modified aldehyde groups (Ald-NP) 
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NP: The PEG-PLA NPs were prepared using nanoprecipitation method as described in previous 
publications.22 A DMF solution of PEG-PLA polymer (200 μL, 10 mg/mL) was added dropwise 
to rapid stirring Millipore water (4 mL). The resulting NPs were collected by ultrafiltration (5 min, 
3000 × g, Ultracel membrane with 10,000 NMWL, Millipore, Billerica, MA, USA), washed with 
DI water and then characterized by DLS and TEM for particle sizes and size distributions. 
 
Ald-NP: A DMF solution of the mixture of Ald-PEG-PLA (100 μL, 10 mg/mL) and PEG-PLA 
polymer (100 μL, 10 mg/mL) was added dropwise to rapid stirring Millipore water (4 mL). The 
resulting Ald-NPs were collected and washed similarly. 
 
For the preparation of fluorescently labeled NP or Ald-NP, Cy5-PLA (100 μL, 10 mg/mL) was 
mixed with the DMF solution of PEG-PLA or PEG-PLA/Ald-PEG-PLA polymer for subsequent 
nanoprecipitation. The resulting fluorescent NPs were collected and washed similarly. 
 
6.2.10 Preparation of radio labeled NP and Ald-NP22 
A DMF solution of the mixture of Ald-PEG-PLA (100 μL, 10 mg/mL), PEG-PLA polymer (100 
μL, 10 mg/mL) and DOTA-PLA (100 μL, 10 mg/mL) was added dropwise to rapid stirring 
Millipore water (6 mL). The resulting DOTA-Ald-NPs were collected and washed similarly. The 
DOTA-NPs were prepared similarly using PEG-PLA polymer (200 μL, 10 mg/mL) and DOTA-
PLA (100 μL, 10 mg/mL). 
 
The 64Cu chloride (300 μCi, Washington University in at St. Louis, MO, USA) was mixed with 
NP or Ald-NP (3 mg) in NH4OAc buffer (pH=5.5, 0.1 M, 0.5 mL). The mixture was incubated for 
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1 h at 60 °C. The NPs were washed by ultrafiltration (10min, 3000 × g, Ultracel membrane with 
10 000 NMWL, Millipore, Billerica, MA, USA). To determine the labeling efficiency, the 
supernatant was collected and measured on γ-counter for the radioactivity. The purified 64Cu-
labeled NP or Ald-NP were used for injection. 
 
6.2.11 In vitro 4T1 cell surface engineering with Rhd-Lip and Oa-Lip 
4T1 cells (50,000) were seeded in a 4-well chamber slide for 24 h. Cells were washed once with 
opti-MEM. A PBS solution of Rhd-Lip (300 μL, 2.1 mM) was added to 4T1 cells in 1 mL opti-
MEM and incubated at 37 °C for 4 h. After liposome fusion, the cells were washed with PBS (3 × 
1 mL), fixed with 4% paraformaldehyde, stained for nucleus with 4',6-diamidino-2-phenylindole 
(DAPI) and then imaged under a confocal microscope. Free Rhd-C12 at equivalent amount in Rhd-
Lip was used as control. 
 
In another study, a PBS solution of Oa-Lip (300 μL, 2.1 mM) was added similarly to 4T1 cells 
(50,000, seeded in a 4-well chamber slide) in 1 mL opti-MEM and incubated at 37 °C for 4 h. 
After liposome fusion, the cells were washed with PBS (3 × 1 mL) and incubated with 1 mL opti-
MEM containing Ald-Rhd (0.1 mM) or Rhd (0.1 mM) at 37 °C for another 4 h. The cells were 
then fixed with 4% paraformaldehyde, stained for nucleus with DAPI and imaged under a confocal 
microscope.  
 
6.2.12 In vitro 4T1 cell targeting with Ald-NP 
Confocal study: 4T1 cells (50,000) were seeded in a 4-well chamber slide for 24 h. Cells were 
washed once with opti-MEM and then incubated for 4 h at 37 °C with opti-MEM (1 mL) containing 
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Oa-Lip (300 μL, 2.1 mM). After liposome fusion, the cells were washed with PBS (3 × 1 mL) and 
incubated with 1-mL opti-MEM containing Ald-NP (0.12 mg/mL) or NP (0.12 mg/mL) at 37 °C 
for another 6 h. The cells were then washed by PBS (3 × 1 mL), fixed with 4% paraformaldehyde 
and subsequently imaged on a confocal laser scanning microscope. Nuclei were stained by DAPI. 
Cells without the addition of Oa-Lip were imaged as the control.  
 
Flow cytometry study: 4T1 cells (200, 000) were seeded in a 12-well plate for 24 h. Cells were 
washed once with opti-MEM and then incubated for 4 h at 37 °C with opti-MEM (1 mL) containing 
Oa-Lip (300 μL, 2.1 mM). After liposome fusion, the cells were washed with PBS (3 × 1 mL) and 
incubated with 1 mL opti-MEM containing Ald-NP (0.12 mg/mL) or NP (0.12 mg/mL) at 37 °C 
for another 6 h. The cells were then washed with PBS (3 × 1 mL) and detached via trypsinization. 
Cells were fixed with 4% paraformaldehyde for flow cytometry analysis (10,000 cells analyzed). 
The mean fluorescence intensity was assessed. All experiments were performed in triplicate. 
 
6.2.13 In vivo tumor cell surface engineering with Rhd-Lip 
BALB/c mice (female, 6-week old) were injected subcutaneously on one flank with 1 × 105 4T1 
cells suspended in a 1:1 mixture of HBS buffer and matrigel (BD Biosciences, Franklin Lakes, NJ, 
USA). 4T1 tumor-bearing BALB/c mice were divided randomly into groups of three (n = 3) and 
were treated when the mean tumor diameter was in the range of ~8.0 mm at Day 12 after 
inoculation. Each animal received a PBS solution of Rhd-Lip (200 L per tumor, 2.1 mM) through 
intratumoral injection. The animals were euthanized 4 h or 24 h post the intratumoral injection and 
the tumors were collected. The flash frozen tumor tissues were embedded with optimum cutting 
temperature compound (OCT) (Sakura Finetek USA, Torrance, CA, USA). Tumor sections (5 µm 
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thickness) were collected by cryostat with a Leica CM3050S cryostat and mounted on glass slides 
for confocal imaging. 
 
6.2.14 In vivo biodistribution study with Micro-PET.  
Six female BALB/c mice (female, 6-8 week old) bearing subcutaneous 4T1 murine breast tumors 
(~8.0 × 8.0 mm) on the both flanks were divided into two groups (n = 3), minimizing the tumor 
size and body weight differences. In both of groups, the left tumor was injected with Oa-Lip (2.1 
mM, 200 µL) and the right tumor was injected PBS (200 µL) as the control. The two groups of 
mice were then injected intravenously with 64Cu-labeled Ald-NPs or NPs at a dose of 50 µCi 4 h 
post the intratumoral injections. Mice were placed on the micro-CT imaging bed and kept 
anaesthetized with a constant isoflurane flow (~2%). The micro-CT scan (80keV/500uA X-rays 
energy, 360 projections, 360 degrees, 75 µm pixel size) was used for determining the anatomical 
localization of different organs. Static micro-PET scans were acquired at three selected time points 
(1 h, 6 h and 24 h p.i.) together with micro-CT scans for anatomical co-registration. The obtained 
micro-PET and micro-CT images were reconstructed using ordered subset expectation 
maximization (OSEM) and cone-beam algorithms with existing commercial software (Inveon 
Acquisition Workspace and Cobra Exxim, respectively). Micro-PET images were processed using 
3-D median filtering and fused with micro-CT images. To quantify the radioactivity of 64Cu in 
different organs, complex irregular volumes of interest (VOIs) were drawn on the micro-CT 
images and registered with the micro-PET images to determine mean counts in each VOI. To 
minimize partial volume effects, the anatomical borders of the organs were not included. The 
radiotracer activity from each VOI was normalized by injected dose and expressed as percent of 
the decay-corrected injected activity per cm3 of tissue, which can be approximated as 
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percentage %I.D./g assuming the density of tissue is ~1 g/cm3. The initial total injected activity 
was determined by dose calibrator before the injection.   
 
6.2.15 Radioactivity measurement with γ-counter 
Mice were euthanized 24 h post injection. Both of 4T1 subcutaneous tumors were collected, 
weighed and measured for radioactivity (64Cu) with a γ-counter (Wizard2, Perkin-Elmer, USA) 
using appropriate energy window centered at photo peak of 511 keV.  Raw counts were corrected 
for background, decay, and weight. Corrected counts were converted to microcurie per gram of 
tissue (μCi/g) with a previously determined calibration curve by counting the 64Cu standards.  
 
Statistical Analyses 
Student T-Test (two tailed) comparisons at 95% confidence interval were used for statistical 
analysis. The results were deemed significant at *p < 0.05. 
 
6.3 Results and Discussion 
To prove the concept, the artificial target, oxyamine group, was labeled on 4T1 murine 
breast cancer cell through liposome delivery and fusion. The cancer targeting efficiency was 
evaluated in vitro and in vivo using PEG-PLA NPs functionalized with aldehyde groups on the 
surface (Ald-NP, Scheme 6.1).  
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Scheme 6.1. Schematic illustration of cancer targeting of poly(ethylene glycol)-b-polylactide 
nanoparticles surface-modified with aldehyde groups (Ald-NPs) through bioorthogonal oxime 
ligation. Oxyamine (Oa) groups were labeled on cancer cells through membrane fusion of 
liposomes bearing Oa groups (Oa-Lip).  
 
6.3.1 Formulation of oxyamine containing liposome 
Effective surface engineering of target cancer cells to present bioorthogonal function 
groups is the prerequisite for cancer targeting via chemical conjugation. Inspired by the recent 
work of Yousaf and others,17,25 we proposed to use tailored liposomes to introduce oxyamine group 
on cancer cells though liposome delivery and fusion. The O-dodecyloxyamine (Oa-C12) was first 
synthesized and incorporated into a liposome composed of a neutral lipid, egg palmitoyloleoyl 
phosphatidylcholine (POPC) and a cationic lipid, 1,2-dioleoyl-3-trimethylammoniumpropane 
(DOTAP) at a mole ratio of 17:81:2 (Oa-Lip, Scheme 6.2). The hydrophobic tail facilitated the 
spontaneous insertion of Oa-C12 into the liposome membrane. The cationic lipid, DOTAP, was 
added to enhance the interaction between the synthesized Oa-Lip and negatively charged cell 
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membrane through electrostatic destabilization and thus increase the liposome fusion and 
presentation of Oa groups on cell surface. The formulated Oa-Lip had a hydrodynamic size of 
135.7 nm determined by dynamic light scattering (DLS) and transmission electronic microscopy 
(TEM) (Figure 6.1). They also exhibited positive ζ-potential on surface (12.3 mV, Table 6.1) at 
neutral pH owing to Oa-C12 and DOTAP. 
 
Scheme 6.2. Preparation of Oa-Lip with POPC/DOTAP lipids and Oa with a hydrophobic tail (Oa-
C12). 
 
 
Figure 6.1. DLS (a) and TEM (b) characterizations of Oa-Lip. 
 
6.3.2 Engineering surfaces of target cancer cells with oxyamine functional group 
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We next used the Oa-Lip to engineer the 4T1 murine breast cancer cell surface. In order to 
verify the successful cell surface labeling, I first conjugated a fluorescence dye, rhodamine (Rhd), 
to Oa-C12 to prepare Rhd-C12 and formulated the fluorescent liposome with POPC/DOTAP at the 
same mole ratio (Rhd-Lip, Figure 6.2a). Rhd-Lips were then added to 4T1 cells and incubated in 
cell culture for 4 h (Figure 6.2b). The high fluorescence signal shown in the confocal microscopy 
image indicates the successful Rhd-Lip fusion and display of Rhd-C12 on 4T1 cells (Figure 6.2c). 
Direct addition of Rhd-C12 to the cell culture only resulted in minimum cell surface labeling of 
fluorescence suggesting the importance of liposome binding and fusion process. Further, I 
investigated whether the Oa groups displayed on the cell surface were still active for oxime 
ligation. The 4T1 cell surface was engineered with Oa-Lip similarly to present Oa groups on 4T1 
cell membrane (denoted as o4T1). A synthesized Rhd dye bearing an aldehyde group (Ald-Rhd) 
was subsequently added after washing off the excess Oa-Lip (Figure 6.3a). Markedly increased 
fluorescence signal was observed on the 4T1 cells with surface expressed Oa groups (o4T1) 
through the specific oxime ligation with Ald-Rhd. In contrast, o4T1 cells treated with 
nonfunctional Rhd or native 4T1 cells treated with Ald-Rhd resulted in limited level of 
fluorescence signal likely due to the nonspecific and low efficient conjugation or adsorption 
(Figure 6.3b). Therefore, these results demonstrated that cancer cell surface could be effectively 
engineered using liposome fusion strategy to express chemically active Oa groups to further 
facilitate specific oxime ligation on cell membrane.  
Intracellular fluorescence was observed during the liposome fusion process suggesting 
endocytosis of these liposomes or their components may occur after membrane fusion (Figure 
6.2c). This could provide a possible method for internal membrane engineering for intracellular 
targeting. However, it is noticed that sufficient functional groups were present on cell surface to 
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facilitate the oxime ligation with the corresponding ligands (Figure 6.3b). Such intracellular 
membrane labelling may be beneficial in the scenario of targeted intracellular drug delivery. 
 
 
Figure 6.2. (a) Preparation of fluorescent liposome (Rhd-Lip). (b) Schematic illustration of 
liposome fusion with 4T1 cells. (c) Confocal microscope imaging of the 4T1 cells after fusion with 
Rhd-Lip or addition of free Rhd-C12, PBS as controls. Blue, DAPI stained nucleus; red, Rhd-Lip. 
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Figure 6.3. (a) Schematic illustration of oxime ligation between Ald-Rhd and Oa groups on 4T1 
cell surface. (b) Verification of the reactivity of cell-surface Oa groups with Ald-Rhd by confocal 
microscope imaging of the 4T1 cells with different treatments. Blue, DAPI stained nucleus; red, 
Ald-Rhd. 
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6.3.3 Preparation of aldehyde functionalized nanoparticle. 
PEG and PLA are FDA approved biocompatible polymers widely used in the formulation 
of polymeric nanomedicines for cancer therapy.1,24 Small molecule anticancer drugs could be 
easily incorporated into the PEG-PLA NPs prepared with the block copolymer via physical 
encapsulation or chemical conjugation. We used a fluorescence dye, Cy5, as a model drug to 
fluorescently label the NPs for cancer cell binding and internalization study. To introduce Ald 
groups to the NP surface, a block polymer of Ald functionalized PEG-PLA was co-
nanoprecipitated with PEG-PLA at 1:1 weight ratio to form Ald-NPs (Scheme 6.3). The resulting 
Ald-NPs were about 119 nm in size with narrow size distribution (Figure 6.4). 
 
Scheme 6.3. Preparation of Ald-NP with Ald-PEG-PLA and PEG-PLA polymer through 
nanoprecipitation.   
 
 
Figure 6.4. DLS (a) and TEM (b) characterizations of Ald- NPs. 
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6.3.4 In vitro cancer cell targeting mediated by oxime ligation reaction. 
To demonstrate the hypothesis, we first studied the in vitro cancer cell targeting of 
nanoparticle toward 4T1 cells using oxime ligation reaction. Native 4T1 or o4T1 cells were then 
treated with Cy5 labeled NPs or Ald-NPs and analyzed by confocal fluorescence microscopy and 
flow cytometry (Figure 6.5). Native 4T1 cells incubated with PEG-PLA NPs showed minimum 
cell binding and/or internalization (Figure 6.5a). Native 4T1 cells treated with Ald-NPs or o4T1 
cells treated with NPs without Ald on surface showed slightly higher level of NP binding or uptake. 
The former maybe due to some non-specific reactions between cell surface groups and Ald; the 
latter could be the result of increased electrostatic interaction between surface Oa groups on o4T1 
with negatively charged NPs (-10.0 mV ζ-potential, Table 6.1). When the o4T1 cells were treated 
with Ald-NPs, the cellular binding and/or internalization was remarkably enhanced likely because 
of the specific and efficient oxime ligation between the cell surface Oa groups and Ald groups on 
Ald-NPs. Further quantification with flow cytometry indicated 2.6 fold increased cell uptake of 
o4T1+Ald-NP compared with 4T1+Ald-NP or o4T1+NP, and 4.2 fold increase compared with 
4T1+NP (Figure 6.5b, c). The results demonstrated that proper Oa-Ald recognition largely 
improves cancer cell targeting via oxime ligation reaction. It is also noticeable that significant 
amount of Ald-NPs were internalized into o4T1 cells. These observations indicate that the 
bioorthogonal oxime ligation mediated not only the enhanced cancer cell-NP binding but also the 
subsequent endocytosis of the NPs, which is important for intracellular delivery of anticancer 
drugs to achieve improved efficacy against cancer cells.  
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Figure 6.5. In vitro cancer cell targeting through oxime ligation. (a) Confocal microscopic images 
of native 4T1 cells (4T1) or 4T1 cells with surface expressed Oa groups (o4T1) treated with Cy5 
labeled PEG-PLA NPs (red) without or with Ald groups (denoted as NP and Ald-NP respectively). 
The nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) (blue). Scale bar: 5 µm. (b) 
Flow cytometry analyses of the cellular binding and/or internalization of NPs. (c) The 
quantification of mean fluorescence intensity in flow cytometry analyses (average±SD; n=3). 
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Table 6.1. ζ-potential measurements of liposome and NPs. 
 
Particles ζ-potential (mV) 
Oa-Lip 12.3 
NP -10.0 
Ald-NP -9.5 
 
6.3.5 In vivo modification of cancer cells with oxyamine functional group. 
To prove the concept of cancer cell surface engineering in vivo using liposome fusion 
technique and subsequent oxime ligation mediated cancer targeting, subcutaneous 4T1 tumor 
model was established on both flanks of BALB/c mice and the mice were received intratumoral 
injection of Oa-Lip to label the cancer cells in vivo. We first verified the cancer cell surface 
presentation of Oa groups inside the tumor tissues by injecting fluorescent Rhd-Lip intratumorally 
(Figure 5.6a). Fluorescently labeled Oa-C12 was expected to present on the cell membrane inside 
tumors through similar liposome fusion process observed in vitro. The tumors were collected 4 h 
or 24 h post injection (p.i.), sectioned and analyzed with confocal microscopy. As expected, robust 
florescence signal from Rhd-C12 was observed on the tumor cells 4 h p.i. indicating the successful 
displaying of functional groups on plasma membrane in vivo through liposome delivery and 
membrane fusion (Figure 6.6b). The fluorescence decreased at 24 h p.i. likely due to the clearance 
or metabolizing of the Rhd-C12 (Figure 6.6b).  
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Figure 6.6. In vitro cancer cell targeting through oxime ligation. (a) Confocal microscopic images 
of native 4T1 cells (4T1) or 4T1 cells with surface expressed Oa groups (o4T1) treated with Cy5 
labeled PEG-PLA NPs (red) without or with Ald groups (denoted as NP and Ald-NP respectively). 
The nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) (blue). Scale bar: 5 µm. (b) 
Flow cytometry analyses of the cellular binding and/or internalization of NPs. (c) The 
quantification of mean fluorescence intensity in flow cytometry analyses (average±SD; n=3). 
 
6.3.6 In vivo cancer cell targeting mediated by oxime ligation reaction. 
We next evaluated the potential of oxime ligation for in vivo cancer targeting. To study it, 
I first injected the Oa-Lip intratumorally to the left tumor (oTM) and PBS to the right one (TM) 
as control (Figure 6.7) to study the cancer targeting in vivo. The mice received intravenous 
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injection of Ald-NPs through tail veins 4 h after the introduction of Oa groups to the cells in the 
left tumors. In order to monitor the in vivo tumor targeting kinetics, the injected Ald-NPs were 
radio labeled with 64Cu isotope using a chelating ligand, DOTA, conjugated to the polymer chain 
for dynamic positron emission tomography (PET) imaging over time without sacrificing the 
animals. All of the PET images were overlaid with micro X-ray computed tomography (CT) 
images to identify the position of tumors (yellow circles and arrows Figure 6.7a). Negligible radio 
activity was detected in tumors on both sides 1 h p.i. of Ald-NPs. At 6 h p.i., the accumulation of 
Ald-NPs in oTM (5.5% I.D./g) was 37.5% higher than that in TM (4.0% I.D./g) with statistical 
significance (Figure 6.7b). Three-dimensional reconstructed image (Figure 6.7c) also provides 
evidence for the significantly enhanced accumulation of Ald-NPs in oTM at 6 h p.i. Over 24 h p.i., 
the tumor accumulation decreased slightly on both sides compare with the amount at 6 h. However, 
Ald-NPs persisted in oTM (3.6% I.D./g) with 63.6% higher amount than that in TM (2.2% I.D./g). 
These results were confirmed by ex vivo measurement of the radioactivity in the excised tumors 
with a γ-counter (0.44 and 0.28 µCi/g for oTM and TM respectively; Figure 6.8). Similar 
experiment was performed to intravenously inject PEG-PLA NPs without Ald groups on surface 
to the mice bearing oTM and TM on each side. No significant difference in tumor accumulation 
of the NPs on two sides at 6 h or 24 h p.i. was observed (Figure 6.9) and the accumulation of NPs 
in oTM was lower than that of Ald-NPs in oTM indicating that the specific oxime ligation was 
responsible for the increased tumor accumulation and retention of Ald-NPs in oTM. These 
observations suggest that in vivo cancer targeting could indeed be achieved using bioorthogonal 
oxime ligation. 
152 
 
 
 
Figure 6.7. In vivo cancer targeting through oxime ligation. (a) In vivo whole-body dynamic 
PET/CT imaging of mice was performed 1, 6 and 24 h post NP injection to assess the accumulation 
of the Ald-NPs in left tumors labeled with Oa groups (oTM) and the right tumors (TM). Tumors 
were indicated with yellow circles and arrows. (b) Accumulation of 64Cu labeled Ald-NPs in the 
tumors over time was quantified by selecting the three dimensional regions of interest in the PET 
images and analyzing with the instrument software (average ± SD; n=3; *p<0.05). (c) 
Corresponding three dimensional PET/CT image at 6 h p.i. shows enhanced accumulation of Ald-
NPs in the left oTM. 
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Figure 6.8. The radioactivity in the excised tumors (24 h p.i.) was measured ex vivo with a γ-
counter. 
 
 
Figure 6.9. (a) In vivo whole-body dynamic PET/CT imaging of mice was performed to assess the 
tumor accumulation of the NPs without Ald groups on surface. (b) Accumulation of 64Cu labeled 
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(Figure 6.9 cont.) NPs in the tumors over time was quantified by selecting the three dimensional 
regions of interest in the PET images and analyzing with the instrument software.A 20-mL poly 
(iohexol) NP solution mixed with 10 mL poppy seed oil was administered to New Zealand white 
rabbit by transarterial chemoembolization to enhance intra-tumoral deposition of NPs. The 
distribution of NPs was tracked by X-ray CT imaging. The cross-sectional imaging clearly 
revealed accumulation of NPs within liver parenchyma, evidenced by focal areas of high tissue 
attenuation (indicated by arrows, Figure 6.8). Given this observation, these poly(iohexol) NPs 
could be potentially combined with drug delivery system, offering extra benefits to visualize the 
accumulation of therapeutic agents within the hepatic tumor tissues non-invasively on CT scan 
and give the outcomes of administrated therapy. Because of a large number of the NPs distributed 
within portal vein and branches (see arrows pointed areas), high attenuation of these vascular 
structures could be observed (Figure 6.8). This signal enhancement of vasculatures holds a great 
promise for the detection of the highly vascular hepatic metastasis.  
 
 
6.4 Conclusions 
In conclusion, I demonstrated a novel cancer targeting strategy in vitro and in vivo using 
bioorthogonal oxime ligation reaction in this chapter. One bioorthogonal functional group (i.e. Oa) 
as unnatural target was efficiently introduced to cancer cells using liposome delivery and fusion 
technique. Ald groups as the targeting ligand toward Oa could be easily synthesized and 
incorporated into nanomedicines. Specific and efficient oxime ligation led to the markedly 
improved cancer targeting in vivo through chemical Oa-Ald recognition. Given the versatility of 
the liposome fusion method for different bioorthogonal groups and a large variety of bioorthogonal 
chemistry available, many bioorthogonal reaction mediated cancer targeting strategies can be 
easily developed, optimized and compared. Future efficacy studies using targeted, drug-loaded 
biocompatible nanomedicine combined with the cancer pretargeting and quenching methods will 
be important to further evaluate the potential of such strategies for targeted cancer therapy. 
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CHAPTER 7  
NANOPARTICLES BASED IN VIVO X-RAY COMPUTED TOMOGRAPHY IMAGING 
CONTRAST AGENT 
 
7.1 Introduction 
In the battle with cancer, people put more emphasis on the cancer early detection. The 
earlier the cancer can be diagnosed, the better chance that cancer patients can be cured. X-ray 
computed tomography (CT) is one of the most frequently used clinical diagnostic tools.1,2 Current 
clinically used CT contrast agents are largely based on iodinated small molecules due to iodine’s 
high X-ray absorption coefficient.3,4 When used in vivo, however, the small-molecule contrast 
agents tend to be quickly eliminated from the circulation system and vascularized tissues because 
of their low molecular weights, huge volume distributions, and fast renal clearance profiles.5 Thus, 
the time window for CT imaging of the interested regions following administration of the small-
molecule contrast agents is typically very narrow, beyond which the CT image would not have 
sufficient contrast and the regions of interest would be missed, resulting in underrepresentation of 
the number of metastatic lesions in a patient and incorrect evaluation of the extent of the disease. 
Recently, nanoparticles (NPs) have emerged as novel CT contrast agents, which overcome some 
of the drawbacks of iodinated small molecular contrast agents.6-8 For instance, iodinated 
liposomes,9 polymer coated bismuth sulfide (Bi2S3),2,10 gold nanoparticles (GNP),11,12 organo-
metallic molecules based nanocolloids13,14 have been reported to exhibit enhanced X-ray 
attenuation in vivo. Nevertheless, some issues central to complex synthesis of iodolipid, safety 
concerns of inorganic NPs and extra cost due to the rare abundance of ytterbium on earth need to 
be considered.   
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Polymeric NPs have recently emerged as promising contrast agents.1,6,15-17 Grafting 
iodinated small molecules to the pendant functional groups of hydrophilic polymers yield 
nanoparticulate contrast agents,18,19 which however, often suffer from low loading efficiency and 
heterogeneous distribution of the iodinated small molecules.20 When contrast agents are 
encapsulated in polymeric NPs, they can be homogenously distributed in the confined hydrophobic 
core and thus enable high X-ray attenuation.21,22 However, undesired burst release of the 
encapsulated contrast agents from NPs upon exposure to the biological media complicates the 
image data analysis and thus prevents successful clinical applications.23 To address these 
challenges, I reported in this chapter the development of poly(iohexol) NPs via cross-linking  of 
iohexol with hexamethylene diisocyanate (HDI) followed by nanoprecipitation with mPEG-
polylactide (mPEG-PLA). Such strategy takes advantage of the pharmacological and 
pharmacokinetic properties of NPs and effectively prevents the undesired leakage of the contrast 
agents. As such, substantially improved tissue retention and CT contrast were achieved using these 
NP contract agents as appose to free iohexol.  
 
7.2 Materials and Methods 
7.2.1 General 
D,L-Lactide (LA) was purchased from TCI America (Portland, OR, USA), recrystallized three 
times in toluene and stored at -30 oC in a glovebox prior to use. (S)-2,2',2'',2'''-(2-(4-
isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (p-SCN-
Bn-DOTA) was purchased from Macrocyclics, Inc. (Dallas, TX, USA). All anhydrous solvents 
used in this study were purified by being passing through dry alumina columns and kept anhydrous 
by using molecular sieves. 5-(N-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-N,N’-bis(2,3-
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dihydroxypropyl)isophthalamide  (iohexol), hexamethylene diisocyanate and other chemicals 
were purchased from Sigma-Aldrich (St Louis, MO, USA) and used as received unless otherwise 
noted.  The molecular weights (MWs) of cross-linked poly(iohexol) were determined by gel 
permeation chromatography (GPC) (also known as size exclusion chromatography (SEC)) 
equipped with an isocratic pump (Model 1100, Agilent Technology, Santa Clara, CA, USA), a 
DAWN HELEOS 18-angle laser light scattering detector (Wyatt Technology, Santa Barbara, CA, 
USA) and an Optilab rEX refractive index detector (Wyatt Technology, Santa Barbara, CA, USA). 
The wavelength of the HELEOS detector was set at 658 nm. The size exclusion columns (Phenogel 
columns 100 Å, 500 Å, 103 Å and 104 Å, 5 µm, 300 × 7.8 mm, Phenomenex, Torrance, CA, USA) 
used for the analysis of polymers were serially connected on the GPC. The GPC analysis was 
conducted with the use of DMF containing 0.1 M LiBr as the mobile phase at a flow rate of 1 
mL/min at 60 oC. The MALLS detector was calibrated using pure toluene with no need for 
calibration using polymer standards and was used for the determination of the absolute molecular 
weights (MWs). The molecular weight of polymer was determined from the dn/dc value calculated 
offline by means of the internal calibration system processed by the ASTRA V software (Version 
5.1.7.3, Wyatt Technology). Infrared spectra were recorded on a Perkin Elmer 100 serial FT-IR 
spectrophotometer calibrated with polystyrene film. The NMR studies were conducted on a Varian 
UI500NB (500 MHz) NMR spectrometer. The sizes and the particle polydispersities of the 
poly(iohexol) NPs were determined on a ZetaPALS dynamic light scattering (DLS) instrument (15 
mW laser, incident beam = 676 nm, Brookhaven Instruments, Holtsville, NY, USA).  The 
lyophilization of the NPs was carried out on a benchtop lyophilizer (FreeZone 2.5, Fisher Scientific, 
PA, USA).  mPEG5k-PLA10 (PLA with degree of polymerization (DP) of 10, molecular weight 
(MW) of 6.3 kDa, and molecular weight distribution (MWD) of 1.07) was synthesized by 
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following the published procedures.24,25 The SEM analysis of NPs was conducted on a Hitachi-
S4700 high-resolution scanning electron microscope. Human breast cancer MCF-7 cells were 
purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA). Cells were 
cultured in DMEM medium containing 10% Fetal Bovine Serum (FBS), 0.01 mg/ml human 
recombinant insulin and 100 units/mL aqueous penicillin G at 37°C in 5% CO2 humidified air. 
Cells were harvested at 80% confluence with EDTA/trypsin, counted and resuspended for 
experiments. Female C57BL/6 or athymic nude mice were purchased from National Cancer 
Institute (NCI, Frederick, MD, USA).  Feed and water were available ad libitum. Artificial light 
was provided in a 12/12 hour cycle. Micro-PET/CT imaging and fluoroscopic imaging was 
performed with small animal on a Siemens Inveon PET-CT system (Siemens Healthcare, USA). 
Ex vivo measurement of the radioactivity was conducted on a 2480 Wizard2 Automatic Gamma 
Counter (Perkin-Elmer).  
 
7.2.2 Synthesis of poly(iohexol) cross-linked polymer   
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Iohexol (500 mg, 0.6 mmol) was dissolved in DMF (20 mL) in a 50-mL round-bottom flask. 
Hexamethylene diisocyanate (307 mg, 1.83 mmol) was added into the flask, in the presence of 
dibutyltin dilaurate (10 L, 16 mol) as the catalyst. The mixture was stirred at 80 oC for 24 h. The 
solution was evaporated and an orange-red oily residue was obtained. The residue was dissolved 
and stirred in ether (50 mL) at room temperature to precipitate a pale yellow solid. The solid was 
isolated by centrifugation and further dried under vacuum (790 mg, 98% yield). The resulting 
polymer was characterized by 1H NMR, FT-IR and GPC.  
 
7.2.3 Formulation of PEGylated poly(iohexol) NPs  
A DMF solution containing the cross-linked poly(iohexol) (100 L, 10 mg/mL) and mPEG5k-
PLA10 (100 L, 10 mg/mL) were added dropwise to vigorously stirred nanopure water (4 mL). 
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The resulting PEGylated poly(iohexol) NPs were collected and washed three times with water by 
ultrafiltration, using a 10,000 MWCO Amicon Ultra membrane (Ultracel YM-10, Millipore Inc., 
Billerica, MA, USA), in order to completely remove DMF. The NPs collected from ultrafiltration 
were characterized by DLS and SEM.  
 
7.2.4 Release study of PEGylated poly(iohexol) NPs 
PEGylated poly(iohexol) NPs were prepared by nanoprecipitation as described above. The 
collected NPs were dispersed in human serum buffer (human serum:PBS=1:1, v/v, 5 mL), divided 
into 10 equal-volume portions, and added to 10 eppendorf microcentrifuge tubes (500 μL NP 
solution in each tube). The tubes were incubated at 37°C. At scheduled time points, two tubes were 
taken out, to which methanol (500 μL) was added to precipitate proteins. The precipitates were 
removed by centrifugation (5 min, 15000 × g). The supernatant then was injected into HPLC for 
analysis of the released iohexol. For the HPLC analysis, acetonitrile:water (containing 1% TFA) 
was used as mobile phase. The gradient for acetonitrile:water (containing 1% TFA) was kept from 
25:75 for 50 min. The flow rate was 1.0 mL/min. Analytical C18 column (Luna C18, 250 × 4.6 
mm, 5 μ, Phenomenex, Torrance, CA, USA) was used to perform the analysis. The results were 
compared to the free iohexol peak identified by the same condition, and confirmed there is no 
release of iohexol from PEGylated poly(iohexol) NPs during 4 day’s incubation in human serum 
buffer at 37 oC. 
 
7.2.5 Stability of PEGylated poly(iohexol) NPs 
A DMF solution containing the cross-linked poly(iohexol) (100 L, 10 mg/mL) and mPEG5k-
PLA10 (100 L, 10 mg/mL)  were added dropwise to vigorously stirred nanopure water (4 mL). 
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To evaluate the stability of NPs against dilutions upon administration, the obtained NPs were 
treated with a series of dilutions with human serum buffer (human serum:PBS = 1:1, v/v), and the 
particle size changes were measured by dynamic light scattering (DLS). For the short-term stability 
study, the particles were dispersed in PBS or human serum buffer (human serum:PBS = 1:1, v/v), 
measured by DLS at rt and followed over 60 min. For the long-term stability study, the particles 
were dispersed in human serum buffer, incubated at 37 oC and continuously monitored by DLS for 
4 days. The results showed that PEGylated poly(iohexol) NPs were able to keep the nanostructure 
against a series of dilutions and remained unchanged in 50% human serum buffer for 4 days. 
 
7.2.6 Lyophilization of poly(iohexol) NPs in the presence of albumin 
A DMF solution of poly(iohexol) (10 mg/mL, 100 L) was mixed with a DMF solution of 
mPEG5k-PLA10 (10 mg/mL, 100 L). The mixture was added dropwise to a vigorously stirred 
water solution (4 mL). The resulting NP solution was washed three times with water by 
ultrafiltration, using a 10,000 MWCO Amicon Ultra membrane (Ultracel YM-10, Millipore Inc., 
Billerica, MA, USA), in order to completely remove DMF. The collected NP was then analyzed 
by DLS. An aqueous solution of human serum albumin (HSA, 10 mg/mL, 500 L) was added to 
the NP solution. The mixture was lyophilized for 16 h at 50 oC. The resulting white powder was 
reconstituted with nanopure water (2 mL). The solution was stirred for 5 min at room temperature. 
The resulting NP solution was analyzed by DLS.  
 
7.2.7 Synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-LA 
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The NH2-LA25 conjugate was synthesized by following the procedures as published.
1 In a reaction 
vial containing NH2-LA25 conjugates (14.4 mg, 0.004 mmol) was added an anhydrous 
dimethylformamide (DMF) solution (0.5 mL) of p-SCN-Bn-DOTA (5.6 mg, 0.008 mmol) and 
triethylamine (3.6 mg, 0.036 mmol). The reaction mixture was stirred for 4 h under nitrogen at rt. 
The solvent and triethylamine were removed under vacuum to give DOTA-LA25, which was used 
directly without further purification. 
 
7.2.8 Synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-iohexol 
 
 
In a reaction vial containing iohexol (40.0 mg, 0.049 mmol) was added an anhydrous 
dimethylformamide (DMF) solution (0.5 mL) of p-SCN-Bn-DOTA (5.6 mg, 0.008 mmol). The 
reaction mixture was stirred overnight under nitrogen at rt. The solvent were precipited with 50 
mL ethyl ether to give DOTA-iohexol with a good yeild (>75%). ESI-MS (m/z): Calcd 
C43H60N8O17SI3  1373.09 (M); found 1373.0 (M)+. 
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7.2.9 Formulation of 64Cu labeled Poly(iohexol) NPs. 
 
A DMF solution containing the cross-linked poly(iohexol) (100 L, 10 mg/mL), DOTA-LA25 (100 
L, 10 mg/mL) and mPEG5k-PLA10 (100 L, 10 mg/mL) were added dropwise to vigorously 
stirred nanopure water (6 mL). The resulting PEGylated DOTA-poly(iohexol) NPs were collected 
and washed three times with water by ultrafiltration, using a 10,000 MWCO Amicon Ultra 
membrane (Ultracel YM-10, Millipore Inc., Billerica, MA, USA), in order to completely remove 
DMF. The 64Cu chloride (300 µCi, obtained from Washington University at St. Louis, MO, USA) 
was mixed with PEGylated DOTA-poly(iohexol) NPs (3 mg) in NH4OAc buffer (pH = 5.5, 0.1 M, 
0.5 mL).  The mixture was incubated for 1 h at 60 °C. To determine the labeling stability, the NPs 
were washed by ultrafiltration (10 min, 3000 × g, Ultracel membrane with 10 000 NMWL, 
Millipore, Billerica, MA, USA), and the radioactivity in the supernatant was measured on γ-
counter at different time points (1 h, 4 h, and 24 h) to determine the diassociated 64Cu (Figure 
S11B). The purified 64Cu-labeled poly(iohexol) NPs were used for injection.    
 
7.2.10 Synthesis of 64Cu labeled iohexol. 
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The 64Cu chloride (300 µCi, obtained from Washington University at St. Louis, MO, USA) was 
mixed with DOTA-iohexol (3 mg) in NH4OAc buffer (pH = 5.5, 0.1 M, 0.5 mL).  The mixture 
was incubated for 1 h at 60 °C. To determine the labeling stability, the DOTA-iohexol was washed 
by ultrafiltration (10 min, 14000 × g, Ultracel membrane with 1,000 NMWL, Millipore, Billerica, 
MA, USA), and the radioactivity in the supernatant was measured on γ-counter at different time 
points (1 h, 4 h, and 24 h)  to determine the diassociated 64Cu. The purified 64Cu-labeled iohexol 
were used for injection.    
 
7.2.11 Rabbit NP chemoembolization 
One male New Zealand white rabbit (weight 2.8 kg) underwent NP chemoembolization, which 
was performed by a single operator (R.C.G.) after the rabbit was intubated and maintained under 
general anesthesia. Angiography was performed with a C-arm unit (OEC Medical Systems series 
9600; GE Healthcare, UK). The femoral artery was accessed through a surgical cut-down and 
catheterized with a 3 French vascular sheath (Cook Medical, Bloomington IN, USA). A 2 French 
JB1 catheter (Cook Medical) was advanced over a guide wire, and the celiac artery was selectively 
catheterized. The catheter was then advanced into the proper hepatic artery. Celiac and hepatic 
arteriography was performed via injections of iohexol (Omnipaque-300; Amersham Health, 
Princeton NJ, USA). After catheter position was confirmed in the proper hepatic artery, hepatic 
lobe chemoembolization was performed by injection of an emulsion consisting of 125 mg/kg 
poly(iohexol) NPs (total volume 20 mL) mixed with 10-mL ethiodized oil (Lipiodol; Geurbet, 
Villepente France). Under fluoroscopic visualization, the NP emulsion was injected by hand into 
the catheter. Chemoembolization was continued until the entire NP emulsion was administered. 
Immediately after completion of chemoembolization, the rabbit was euthanized using a lethal 
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intravenous dose of 390 mg/mL pentobarbital sodium solution (Schering-Plough, Kenilworth, NJ, 
USA). A computed tomography (CT) scan was obtained within 30 min of euthanasia using a 
BrightSpeed 16 slice scanner (GE Healthcare, UK) to delineate the anatomic distribution of 
injected NC mixture. The CT protocol included helical acquisition with mA = 150, kV = 120, pitch 
= 1.375:1, and 0.625 mm acquisition slice thickness. The Animal Care and Use Committee at the 
University of Illinois at Chicago approved this study. 
 
7.2.12 MicroCT imaging 
Six female athymic nude mice bearing MCF-7 human breast cancer xenografts (6-8 weeks) were 
divided into two groups (n = 3), minimizing their weight differences. The two groups of mice were 
treated with iohexol and poly(iohexol) NPs at a dose of 50 mg/kg through intratumoral injection, 
respectively. MicroCT imaging was performed with a hybrid small-animal scanner (Inveon 
SPECT/CT; Siemens Medical Solutions USA, Inc.). Animals were placed prone on the imaging 
bed with legs secured in an extended position. Five minutes after injection, mice underwent high-
resolution anatomic CT (360 projections, 80 kVp/500 A penetration energy, effective pixel size 
of 96 µm) imaging. Another two groups of MCF-7 human breast cancer xenografts bearing female 
athymic nude mice (6-8 weeks, n=2) were treated with iohexol and poly(iohexol) NPs at a dose of 
250 mg/kg through jugular vein injection, respectively. MicroCT imaging was performed with a 
hybrid small-animal scanner (Inveon SPECT/CT; Siemens Medical Solutions USA, Inc.). Animals 
were placed prone on the imaging bed with legs secured in an extended position. High-resolution 
anatomic CT (360 projections, 80 kVp/500 A penetration energy, effective pixel size of 96 µm) 
imaging was collected at the same time with administration, as well as at 10 min, 20 min, 30 min, 
40 min and 60 min post injection. The microCT images were reconstructed using cone-beam 
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algorithm with existing commercial software (Cobra Exxim) and intensity values converted to 
Hounsfield units (HU). The quantitative analysis was measured using Inveon Research Workspace 
(Siemens Medical Solutions USA, Inc.). Briefly, complex irregular volumes of interest (VOIs) 
were drawn on the microCT images to determine mean counts in each VOI. The study protocol 
was reviewed and approved by the Illinois Institutional Animal Care and Use Committee (IACUC) 
of the University of Illinois at Urbana‒Champaign. 
 
7.2.13 Fluoroscopic imaging 
Female C57BL/6 mice (6-8 weeks) were divided into two groups (n = 2), minimizing their weight 
differences. The two groups of mice were treated with iohexol and poly(iohexol) NPs at a dose of 
250 mg/kg through jugular vein injection, respectively. Fluoroscopic imaging was performed with 
a hybrid small-animal scanner (Inveon SPECT/CT; Siemens Medical Solutions USA, Inc.). 
Animals were placed prone on the imaging bed with legs secured in an extended position. High-
resolution fluoroscopic imaging (80 kVp/500 A penetration energy, effective pixel size of 96 
µm) was collected at the same time with administration started. The images were collected every 
10s from 0 min to 5 min post injection followed by every 10 s from 5 min to 60 min post injection. 
The quantitative analysis of collected images was performed using Image J. Briefly, the region of 
interest (ROI) were drawn on the inverted images and the mean intensity were measured and 
normalized by area of ROI (pixel2). The dynamic movies were also generated by Image J. The 
study protocol was reviewed and approved by the Illinois Institutional Animal Care and Use 
Committee (IACUC) of the University of Illinois at Urbana‒Champaign. 
 
7.2.14 Micro-PET/CT Imaging  
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Six female athymic nude mice bearing MCF-7 human breast cancer xenografts (6-8 weeks) were 
divided into two groups (n = 3), minimizing their weight differences. The two groups of mice were 
treated with iohexol and poly(iohexol) NPs at a dose of 50 mg/kg through tail vein injection, 
respectively. Mice were placed on the micro-CT imaging bed and kept anaesthetised with a 
constant isoflurane flow (~2%).  The micro-CT scan (80keV/500uA X-rays energy, 360 
projections, 360 degrees, 75 µm pixel size) was used for determining the anatomical localization 
of different organs. Static micro-PET scans were acquired at three selected time points (1 h, 6 h 
and 24 h p.i.) together with micro-CT scans for anatomical co-registration. The obtained micro-
PET and micro-CT images were reconstructed using ordered subset expectation maximization 
(OSEM) and cone-beam algorithms with existing commercial software (Inveon Acquisition 
Workspace and Cobra Exxim, respectively). Micro-PET images were processed using 3-D median 
filtering and fused with micro-CT images. To quantify the radioactivity of 64Cu in different organs, 
complex irregular volumes of interest (VOIs) were drawn on the micro-CT images and registered 
with the micro-PET images to determine mean counts in each VOI.  To minimize partial volume 
effects, the anatomical borders of the organs were not included. The radiotracer activity from each 
VOI was normalized by injected dose and expressed as percent of the decay-corrected injected 
activity per cm3 of tissue, which can be approximated as percentage % I.D./g assuming the density 
of tissue is ~1 g/cm3. The initial total injected activity was determined by dose calibrator before 
the injection.   
 
7.2.15 Radioactivity measurement with γ-counter 
Mice were euthanized 24 h post injection. Various organs (liver, lung, spleen, kidney, heart, small 
intestine, large intestine, bladder and thyroid), as well as MCF-7 subcutaneous tumors were 
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collected, weighed and measured for radioactivity (64Cu) with a γ-counter (Wizard2, Perkin-Elmer, 
USA) using appropriate energy window centered at photo peak of 511 keV.  Raw counts were 
corrected for background, decay, and weight. Corrected counts were converted to microcurie per 
gram of tissue (μCi/g) with a previously determined calibration curve by counting the 64Cu 
standards. The activity in each collected tissue sample was calculated as percentage of the injected 
dose per gram of tissue (% I.D./g).  For this calculation, the tissue radioactivity was corrected for 
the 64Cu decay (T(1/2)=12.7 h)  to the time of γ-well counting. 
 
7.2.16 Pharmacokinetic Study of poly(iohexol) NP and iohexol. 
Female athymic nude mice (6-8 weeks) were divided into two groups (n = 3), minimizing the 
weight differences. The two groups of mice were treated with 64Cu-labeled PEGylated 
poly(iohexol) NPs and 64Cu-labeled iohexol intravenously at a dose of 35 µCi, respectively. Blood 
was collected intraorbitally from mice at scheduled time points (5 min, 15 min, 30 min, 60 min, 2 
h, 4 h, 8 h, 12 h, 24 h and 48 h post injection) for pharmacokinetic profiling. The collected blood 
samples were weighed and measured for radioactivity (64Cu) with a γ-counter (Wizard2, Perkin-
Elmer, USA) using appropriate energy window centered at photo peak of 511 keV. Raw counts 
were corrected for background, decay, and weight. Corrected counts were converted to microcurie 
per gram of tissue (μCi/g) with a previously determined calibration curve by counting the 64Cu 
standards. The activity in each collected blood sample was calculated as percentage of injected 
dose per gram of blood (% I.D./g). For this calculation, the blood radioactivity was corrected for 
the 64Cu decay to the time of γ-well counting. 
Plasma half-life = 0.693 × timeinterval/[ln(Concentrationpeak) -ln(Concentrationtrough)] 
where timeinterval is the time between the peak and the end point, Concentrationpeak is the maximum 
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concentration  in  plasma  and Concentrationtrough is  the  concentration  at  the  end  point. 
 
7.2.17 In vitro cytotoxicity evaluation 
MCF-7 cells were placed in a 96-well plate for 24 h (8 000 cells per well). Cells were washed with 
100 μL of prewarmed PBS. Freshly prepared PEGylated poly(iohexol) NPs with a series of 
concentrations (prepared in 1× PBS, 100 μL) were added to the cells. Untreated cells used as 
negative controls in this assay. The cells were incubated for 72 h in a 5% CO2 incubator at 37 °C. 
The standard MTT assay protocols were followed thereafter.  
 
7.2.18 Histological evaluation 
Six female athymic nude mice (6-8 weeks) were divided into two groups (n = 3), minimizing the 
weight differences. In 3 mice, poly(iohexol) NPs were administered intravenously (200 L, 30 
mg/mL) via lateral tail vein to the athymic nude mice (n = 3) at a dose of 150 mg NP/kg. The other 
3 mice received intravenous PBS and served as the control group. All the animals were sacrificed 
24 h later, and major organs including heart, lung, liver, spleen, kidney, and intestine were 
collected followed by flash freezing in optimum cutting temperature (O.C.T.) compound (Sakura 
Finetek USA, Torrance, CA, USA). Organs were sectioned using cryostat at the thickness of 10 
m, followed by standard hematoxylin and eosin (H&E) staining. Characterization for 
inflammatory cell infiltrate including macrophages and neutrophils were performed on a 
Nanozoomer Virtual Microscopy (Hamamatsu) evaluated at 20× magnification and analyzed by 
an independent pathologist. 
 
7.3 Results and Discussion 
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Scheme 7.1. Synthetic illustration of cross-linked poly(iohexol) and formulation of 
PEGylated poly(iohexol) NPs. 
 
 
7.3.1 Synthesis of cross-linked poly(iohexol) polymer  
Iohexol, one of clinically used iodinated contrast agents, has multiple functional groups. 
Thus, a simple, straightforward strategy to make polymeric NP contrast agents with high molecular 
weight (MW) and high iodine loading would be cross-linking of these multifunctional contrast 
agents. The resulting cross-linked poly(contrast agent) would have very high X-ray absorption 
efficiency because of, high-content iodinated residues that are homogeneously distributed and 
stably attached to the polymeric network. To demonstrate such hypothesis, I used iohexol, a widely 
used contrast agent with multiple hydroxyl groups as a co-monomer to prepare poly(iohexol) upon 
cross-linking by hexamethylene diisocyanate (HDI) via the addition reaction (Scheme 6.1). The 
reaction was mediated via dibutyltin dilaurate assisted O-acylation of diisocyanate with the 
primary hydroxyl groups of iohexol. The molecular weights of the iohexol polymer can be tuned 
by altering the ratios of the monomers. By changing the molar ratios of iohexol to hexamethylene 
diisocyanate (I/H) from 1:1 to 3:1, a series of polymers (P1-P5) with different molecular weights 
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(Figure 7.1) were obtained. GPC analysis revealed that cross-linked iohexol polymer 
(poly(iohexol)) prepared at an I/H ratio of 1:3 gave highest molecular weight (68.5 kDa) among 
all five polymers synthesized. The molecular weight distribution (MWD = Mw/Mn) of the 
poly(iohexol) was 2.23, consistent with the expected broad MWD given the network architecture 
of the poly(iohexol). The successful synthesis of poly(iohexol) was confirmed by FT-IR 
spectroscopy (Figure 7.2). At the completion of the polymerization, the NCO groups of 
hexamethylene diisocyanate (2250 cm-1) completely disappeared and the stretching vibration band 
of the urethane carbonyl group (1750 cm-1) was detected.19 The 1H NMR spectra further confirmed 
the structure of the obtained polymer (Figure 7.3). The peak at 5.5-7.5 ppm, which is attributed to 
the secondary –NH proton in urethane, confirmed the structure of poly(urethane). The aliphatic 
CH2 proton appeared at 1.0-1.5 ppm indicated the successful covalent conjugation of 
hexamethylene diisocyanate with iohexol. The iodine loading of the final product was determined 
to be as high as 30.6%, close to the calculated value based on the stoichiometric ratios. It is of 
great importance that I am able to synthesize high MW poly(iohexol) via polyaddition/crosslinking 
reactions as it has been demonstrated that polymers with high MWs (above 50 kDa) have reduced 
rate of excretion through the renal system.18  The synthesis of poly(iohexol) was monitored and 
confirmed by FT-IR spectroscopy. At the completion of the polymerization, the isocyanate groups 
of hexamethylene diisocyanate (2250 cm-1) completely disappeared and the stretching vibration 
band of the urethane carbonyl group (1750 cm-1) was detected. The 1H NMR spectra further 
confirmed the structure of the obtained polymer. The peak at 5.5-7.5 ppm, which is attributed to 
the secondary –NH proton in urethane, confirmed the urethane structure of poly(iohexol). The 
aliphatic CH2 proton appeared at 1.0-1.5 ppm, which indicates the successful covalent conjugation 
of hexamethylene diisocyanate with iohexol. 
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Figure 7.1. GPC analysis of cross-linked poly(iohexol) at different molar ratios of iohexol 
(I)/Hexamethylene diisocyanate (H). 
 
 
Figure 7.2. FT-IR spectra of hexamethylene diisocyanate (a), iohexol (b), and poly(iohexol) (c) 
at the I/H ratio of 1/3 (P3). 
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Figure 7.3. 1H NMR spectrum of cross-linked poly(iohexol) in d6-DMSO. 
 
7.3.2 Physicochemical properties of poly(iohexol) nanoparticles 
Plasma proteins in blood tend to non-specifically adsorb to the surface of unprotected NPs 
via hydrophobic or electrostatic interaction to form large particle aggregates,20-21 which 
subsequently results in rapid clearance of NPs from the blood stream due to the recognition and 
subsequent phagocytosis of the NPs by the reticular endothelial systems.22 Modification of NP 
surfaces with poly(ethylene glycol) (PEG), termed “PEGylation”, can reduce non-specific protein 
binding and elongate the circulation half-life of NPs.23-24 I next attempted to incorporate PEG to 
poly(iohexol) via a co-precipitation method.  Poly(iohexol) was nanoprecipitated with a mPEG-
PLA copolymer (PLA block of 1.4 kDa and mPEG segment of 5 kDa) to yield PEGylated 
poly(iohexol) NPs via the hydrophobic interaction of PLA segments of mPEG-PLA and the 
poly(urethane) segment of poly(iohexol). The average size of the resulting NPs was 150 nm with 
very narrow size distributions, as determined by DLS and also confirmed by SEM (Figure 7.4). I 
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analyzed the aqueous filtrate using HPLC and found that the released iohexol was negligible, 
substantiating the design of urethane linkages to stably conjugate iohexol to the polymer. In order 
to facilitate their clinical application, NPs would be ideally formulated in solid form with well-
controlled properties, making it possible for the long-term storage and ease of transport prior to 
their commercial clinical use.23-25 As shown in Figure 7.5, human serum albumin (HSA), an 
abundant protein in the blood, can be used to stabilize poly(iohexol) NPs and effectively prevent 
the severe aggregation of NPs during lyophilization process.26 In addition, the poly(iohexol) NPs 
exhibited remarkable stability in both PBS and human serum buffer solution (Figure 7.6).  
 
 
 
 
 
 
 
 
 
 
Figure 7.4. Dynamic light scattering (DLS) analysis of NPs in water (0.5 mg/mL) and SEM image 
of NPs.  
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Figure 7.5. DLS analysis of NP reconstitution. Monodispersed NPs mixed with human serum 
albumin (HSA) in water before lyophilization, and the reconstituted NPs after lyophilization in the 
presence of HSA (HSA: NC =10 : 1, wt/wt).  
 
 
 
 
 
 
 
Figure 7.6. Stability of NPs following dilution with PBS (1×) or human serum (HS) buffer 
(HS/PBS = 1/1, v/v) for one fold and further incubation at RT for different time. 
 
7.3.3 X-ray adsorption of poly(iohexol) nanoparticles 
Prior to using poly(iohexol) NPs as a probe for in vivo CT imaging, I first evaluated the X-
ray absorption of poly(iohexol) NPs by acquiring images of a serials of NP solutions with increased 
concentrations and subsequently converting them to Hounsfield maps for quantitative analysis. A 
linear correlation between NP concentration and the calculated CT attenuation (measured in 
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Hounsfield units (HU), R2 = 0.98) was observed (Figure 7.7), demonstrating that poly(iohexol) 
NPs can function as contrast agents for quantitative CT studies. 
 
 
Figure 7.7. HU measurements of poly(iohexol) NP ex vivo. The plot showed linear correlation 
between concentration of the poly(iohexol) NPs and CT calculated solution attenuation measured 
in Hounsfield units (HU). 
 
 
7.3.4 In vivo CT imaging of poly(iohexol) nanoparticles in rabbit model 
A 20-mL poly (iohexol) NP solution mixed with 10 mL poppy seed oil was administered 
to New Zealand white rabbit by transarterial chemoembolization to enhance intra-tumoral 
deposition of NPs. The distribution of NPs was tracked by X-ray CT imaging. The cross-sectional 
imaging clearly revealed accumulation of NPs within liver parenchyma, evidenced by focal areas 
of high tissue attenuation (indicated by arrows, Figure 7.8). Given this observation, these 
poly(iohexol) NPs could be potentially combined with drug delivery system, offering extra 
benefits to visualize the accumulation of therapeutic agents within the hepatic tumor tissues non-
invasively on CT scan and give the outcomes of administrated therapy.17 Because of a large number 
of the NPs distributed within portal vein and branches (see arrows pointed areas), high attenuation 
of these vascular structures could be observed (Figure 7.8). This signal enhancement of 
vasculatures holds a great promise for the detection of the highly vascular hepatic metastasis.15 
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Figure 7.8. Axial CT images after transarterial chemoembolization using poly(iohexol) NPs in a 
New Zealand white rabbit. Dose administered was approximately 125 mg/kg. After injection of 30 
mL of nanoparticle emulsion (consisting of 20 mL NP solution mixed with 10 mL poppy seed oil), 
cross-sectional imaging reveals accumulation of nanoparticles within liver parenchyma, evidenced 
by focal areas of high tissue attenuation (arrowheads). Arrow indicated high attenuation of vascular 
structures. 
 
 
7.3.5 Time course study of poly(iohexol) nanoparticles in murine model 
I next performed a time course study by collecting a series of CT imaging at selected time 
intervals and evaluating the protracted retention of poly(iohexol) NPs as compared to free iohexol 
in the tumor bed in athymic nude mice bearing MCF-7 xenografts. Strong CT signals in the tumors 
were detected 5 min after intratumoral injection of iohexol to the control mice (Figure 7.9), with 
enhanced density ΔHU (Hounsfield unit (HU) obtained at the scheduled time point subtracting that 
of untreated tumor tissues) of 101.0. However, the CT signal quickly decreased to 26.1 at 1 h post-
administration (a 3.9-fold decrease) and became fairly weak, and further decreased to 1.5 at 4 h 
post-administration (a 67.3-fold decrease from that of 5 min) and became non-detectable. In 
contrast, mice receiving poly(iohexol) NPs at equivalent dose of iohexol showed similar CT signal 
in the tumor (enhanced density ΔHU of 104.4) when CT image was collected 5 min after 
administration. As expected, protracted tumor tissue retention of the nanoparticulate contrast agent 
was observed. The enhanced density in tumor was 80.2 and 53.7 1 h and 4 h post-administration, 
representing a decrease of CT signal intensity by only 23.2% and 48.6%, respectively, from that 
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measured 5 min post-administration. The CT signal of the tumor bed of poly(iohexol) NPs treated 
mice was approximately 36 times higher than that of iohexol-treated mice 4 h post-administration 
(Figure 7.10). The protracted tumor tissue retention of poly(iohexol) NPs would also result in 
slower renal clearance. As shown in Figure 7.11, the CT signal in the bladder was remarkably 
augmented immediately after administration of iohexol and the high CT signal lasted for 1 h, which 
accorded well with the fast renal clearance of small molecule contrast agents. In comparison, 
poly(iohexol) NPs showed slower renal clearance; the CT signal in the bladder of the poly(iohexol) 
NP-treated mice were substantially weaker 5 min after administration (Figure 7.11). These results 
therefore clearly demonstrated the benefit of using poly(iohexol) NPs over free iohexol for 
prolonged retention in the CT imaging of the region of interest. CT images at multiple time points 
can thus be acquired over a wide time window without the necessity of multiple contrast agent 
administrations, and more accurate representation of the metastatic lesions in the patients can also 
be ensured.  The advantages of the protracted tumor retention of this designed poly(iohexol) NPs 
after intra-tumoral injection brought the promise for the feasibility of dynamic studies with CT 
modality. As a proof of concept, I did the preliminary fluoroscopic imaging to further evaluate the 
in vivo circulation and retention of poly(iohexol) NPs and iohexol when they were administered 
systemically. Imaging collection started at the same time with jugular vein injection of 
poly(iohexol) NPs or iohexol in C57BL/6 mice and continued for 1 h. As Figure 7.12 showed, 
strong contrast in the bladder region was noticed 5 min after jugular vein injection of iohexol to 
the control mice, and kept increasing dramatically until 1 h. While the contrasts in other internal 
organs such as heart, liver and kidney were continuously decreased to ≈ 90 % at 1 h post-
administration. In sharp contrast, the bladder region of mice receiving poly(iohexol) NPs stayed 
non-detectable for the whole imaging process while the contrast in other organs showed negligible 
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decrease after 1 h after administration (Figure 7.12). This observation is presumably due to the 
long circulation of poly(iohexol) NPs and rapid elimination of small molecular iohexol when used 
for in vivo imaging. To demonstrate this hypothesis, we then studied the pharmacokinetics of these 
two contrast agents. Following by the intravenous injection, poly(iohexol) NPs exhibited 
significantly longer half-life (15.9 h) compared to iohexol (3.8 h) (Figure 7.13). These studies 
clearly demonstrated the potential of poly(iohexol) NPs over the small molecular iohexol to 
increase the temporal window for imaging and allow data acquisition is independent of timing of 
intravenous contrast administration, thus provide longer imaging time and generated more 
accuracy for disease diagnosis. 
 
Figure 7.9. Serial axial CT images of the MCF-7 tumors in mice following intratumoral 
injection of 200 μL of iohexol (upper panel) and poly(iohexol) NPs (bottom panel) at 50 mg 
iohexol/kg. Images were taken before injection, and 5 min, 1 h and 4 h post injection. Arrows 
indicate the enhanced contrast regions in the tumor bed. 
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Figure 7.10. Enhanced density (ΔHU, HU = Hounsfield unit) of tumors 5 min, 1 h and 4 h after 
injection of poly(iohexol) NPs or iohexol.  
 
 
 
 
 
 
 
Figure 7.11. Serial sections of coronal CT images in MCF-7 xenografts bearing mice following 
the same treatment as described in Figure 6.9. Arrows indicate the enhanced contrast regions in 
the bladder. 
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Figure 7.12. Serial fluoroscopic images of C57BL/6 mice following jugular vein injection of 200 
L of conventional iodinated contrast agent (iohexol) solution (upper panel) and poly(iohexol) NP 
solution (bottom panel) at 250 mg iohexol/ kg, respectively. Images taken at 0 min and 60 min 
after injection were as shown. Arrows indicated the enhanced contrast in the bladder region. 
 
 
 
Figure 7.13. In vivo circulation time of poly(iohexol) NP and iohexol. 
64
Cu labeled poly(iohexol) 
NP and iohexol were injected in intravenously through the tail vein of mice, respectively. At 
various time points (5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, and 48 h), blood was 
withdrawn intraorbitally and measured the radioactivity by the γ-counter to evaluate the systemic 
circulation of the Poly(iohexol) NP (red) and iohexol (blue) (n=3).  
 
 
7.3.6 Safety evaluation of poly(iohexol) nanoparticles  
Safety profile is one of critical requirement for clinical translation.21  To determine the 
safety of poly(iohexol) NPs, I first investigated their in vivo acute toxicity by histological 
assessment on major organs such as heart, liver, spleen, lung, kidney and intestine, after 
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intravenous administration of NPs in athymic nude mice at a high dose of poly(iohexol) NPs (up 
to 300 mg/kg). No mortality or obvious behavioral abnormalities were observed in any of the 
groups. In addition, no treatment related clinical signs and changes of body weights were noted. 
Representative sections of various organs taken 24 h after administrations were stained by 
hematoxylin and eosin (H&E), and evaluated by an independent pathologist (Figure 7.14). The 
absence of immune or inflammatory responses indicated low toxicity of the NPs. Besides single-
dose toxicity, diodination with thyroid uptake and whole body bioelimination is another two 
critical evaluation parameters for these iodinated contrast media. Thus, the biodsistribution of 
these NPs were studied by injecting 64Cu-labeled poly(iohexol) NPs into MCF-7 xenografts 
bearing athymic nude mice intravenously. The accumulation of poly(iohexol) NPs in various 
organs such as heart, lung, liver, spleen, kidney and bladder at the three selected time points (1 h, 
4 h and 24 h post injection) were quantified by PET/CT imaging (Figure 7.15). More quantitative 
assessment was achieved by euthanizing mice at 24 h post injection and measuring the 
radioactivity of different organs using a γ-counter. As Figure 7.16 showed, the accumulation of 
poly(iohexol) NPs in the thyroid is only 1.19 % I.D./g at 24 h post injection. Due to the fact of 
such a low uptake of thyroid, I postulated that using this nanoparticlate contrast agent might not 
cause iodine-provoked hyperthyroidism. However, the detailed effect on the thyroid function needs 
to be further explored. Interestingly, I noticed that the majority of poly(iohexol) NPs got 
accumulated into the liver, spleen and kidney, which is consistent with the expects the clearances 
of NPs is mainly because of the reticuloendothelial system uptake. It is also noted that the 
accumulation of poly(iohexol) NPs in the bladder, urine and feces were 2.17 % I.D./g, 0.95 % 
I.D./g and 11.36 % I.D./g, respectively. This observation demonstrated that the poly(iohexol) NPs 
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could also be bioeliminated from the body via urine and feces. These results collectively suggested 
that poly(iohexol) NPs is a promising CT contrast agent for future clinical applications. 
 
 
Figure 7.14. In vivo circulation time of poly(iohexol) NP and iohexol. 
64
Cu labeled poly(iohexol) 
NP and iohexol were injected in intravenously through the tail vein of mice, respectively. At 
various time points (5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, and 48 h), blood was 
withdrawn intraorbitally and measured the radioactivity by the γ-counter to evaluate the systemic 
circulation of the Poly(iohexol) NP (red) and iohexol (blue) (n=3).  
 
Figure 7.15. In vivo biodistribution of poly(iohexol) NP and iohexol. (A) In vivo whole-body 
dynamic PET/CT imaging of mice treated with 64Cu labeled poly(iohexol) NP (upper panel) and 
iohexol (bottom panel). Images were taken at t 1 h, 4 h and 24 h after tail vein injection of 
poly(iohexol) NP and iohexol, respectively. (B) The accumulation of 64Cu labeled poly(iohexol) 
NP (upper panel) and iohexol (bottom panel) in various organs at 1 h, 4 h and 24 h after tail vein 
injection of poly(iohexol) NP and iohexol, respectively. Data was obstained from direct analysis 
of PET/CT imaging. 
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Figure 7.16. In vivo biodistribution of 64Cu labeled poly(iohexol) NP (red bar) and iohexol (blue 
bar) in MCF-7 xenografts bearing athymic nude mice, assessed by γ-counter. All the data was 
presented as percentage of injected dose per gram of tissues (% I.D. /g). 
 
7.4 Conclusions 
In conclusion, I designed and synthesized poly(iohexol) by using iohexol as a 
multifunctional monomer to mediate cross-linking polymerization. The resulting poly(iohexol) 
was co-precipitated with mPEG-PLA to form PEGylated poly(iohexol) NPs as an in vivo 
applicable contrast nanoprobe. These NPs showed negligible toxicity, remarkable stability and 
substantially improved protracted retention in the tumor bed, which makes it possible to acquire 
CT images over a wide time frame without multiple administrations and improves the diagnosis 
accuracy for the representation of the region of interest. Because degradable domains (e.g., ester 
bond) can be easily integrated to poly(iohexol) by selecting ester-containing bis-isocyanate as the 
co-monomer, degradable poly(iohexol) can be developed to ensure complete renal clearance at the 
end of the study, which will be far superior to inorganic nanoparticulate contrast agents (e.g., gold 
NPs) with unfavorable clearance profiles and long-term safety concerns. Given the simplicity of 
the synthesis and the fact that the poly(iohexol) NPs can be easily scaled up and formulated in 
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solid form with well-preserved nanoparticle property with negligible aggregation, I anticipate that 
the biocompatible poly(iohexol) NPs could potentially be used as CT imaging contrast agents in 
the clinic to improve diagnostic accuracy and patient compliance.   
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